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Abstract 
Cymbopogon citratus (DC). Stapf (Poaceae), commonly known as 
lemongrass, is a tropical perennial shrub originated from the Southeast Asia. This 
plant is reported to possess antifungal, insecticidal, anti-diabetic, anti-septic, anti-
mutagenic, anti-carcinogenic activities as well as anti-inflammatory. In fact, 
aqueous extracts of dried leaves are used all over the year in folk medicine for the 
treatment of peptic ulcers and inflammatory conditions. Recently, some phenolic 
compounds, such as luteolin and apigenin glycosides and condensed tannins, were 
identified and related to both antioxidant and anti-inflammatory properties. The 
purposes of this work were to i) validate an analytical method for quantification of 
phenolic compounds of C. citratus; ii) study the influence of harvest time and 
plant quality on the phenolic composition and antioxidant activity; iii) characterize 
the tannins; iv) validate the traditional uses of lemongrass infusion as anti-
inflammatory in vivo; v) obtain a topical formulation to evaluate the phenolic 
compounds permeation and their anti-inflammatory activity; vi) trace the 
pharmacokinetic profile of the main phenolic compounds in rats.   
Three different extracts: infusion (CcI), 50% aqueous ethanol (CcM50%) 
and ethanol (CcM100%) extracts were prepared and a simple and efficient RP-
HPLC-PDA method was successfully validated for simultaneous identification and 
quantification of phenolic acids and flavonoids. Infusions were also obtained from 
different harvest dates (April, June, July, August and September) and quality 
grades (High, Medium and Low). It was verified that the content on polyphenols 
and the antioxidant capacity of CcI is strongly related with the quality of the plant. 
The total phenols assay showed a substantial loss from August to September. It 
was possible to find out the best month to harvest the plant to get the most of 
each phenolic group: April and June for hydroxycinnamic acids; June and 
September for flavonoids; June, July and August for tannins. Regardless the group 
of phenolic compound addressed, its content was always inversely proportional to 
the degree of leaves ageing. For all tested oxidant species, the high-quality samples 
exhibited the best antioxidant results.  
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CcI was fractionated by column chromatography and polyphenol-rich 
fractions, namely phenolic acids (CcPA), flavonoids (CcF) and tannins (CcT) were 
obtained. CcT was characterized by HPLC-PDA-ESI/MSn, revealing the presence 
of proanthocyanidin hetero-dimers, along with some common procyanidin dimers. 
These hetero-dimeric flavan structures have been described for the first time in 
lemongrass and consist of apigeniflavan or luteoliflavan units linked to a flavanone, 
either naringenin or eriodictyol, and may occur as aglycone or glycosylated forms.  
For the in vivo assays, CcI, CcF and CcT were tested. CcI administered 
before and after ethanol stimulus, significantly reduced the incidence and severity 
of gastric lesions and, consequently, the ulcer index, corroborating the traditional 
medicinal use of this plant to ameliorate gastritis and/or peptic ulcers symptoms. 
On the other hand, CcI, CcF and CcT were orally administered to rats, in order to 
evaluate the anti-inflammatory effect at the carrageenan-induced paw edema assay. 
The observed effect by CcI (68.24 mg/kg), 82.30% of edema inhibition, was very 
similar to that obtained by the reference NSAID used (diclofenac, 10 mg/kg), 
84.00%. On the other hand, flavonoid (7.42 mg/kg) and the tannin-rich (5.96 
mg/kg) fractions significantly contributed for the anti-inflammatory activity on the 
edema volume (59 and 61%, respectively).  
The topical anti-inflammatory activity of CcI was also addressed. The results 
suggest that flavonoids, mainly, luteolin 7-O-neohesperidoside, cassiaoccidentalin 
B, carlinoside and cynaroside, may contribute to the topical anti-inflammatory 
effect. CcF (0.6%), CcT (0.3%) and CcF+CcT (0.66%+0.34%) topical 
formulations were also tested, and the results obtained suggest that tannins and 
flavonoids also possess a significant activity and that a synergistic mechanism of 
action may occur. In fact, edema inhibitions of 43%, 47% and 59% were 
respectively verified, being CcF+CcT effect very close to that of 1% diclofenac 
(65.9%).  
Pharmacokinetic analysis was performed in plasma, liver and kidney and 
showed that the compounds present in CcI are not detected in vivo after a single-
dose oral administration. In contrary, the metabolites, luteolin 7-O-glucuronide 
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and luteolin 3’-O-sulfate, present at the highest bioavailability, are probably the 
main responsible for the anti-inflammatory activity previously reported.  
In conclusion, this work has developed a method to quantify the phenolic 
compounds contained in C. citratus; pointed the importance of harvesting and 
storing the plant material, in order to take the maximum advantages from the 
phenolic compounds use; and demonstrated, in safe doses, its anti-inflammatory 
activity, using an in vivo approach, which supports the traditional use of 
lemongrass infusion. Furthermore, C. citratus leaves flavonoids and tannins were 
highlighted as bioactive compounds, encouraging the development of new anti-
inflammatory drugs or nutraceuticals. 
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Resumo 
Cymbopogon citratus (DC). Stapf (Poaceae), vulgarmente conhecida como 
erva-príncipe, é um arbusto perene tropical originário do Sudeste Asiático. Nos 
países asiáticos e latino-americanos, é uma planta comummente consumida como 
bebida ou condimento aromático. A esta planta são lhe atribuídas propriedades 
antifúngicas, insecticidas, antidiabéticas, antissépticas, antimutagénicas, 
anticancerígenas e anti-inflamatórias. Na verdade, extratos aquosos das folhas secas 
são utilizados, durante todo o ano, na medicina popular para o tratamento de 
úlceras pépticas e problemas inflamatórios. Recentemente, alguns compostos 
fenólicos, tais como os glicósidos da luteolina e da apigenina e os taninos 
condensados, foram identificados e relacionados com efeitos antioxidantes e anti-
inflamatórios. O objetivo deste trabalho foi i) validar um método analítico para a 
quantificação de compostos fenólicos de C. citratus; ii) estudar a influência da 
época de colheita e da qualidade da planta na composição fenólica e na atividade 
antioxidante do infuso usado na medicinal popular; iii) caracterizar os taninos por 
HPLC-PDA-ESI/MSn; iv) validar os usos tradicionais da infusão como anti-
inflamatória in vivo; v) obter uma formulação tópica para avaliar a permeação dos 
compostos fenólicos e a sua actividade anti-inflamatória; vi) traçar o perfil 
farmacocinético dos principais compostos fenólicos em ratos. 
Três extractos - infusão (CcI), macerado com etanol a 50% (CcM50%) e 
macerado com etanol absoluto (CcM100%) - foram preparados e um método de 
HPLC-PDA, simples e eficiente, foi validado com êxito, pela primeira vez, para a 
identificação simultânea e quantificação dos ácidos fenólicos e flavonóides. 
Diferentes infusões foram também obtidas a partir de folhas colhidas em diferentes 
épocas (Abril, Junho, Julho, Agosto e Setembro) e diversos graus de qualidade 
(Alto, Médio e Baixo). Foi verificado que o conteúdo em polifenóis e a capacidade 
antioxidante do CcI estão fortemente relacionados com a qualidade da planta. O 
ensaio dos fenóis totais mostrou uma perda substancial de Agosto para Setembro. 
Além disso, foi possível descobrir o melhor mês para a colheita da planta no 
sentido de obter o máximo teor de cada grupo fenólico: Abril e Junho, para ácidos 
hidroxicinâmicos; Junho e Setembro, para flavonóides; e Junho, Julho e Agosto, 
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para taninos. Independentemente do grupo de compostos fenólicos estudado, o seu 
conteúdo foi sempre inversamente proporcional ao grau de envelhecimento das 
folhas. Para todas as espécies oxidantes testadas, as amostras de alta qualidade 
apresentaram os melhores resultados como antioxidantes. 
A CcI foi fraccionada por cromatografia em coluna e fracções ricas em 
polifenóis, nomeadamente ácidos fenólicos (CcPA), flavonóides (CcF) e taninos 
(CcT) foram obtidos. A CcT foi caracterizada por HPLC-PDA-ESI/MSn, revelando 
a presença de pro-desoxi-antocianidinas hetero-diméricas, juntamente com algumas 
proantocianidinas comuns. Estas estruturas flavânicas hetero-diméricas foram 
descritas, pela primeira vez, nesta planta e consistem em unidades de luteoliflavano 
ou apigeniflavano ligados a uma flavanona, naringenina ou eriodictiol, podendo 
apresentar-se na forma livre ou glicosilada. 
CcI, CcF e CcT foram testados in vivo. A CcI, administrada antes e após o 
estímulo etanólico, reduziu significativamente a incidência e a gravidade das lesões 
gástricas e, consequentemente, o índice ulceroso, corroborando o uso tradicional 
desta planta no alívio dos sintomas da gastrite e/ou das úlceras pépticas. Por outro 
lado, CcI, CcF e CcT foram administrados por via oral a ratos, para avaliar o efeito 
anti-inflamatório no ensaio do edema da pata induzido pela carragenina. O efeito 
observado para a dose mais alta (68.24 mg/kg), 82.30%, foi muito semelhante ao 
obtido pelo fármaco de referência utilizado (diclofenac - 10 mg/kg), 84.00%. Por 
outro lado, as fracções CcF (7.42 mg/kg) e CcT (5.96 mg/kg) contribuíram 
significativamente para o efeito anti-inflamatório (59 e 61%, respectivamente). 
A actividade anti-inflamatória tópica de CcI foi também estudada. Os 
resultados sugerem que os flavonóides, principalmente, a luteolina 7-O-
neohesperidósido, a cassiaoccidentalin B, o carlinósido e o cinarósido, podem 
contribuir para o efeito anti-inflamatório tópico verificado. Formulações tópicas de 
CcF (0.6%), CcT (0.3%) e CcF+CcT (0.66%+0.34%) foram também testados in 
vivo, e os resultados obtidos sugerem que os taninos e flavonóides possuem 
também uma significativa actividade e que um sinergismo deverá ocorrer pela 
função das duas fracções fenólicas. Todas as amostras testadas demonstraram 
ausência de toxicidade in vivo. 
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A análise farmacocinética foi realizada no plasma, fígado e rim e mostraram 
que os compostos presentes no CcI não foram detectados in vivo após uma 
administração oral de dose única. Ao contrário, os metabolitos, luteolina 7-O-
glucurónido e luteolina 3'-O-sulfato, demonstraram possuir maior 
biodisponibilidade, sendo provavelmente os principais flavonóides responsáveis 
pela actividade anti-inflamatória anteriormente descrita. 
Em conclusão, este trabalho desenvolveu um método para quantificar os 
compostos fenólicos de C. citratus; apontou a importância da colheita, do 
armazenagem e do embalamento do material vegetal, a fim de tirar as máximas 
vantagens dos compostos fenólicos a utilizar; e demonstrou a sua actividade anti-
inflamatória in vivo, sistémica e tópica, utilizando doses não tóxicas, que suporta o 
uso tradicional da infusão de erva-príncipe. Além disso, os flavonóides e taninos 
das folhas de C. citratus foram destacados como compostos bioativos, incentivando 
o desenvolvimento de novos produtos anti-inflamatórios, fitoterápicos ou 
nutracêuticos. 
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FS2 Flavone synthase 2 
FSDC Fetal skin-derived dendritic cell line 
GC Gas chromatography 
GT Glycosyltransferase 
H High 
HE Hematoxylin and eosin 
HFA Human flora-associated 
HPLC High-performance liquid chromatography 
I Number of i concentration levels 
i.p. Intraperitoneal 
ICAM Intercellular adhesion molecule 
ICH International Conference on Harmonization 
ICR Imprinting Control Region mice 
IgE Immunoglobulin E 
IKK IκB kinase 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
ISO Isoorientin 
ISV Isovitexin 
IV Intravenous 
IκB NF-κB activators family 
XLIV 
 
J Total number of j injections per i concentration levels 
JNK c-Jun NH2-terminal kinase 
Jul July 
Jun June 
k Elimination rate constant 
L Low 
L3’S Luteolin 3’-O-sulfate 
L7G Luteolin 7-O-glucuronide 
LAR Leucoanthocyanidin reductase 
LC Liquid chromatography 
LD50 Lethal dose, 50% 
LDL Low-density lipoprotein 
LDOX Leucoanthocyanidin oxidase 
LLOQ Lower limit of quantification 
LOD Limit of detection 
LOQ Limit of quantification 
LOX Lipoxygenase 
LPH Lactase phlorizin hydrolase 
LPS Lipopolysaccharide 
LT Leukotriene 
LTB4 Leukotriene B4 
LUT Luteolin 
M Medium 
m/z Mass-to-charge ratio 
MAPK Mitogen-activated protein kinase 
MIP-2 Macrophage inflammatory protein 2 
MPO Myeloperoxidase 
mRNA Messenger ribonucleic acid 
MRP Multidrug resistance-associated protein 
MRT Mean residence time 
MS Mass spectrometry 
XLV 
 
MS2 Tandem mass spectrometry 
MW Molecular weight 
n.a. Not applicable 
n.d. Not detected 
NC Not calculated 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NMR Nuclear Magnetic Resonance 
NO Nitric oxide 
NO• Nitric oxide radical 
Nrf2 Nuclear factor (erythroid-derived 2)-like 2 
NSAID Non-steroid anti-inflammatory drug 
OMTS O-Methyltransferases 
p.o. Per os 
p38 Protein from the MAPK family 
p65 Protein from the NK-ΚB family 
PAL Phenylalanine ammonia lyase 
PBS Phosphate buffer saline 
PCA Protocatechuic acid 
PDA Photo-diode array 
PG Prostaglandin 
PGD2 Prostaglandin D2 
PGE2 Prostaglandin E2 
PLA2 Phospholipase A2 
PPAR Peroxisome proliferator-activated receptor 
PPAR- Peroxisome proliferator-activated receptor  
PPAR-γ Peroxisome proliferator-activated receptor γ 
QM Quinone methide cleavage 
RANTES see CCL5 
RAW 264.7 Abelson murine leukemia virus-transformed macrophages 
RDA Retro Diels-Alder reaction 
RER Rough endoplasmic reticulum 
XLVI 
 
RP Reverse phase 
RSD Relative standard deviation 
RUT Rutin 
SD Standard deviation 
SEM Standard error of the mean 
Sep September 
SER Smooth endoplasmic reticulum 
SPE Solid-phase extraction 
SSlof
   Lack-of-fit sum squares 
SSε Purely experimental sum squares 
STAT Signal transducers and activators of transcription 
SULT Sulfotransferase 
T1/2 Half-life time 
t1/2 Half-life time 
Tb Mean reaction time of blank rats 
TEAC Trolox-equivalent antioxidant capacity 
TEM Transmission electron microscopy 
TF Tannin fraction from CcI 
TLC Thin layer chromatography 
tmax Maximum time 
TNBS 2,4,6-Trinitrobenzenesulfonic acid 
TNF- Tumor necrosis factor  
TPA 12-O-tetradecanoylphorbol-13-acetate 
TPA Texture profile analysis 
TPTZ 2,4,6-Tripyridyl-S-triazine 
Tt Mean reaction time of treated rats 
Tyk2 Tyrosine-protein kinase 2 
U.I. Ulcer index 
UDP Uridine diphosphate 
UGT UDP-glucuronosyltransferase 
UPLC Ultra-performance liquid chromatography 
XLVII 
 
UV Ultraviolet radiation 
UV-A A-type ultraviolet radiation 
UV-B B-type ultraviolet radiation 
Vc Mean variation of the paw volume in control rats 
VCAM Vascular cell adhesion molecule 
Vd Volume of distribution 
Vt Mean variation of the paw volume in treated rats  
Wc Average number of writhes in control rats 
Wt Average number of writhes in test rats 
ŷi Estimated experimental response for the level i 
ȳi Average response for the level i 
σlof
 2 Lack-of-fit variance 
σε2 Purely experimental variance 
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A. Cymbopogon citratus 
1. Botanic characterization  
1.1 Classification and etymology 
The accepted name Cymbopogon citratus (DC.) Stapf (Table I.1) was 
originally described in 1906 and published in the Bulletin of Miscellaneous 
Information (see Attach). The genus Cymbopogon belongs to the family Poaceae 
(formerly Gramineae). Poaceae encompasses approximately 800 genera and 10.000 
species (Watson and Dallwitz, 1992). The economic importance of this family is 
unquestionable for it has many different types of use, and it includes cereals, 
sugarcane, fodder and pasture, bamboo, etc.  
The genus Cymbopogon includes about 70 species distributed throughout 
the tropics and subtropics of Africa, Asia and Australia, predominantly in Asia,  
having been introduced in tropical America (Shouliang and Phillips, 2006). The 
name of the genus Cymbopogon derives from the Greek “kymbe” meaning boat 
and “pogon” (beard), for the arrangement of the inflorescence, and the epithet 
“citratus” derives from the ancient Latin “citrus” related to the lemon-scented of 
the leaves. 
 
1.2 Synonyms and common names 
There is a quite large list of scientific names used in the past to refer this 
species, the synonyms. Following the most recent and reliable revision of the 
species, the synonyms are listed below:  
Andropogon citratus DC., Cat. Pl. Horti Monsp. 78. 1813 [basionym]. 
Andropogon cerifer Hack., Fl. Bras. 2(4): 281 1883. 
Andropogon citriodorus Desf., Tabl. École Bot. ed. 2: 15 1815. 
Andropogon fragrans C.Cordem., Fl. Réunion 122 1895. 
Andropogon nardus subsp. ceriferus (Hack.) Hack. Monogr. Phan. 6: 605 1889. 
Andropogon roxburghii Nees ex Steud. Syn. Pl. Glumac. 1: 395 1854. 
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Table I.1. Taxonomic hierarchy of Cymbopogon citratus (DC.) 
Stapf (Integrated Taxonomic Information System, 2015). 
Kingdom Plantae (plants) 
Subkingdom Viridiplantae 
Infrakingdom Streptophyta (land plants) 
Superdivision Embryophyta 
Division Tracheophyta (vascular plants; tracheophytes) 
Subdivision Spermatophytina (seed plants; spermatophytes) 
Class Magnoliopsida 
Superorder Lilianae (monocots; monocotyledons) 
Order Poales 
Family Poaceae (grasses) 
Genus Cymbopogon Spreng. 
Species Cymbopogon citratus (DC.) Stapf 
 
This information is very important because often scientific papers 
concerning chemical characterization, ethnopharmacology and biological activities 
could be referred to Cymbopogon citratus (DC.) Stapf but under the name of a 
synonym. 
The common name given to a species is another important question to 
ascertain the identity of each plant. In the various vernacular languages, the species 
C. citratus is known by a multitude of different names, sometimes leading to 
uncertain identification. In Table I.2 are some examples of common names 
attributed to C. citratus in several countries. 
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Table I.2. Common names used in different countries for the Cymbopogon 
citratus. 
Country(ies) Common name(s) 
Angola “Chá de caxinde” 
Brazil “Capim-limão”, “Capim-santo”, Capim-cidreira” 
China 香茅 
English-speaking countries “Lemongrass”, “Citronella”, “Squinant” 
Ethiopia “Tej-sar” 
France “Citronelle”, “Verveine des Indes” 
Germany “Zitronengrass” 
India “Sera”, “Verveine” 
Indonesia “Sereh”, “Tanglad” 
Israel “Limonit” 
Italy “Citronella”, “Cimbopogone” 
Japan レモングラス 
Korea 레몬 그라스 
Malaysia “Sakumau” 
Mexico “Zacate-limón” 
Netherlands “Citroengras” 
Portugal “Erva-príncipe” 
São Tomé e Príncipe “Fiá-xalela” 
Spain “Hierba-luisa”, “Hierba-limón”, “Limoncillo” 
Sweden “Citrongräss” 
Thailan “Ta-khrai” 
Turkey “Limon otu” 
Venezuela “Citronera” 
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1.3 Botanic description 
C. citratus is native in Sri Lanka and South India, being widely cultivated in 
tropical Asia and South America.  
It is a tropical grass, shortly rhizomatous, that grows in dense clumps, up to 
1.8 m in height and about 1.2 m in width (Figure I.1). The leaves are evergreen, 
bright bluish-green and release a citrus aroma when crushed. They are strap-like, 
1.3-2.5 cm wide, about 0.9 m long, ending by drooping tips. The flowers are 
arranged in inflorescences (panicles), 30-60 cm long, however, the plants that are 
more likely to find are cultivars and do not typically produce flowers. The fruit is 
an oblong caryopsis (Figure I.2) (Metcalfe, 1960). 
 
 
Figure I.1. Cymbopogon citratus 
(http://zipcodezoo.com/index.php/Cymbo
pogon_citratus). 
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The upper epidermis of C. citratus consists of a single layer of elongated 
cells interrupted by large bulliform cells (with thin walls and large vacuoles), which 
are involved in involution and folding of leaves (Eltahir and AbuEReish, 2010). 
The spongy parenchyma is formed by 1-2 cell layers under the upper epidermis. 
The vascular bundles, of about 3-4 layers of sclerenchyma, are embedded in 
chlorenchyma cells forming a Kranz structure (Metcalfe, 1960).  
 
 
Figure I.2. (A) Botanical illustration of Andropogon citratus DC., basionym of 
Cymbopogon citratus (DC.) Stapf, representing the structures of the plant: 1. 
young plant; 2. lower portion of adult plant; 3. adult leaves; 4. inflorescence 
(panicle); 5. spikelet; 6. flower (floret); 7. lower glume; 8. upper glume; 9. lemma; 
10. palea (Bulletin of Miscellaneous Information, 1906). (B) Herbarium specimen 
of Cymbopogon citratus (DC.) Stapf collected in Portugal and deposited at the 
Herbarium of Aromatic and Medicinal Plants of the Faculty of Pharmacy – 
University of Coimbra (A. Figueirinha 0109). 
 
 
CHAPTER I | INTRODUCTION 
 
8 
 
2. Ethnopharmacology 
The use of the plant in folk medicine occurs in almost all continents 
although the largest source of ethnopharmacological information on the C. citratus 
is originally from tropical countries of Africa, Asia and South American, covering a 
wide range of applications. Of these, stands out its use in the treatment of 
respiratory, gastric and nervous system problems. 
C. citratus has been used in various formulations alone or in association 
with other plants and administered externally or orally. It is predominantly used in 
the form of infusion or decoction of leaves fresh and dried (Arrey Tarkang et al., 
2013; Carbajal et al., 1989; Hilgert, 2001; Leite et al., 1986; Lorenzetti et al., 
1991; Melo et al., 2001; Shah et al., 2011; Soares et al., 2013), or through its the 
essential oil (Gupta, 1995; Ross, 2010). Sometimes the plant is also used in 
bathing (Coelho-Ferreira, 2009; Ruysschaert et al., 2009; Zumsteg and Weckerle, 
2007). The root is less used than the leaves, often in the form of decoction. In 
Brazil, folk medicine discourages the intake of the root extracts by pregnant, since 
causes uterine contractions (Rodrigues, 2007). There are numerous sources of 
information gathering ethnomedicinal studies performed in the course of the 
twentieth century. The most relevant ethnopharmacological studies are presented 
in Table I.3. 
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Table I.3. Ethnopharmacological studies on Cymbopogon citratus (cont.). 
Country Extract Uses Reference 
Argentina 
Leaf infusion Colds and cough Hilgert, 2001 
Leaf decoction Stomachic, hypotensive and cardiotonic 
Scarpa, 2004 Leaf placed 
directly 
Toothaches  
Bolivia Leaf decoction 
Stomach pain, swellings by freezing 
cold and tranquilizer  
Macía et al., 2005 
Brazil 
Leaf infusion 
Diarrhea, bad cold, headache, muscular 
pain, rheumatism, fever, hypertension, 
blood circulation, general pains and 
sedative  
de Albuquerque et 
al., 2007 
Leaf decoction Bad cold and rheumatism  Di Stasi et al., 
2002 Root infusion Antidiuretic  
Bath Flu with scratching throat 
Coelho-Ferreira, 
2009 
China Bath Relieve pain Au et al., 2008 
Costa Rica Leaf 
Cough, carminative, expectorant and 
depurative 
Morton, 1981 
Cuba 
Leaf infusion Hypertension, catarrh and rheumatism 
Carbajal et al., 
1989 
Decoction Nervousness, insomnia and fever  
Cano and 
Volpato, 2004 
Democratic 
Republic of 
Congo 
Leaf decoction 
Cough, stomach problems, diarrhea, 
fever, malaria, oedema and to stimulate 
digestion  
Mesia et al., 2007 
Egypt Leaf infusion Renal antispasmodic and diuretic 
Locksley et al., 
1982 
Equator Leaf infusion 
Gastritis, relaxant, stomach, pain and 
diarrhea  
Tene et al., 2007 
Ethiopia Root Stomachache 
Teklehaymanot et 
al., 2007 
Ghana Poultice Boils, swellings 
Agyare et al., 
2009 
French Guiana 
Leaf (with other 
plants) 
Antimalarial  
Vigneron et al., 
2005 
Honduras Leaf decoction 
Postpartum abdominal pain and 
lactation  
Ticktin and Dalle, 
2005 
India 
Oil Carminative  
Poonam and 
Singh, 2009 
Leaf 
Stimulant, sudorific, antiperiodic and 
anti-catarrhal  
Khare, 2007 
Essential Oil 
Carminative, analgesic, antipyretic, 
antibacterial and antifungal  
Indonesia Essential Oil Sedative, antiseptic 
Zumsteg and 
Weckerle, 2007 
Malaysia Leaf infusion 
 
Emmenagogue 
 
Burkill et al., 
1936 
Mexico 
Leaf infusion Influenza and gastrointestinal disorders  
Andrade-Cetto, 
2009 
Leaf decoction Cough 
Giovannini and 
Heinrich, 2009 
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Table I.3. Ethnopharmacological studies on Cymbopogon citratus. 
Country Extract Uses Reference 
Nepal 
Pounded plant 
and juice taken 
with hot water 
Cold 
Shrestha and 
Dhillion, 2003 
Nicaragua 
Leaf infusion 
Abdominal and back pain, postpartum 
abdominal pain, promote lactation, 
fever, digestive ailments (flatulence, 
heartburn and stomachache)  
Coe, 2008 
Root liniment Backache 
Nigeria Leaf decoction 
Antimalarial 
Ajibesin et al., 
2007 
Yellow fever 
Ajaiyeoba et al., 
2003 
Peru Leaf Antimalarial, anti-leishmania Kvist et al., 2006 
Philippines Leaf infusion 
Indigestion and stomach problems, 
anti-stress, colds, fevers, pain and 
arthritis 
Dagupen et al., 
2011 
Portugal Leaf infusion 
Gastric analgesic, digestive system, 
gall-bladder ailments, intestinal anti-
inflammatory, sea-sickness, renal 
antispasmodic and bladder ailments 
Novais et al., 
2004 
Suriname Bath 
Baby´s abdominal pain, fever, cold and 
viral infections  
Ruysschaert et al., 
2009 
Thailand Leaf or stem Carminative, diuretic, antipyretic  
Wannissorn et al., 
2005 
Trinidad & 
Tobago 
Leaf or root Cold, flu, fever and diabetes 
Mahabir and 
Gulliford, 1997 
Leaf and root Cough, cold, fever 
Clement and 
Seaforth, 2015 
Uganda 
Leaf aqueous 
extract (with 
other plants) 
Antimalarial  Tabuti, 2008 
Leaf Influenza Tabuti et al., 2003 
United States 
of America 
Leaf infusion 
Externally for healing wounds and bone 
fractures 
Spring, 1989 
 
3. Phytochemistry 
The non-volatile constituents of C. citratus have been much less studied 
because of the higher economic interest so far has been attributed to the essential 
oil. The literature review highlights the existence of a large variability in chemical 
composition of the fixed constituents of C. citratus. Isolation of luteolin, luteolin 
7-O-glucoside (cynaroside), isoscoparin and 2''-O-rhamnosyl isoorientin from the 
leaves and rhizomes of C. citratus has been reported (Avoseh et al., 2015). Other 
phenolic compounds referred to aerial parts of C. citratus are quercetin, kaempferol 
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and apigenin, catechol, chlorogenic acid, caffeic acid and hydroquinone (Faruq, 
1994; Miean and Mohamed, 2001; Tapia et al., 2007). It is observed, in particular, 
predominance of flavone glycosides (luteolin and apigenin) and seldom their 
aglycones (Cagiotti et al., 2001). Only one author refers to the presence of 
kaempferol as the only flavonoid present, although not specify whether it is the 
aglycone or a glycoside (Miean and Mohamed, 2001), while in another study the 
presence of methylated aglycones was cited (Cheel et al., 2005). 
The prevalence of flavonoids, mainly flavones and their C- and O-type 
glycosides, and phenolic acids, is a characteristic feature common to other species 
of the same family (Poaceae) (Harborne and Williams, 1976). Some authors 
identified both types of glycosides (C- and/or O-) (Figueirinha et al., 2008; 
Gunasingh and Nagarajan, 1981 Orrego et al., 2009; Tapia et al., 2007). The 
positions of glycosylation at C-glycosides were identified in C6 and C8, while in 
the case of the O-glycosides, the sugar portion was bound in position O7 (Cheel et 
al., 2005; De Matouschek and Stahl-Biskup, 1991; Figueirinha et al., 2008). These 
differences may be originated by different environmental conditions in which the 
plant grew. Glycosides have been identified with more than two sugars, these being 
often glucose and rhamnose (Cheel et al., 2005; De Matouschek and Stahl-Biskup, 
1991; Figueirinha et al., 2008; Gunasingh and Nagarajan, 1981).   
Phenolic acids are most often identified phenolic compounds in the plant 
leaves, especially being the hydroxycinnamic type (caffeic, chlorogenic and p-
coumaric) (Cheel et al., 2005; De Matouschek and Stahl-Biskup, 1991; 
Figueirinha et al., 2008; Tapia et al., 2007), but also hydroxybenzoic acids (Tapia 
et al., 2007). Marques et al. (2008) identified and quantified various isomers of 
derivatives of hydroxycinnamic acids in infusions and methanolic extracts: isomers 
3, 4 and 5 of caffeoylquinic acid, representing the 5-isomer, 53% of total phenolic 
acids identified. Also identified the isomers 3, 4 and 5-feruloylquinic acid, isomers 
3 and 4; and 3, 5 and 4, 5-dicaffeoylquinic acid. This study did not detect caffeic 
acid nor gallic acid (Marques and Farah, 2009). Another study on the 
phytochemical composition of C. citratus also revealed the presence of tannins, 
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however, very little effort has been made in the isolation of these compounds 
despite the appreciable amounts reported through quantitative phytochemical 
tests. Figueirinha and collaborators (2008) fractionated extracts of the species 
cultivated in Portugal and reported about 4.35% (dry weight) of condensed 
tannins, while C. citratus from Nigeria showed about 0.6% of tannins (Asaolu et 
al., 2009). C. citratus is the single species of Cymbopogon which is most exploited 
for its tannin content (Avoseh et al., 2015). Nevertheless, at present there is no 
data that characterize the chemical structure of this class of phenolic compounds.  
Other compounds have been studied in C. citratus leaves;  two terpenoids 
(cymbopogonol and cymbopogone) were identified in its coating (Avoseh et al., 
2015) and the wax presence was studied with the aim of establishing grasses 
classification criteria (Maffei, 1996), while in plant rhizomes alkaloids and 
saponins were detected (Negrelle and Gomes, 2007). Another recent studies 
revealed the presence of other minor groups of phytochemicals, namely alkaloids, 
saponins, anthraquinones and steroids in lemongrass leaves (Asaolu et al., 2009; 
Oloyede, 2009; Soares et al., 2013). More recently, it has been reported the 
existence of phenolic compounds with medicinal properties in the hydrodistillation 
water of lemongrass leaves (Tavares et al., 2015). Table I.4 summarizes the non-
volatile compounds identified in extracts of C. citratus. 
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Table I.4. Non-volatile compounds identified in Cymbopogon citratus (cont.). 
Compounds Identified Structure Reference 
Phenolic acids 
p-Hydroxybenzoic acid OH
O
OH  
Tapia et al., 2007 
p-Hydroxybenzoic acid 
3-O-glucoside 
OH
O
OH
OO
OH
OH
OH
OH
 
Tapia et al., 2007 
p-Coumaric acid 
OH
OH
O
 
De Matouschek and 
Stahl-Biskup, 1991; 
Figueirinha et al., 
2008 
Caffeic acid 
OH
OH
O
OH
 
Cheel et al., 2005; 
De Matouschek and 
Stahl-Biskup, 1991; 
Tapia et al., 2007 
3-O-Caffeoylquinic acid OH
O
O
OH
OH
OH
OH
OH
O
 
Cheel et al., 2005; 
Marques and Farah, 
2009; Tapia et al., 
2007 
4-O-Caffeoylquinic acid OH
O
O
OH
OH
OH
OH
O
OH
 
Marques and Farah, 
2009 
5-O-Caffeoylquinic acid OH
O
O
OH
OH
OH
OH
O
OH
 
Marques and Farah, 
2009; Tapia et al., 
2007 
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Table I.4. Non-volatile compounds identified in Cymbopogon citratus (cont.). 
Compounds Identified Structure Reference 
4-O-Feruloylquinic acid OH
O
O
O
OH
OH
OH
O
OH
 
Marques and Farah, 
2009 
5-O-Feruloylquinic acid OH
O
O
O
OH
OH
OH
O
OH
 
Marques and Farah, 
2009 
3,4-O-Dicaffeoylquinic 
acid 
OH OH
O
O OH
O
OH
OH
OO
OH
OH
 
(Marques and Farah, 
2009) 
3,5-O-Dicaffeoylquinic 
acid 
OH OH
O
O
O
OH
OH
O
OH
O
OH
OH  
Marques and Farah, 
2009 
4,5-O-Dicaffeoylquinic 
acid 
OH OH
O
OO
OH
OH
O
O
OH
OH
OH
 
Marques and Farah, 
2009 
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Table I.4. Non-volatile compounds identified in Cymbopogon citratus (cont.). 
Compounds Identified Structure Reference 
Flavonoids 
Luteolin OOH
OH
OH
OH
O  
Cagiotti et al., 2001; 
De Matouschek and 
Stahl-Biskup, 1991 
Luteolin 7-O-glucoside 
(Cynaroside) 
OO
OH
OH
OH
O
O
OH
OH
OH
OH
 
Figueirinha et al., 
2008; Gunasingh 
and Nagarajan, 1981 
Luteolin 7-O-
neohesperidoside 
O
OH
OH
OH
OO
OH
OH
OH
O
O
O
OH
OH
OH
 
De Matouschek and 
Stahl-Biskup, 1991; 
Figueirinha et al., 
2008 
Luteolin 6-C-glucoside 
(Isoorientin)  
 
OOH
OH
OH
OH
O
O
OH
OH
OH
OH
 
Cheel et al., 2005; 
De Matouschek and 
Stahl-Biskup, 1991; 
Figueirinha et al., 
2008; Gunasingh 
and Nagarajan, 1981 
Luteolin (2’’-O-
rhamnosyl)-6-C-
glucoside 
OOH
OH
OH
OH
O
O
OH
OH
OH
O
O
OH
OH
OH
 
Cheel et al., 2005; 
De Matouschek and 
Stahl-Biskup, 1991; 
Figueirinha et al., 
2008 
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Table I.4. Non-volatile compounds identified in Cymbopogon citratus (cont.). 
Compounds Identified Structure Reference 
Luteolin 8-C-glucoside 
(Orientin) 
 OOH
OH
OH
OH
O
O
OH
OH
OH OH
 
Cheel et al., 2005 
Luteolin (2’’-O-
rhamnosyl)-8-C-
glucoside 
 
 
OOH
OH
OH
OH
O
O
O
OH
OH OH
O
OH
OH
OH
 
 
De Matouschek and 
Stahl-Biskup, 1991 
Chrysoeriol 6-C-
glucoside  
(Isoscoparin) 
 
 
OOH
OH
OH
O
O
OH
OH
OH
OH
O
 
 Cheel et al., 2005 
7-Mehtoxyluteolin 6-C-
glucoside 
(Swertiajaponin) 
OO
OH
OH
O
O
OH
OH
OH
OH
OH
 
Cheel et al., 2005 
Luteolin 6-C-glucosyl-8-
C-arabinoside 
(Carlinoside) 
O
OH
OH
OH
OOH
OH
OH
O
O
OH
OH
OH
OH
OH
 
Figueirinha et al., 
2008 
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Table I.4. Non-volatile compounds identified in Cymbopogon citratus (cont.). 
Compounds Identified Structure Reference 
Luteolin 6-C-pentoside 
OOH
OH
OH
O
O
OH
OH
OH
OH
 
Figueirinha et al., 
2008 
Luteolin 6-C-pentosyl-8-
C-pentoside 
O
OH
OH
OH
OOH
OH
OH
O
O
OH
OH
OH
OH
 
Figueirinha et al., 
2008 
 
Luteolin 6-C-pentosyl-8-
C-deoxyhexoside 
(Kurilensin A) 
O
O
OH
OH
OH
OH
O
O
OH
OH
O
OH
OH
OH  
Figueirinha et al., 
2008 
Luteolin 6-C-(6-
deoxyribo-hexos-3-
ulosyl)-2''-O-rhamnoside 
(Cassiaoccidentalin B) 
O
O
O
OH
OH
OH
OH
OH
O
O
O
OH
OH
OH
 
Figueirinha et al., 
2008 
Apigenin 
OOH
OH
OH
O  
Miean and 
Mohamed, 2001 
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Table I.4. Non-volatile compounds identified in Cymbopogon citratus (cont.). 
Compounds Identified Structure Reference 
Apigenin 6-C-
arabinosyl-8-C-glucoside 
(Isoschaftoside) 
OOH
OH
OH
O
O
OH
OH
OH
O
OH
OH
OH OH
 
Figueirinha et al., 
2008 
Kaempferol 
OOH
OH
OH
O
OH
 
Miean and 
Mohamed, 2001 
Quercetin OOH
OH
OH
O
OH
OH
 
Miean and 
Mohamed, 2001 
Others 
Glutamic acid 
OH
O
NH2
OH O  
Tapia et al., 2007 
Catechol 
OH
OH
 
Faruq, 1994 
Hydroquinone OHOH
 
Faruq, 1994 
Elemicin 
O
OO
 
Faruq, 1994 
Cymbopogonol OH
 
Avoseh et al., 2015 
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Table I.4. Non-volatile compounds identified in Cymbopogon citratus. 
Compounds Identified Structure Reference 
Cymbopogone O
 
Avoseh et al., 2015 
-Sitosterol 
OH
 
Negrelle and Gomes, 
2007 
 
4. Anti-inflammatory properties 
The anti-inflammatory activity is often referred to C. citratus in 
ethnopharmacological studies. Despite this fact, has not been carried out much 
work with extracts, both in vitro and in vivo. In addition, results are often 
contradictory, eventually due to the complexity of the mechanisms involved in the 
inflammatory response, and also to the methodological approaches to assess this 
activity. 
In vitro studies usually evaluate the activity on the production of various 
mediators of inflammation in cell lines. Typically, it is determined the ability of 
the extracts to capture the radical nitric oxide (NO•) released by the cells 
stimulated with an inflammatory agent. An infusion of C. citratus inhibited NO• 
radical produced by RAW 264.7 macrophages activated with lipopolyssacharide 
(LPS), even though to a lesser extent than green tea (Tsai et al., 2007).  
The action on the production of pro-inflammatory and anti-inflammatory 
cytokines by cells of the immune system is often also studied. A 70% methanolic 
extract of C. citratus applied in BALB/c mouse macrophages inhibited the 
production of pro-inflammatory IL-1β and induced the production of anti-
inflammatory IL-6 cytokines. The essential oil also had the same effect on the 
production of these cytokines (Sforcin et al., 2009). Another recent work 
demonstrated the capacity of a lemongrass 50% ethanol extract to suppress some 
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pro-inflammatory mediators in LPS-stimulated murine alveolar macrophages 
(Tiwari et al., 2010). A lemongrass decoction has been reported as having a 
beneficial effect in ameliorating murine spontaneous ileitis, by decreasing 
lymphocyte recruitment to the inflamed intestine (Watanabe et al., 2010). 
Recently, a work has been published, reporting the inhibition of IL-1 production 
by a methanolic extract from C. citratus in LPS-induced human peripheral blood 
mononuclear cells (Salim et al., 2014).  
The infusion of C. citratus continues to be the most studied polar extract. It 
has been described to have an anti-inflammatory effect on LPS-stimulated 
dendritic cells (FSDC), and this activity is mainly attributed to its polyphenols, 
mono- and polymeric flavonoids, luteolin glycosides and condensed tannins, 
respectively. The same study proved that lemongrass infusion was able to scavenge 
NO and inhibit iNOS expression in vitro (Figueirinha et al., 2010). Moreover, the 
same extract was used in RAW 264.7 macrophages, and demonstrated inhibition 
on iNOS expression, NO production and various LPS-induced pathways, including 
p38 mitogen-activated protein kinase (MAPK), c-jun NH2-terminal kinase 
(JNK)1/2 and the transcription nuclear factor (NF)-κB activation; and also the 
PGE2 production (Francisco et al., 2011). Another aqueous extract 
(hydrodistillation water, a waste obtained from essential oil extraction) was also 
investigated and its phenolic composition was found to be similar to the infusion. 
Curiously, this hydrodistillation aqueous extract was able to inhibit the NO 
production in LPS-induced RAW 264.7 macrophages as well. Therefore, we may 
speculate that this kind of anti-inflammatory activity is tightly linked to the nature 
of the phenolic compounds present in the plant (Tavares et al., 2015). 
In in vivo studies, the anti-inflammatory activity is typically tested in mice, 
in which the inflammation is induced. The results are then evaluated by 
observation of macroscopic signals, but certain inflammatory markers (e.g. 
cytokines from immune cells) can also be quantified. The very first study reporting 
the anti-inflammatory activity of a lemongrass polar extract was achieved using a 
decoction, orally administrated to rats, 5h after the inflammatory stimulus by 
carrageenan. The extract exhibited an oedema reduction of 20% (Carbajal et al., 
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1989). In another in vivo study for anti-inflammatory activity evaluation in mice, 
using the induced granuloma model, it was demonstrated that a 30% ethanol 
extract, administered orally, showed no anti-inflammatory activity (Rodríguez et 
al., 1996). However, the oral administration of a decoction during two weeks to 
mice with chronic intestinal inflammation, lead to an improvement of colitis and 
reverted the weight loss. In addition to the improvements in histological 
examination, there was a smaller amount of T lymphocytes in the mucosa and an 
inhibition of the expression of integrin β7, which is responsible for the migration of 
leukocytes to the site of inflammation (Watanabe et al., 2008). Another study 
showed that oral administration of a hexane extract reduced the 
leukocytes/eosinophils in Bagg Albino mice (BAL), the eosinophil peroxidase 
activity in BAL, the infiltration of leukocytes in lung tissue, the production of 
mucus in the respiratory tract, the level of IL-4 in BAL and the nuclear expression 
of NF-κB (Santos et al., 2015). A recent work suggests that lemongrass possess 
biologically active compounds with antipyretic, anti-inflammatory and 
antinociceptive activities, useful in the symptomatic treatment of malaria fever 
(Tarkang et al., 2015). 
C. citratus extracts are also used in the treatment of gastro-intestinal 
disorders. The diversity of symptoms for which it is indicated in traditional 
medicine suggests that the use of this plant is rather complex, either in the 
aetiology or in the likely mechanisms of action. However, in vivo or in vitro studies 
in the literature are very scarce. In the light of the studies in this field, the action of 
C. citratus on the digestive tract may be in part related to the antimicrobial 
activity against Helicobacter pylori, one of the triggering agents of gastric ulcers 
(Bergonzelli et al., 2003; Ohno et al., 2003) or its local anti-inflammatory action 
(Watanabe et al., 2008). Regarding the adverse effects, it was found that infusion 
administration, in mice, from twenty to one hundred times more concentrated 
than preparations for human consumption, did not cause any gastric alterations 
when administered orally, but did so intraperitoneally, in which it was observed a 
reduction of the intestinal transit (Leite et al., 1986). 
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In summary, the anti-inflammatory activity studies using extracts from C. 
citratus are scarce and have contradictory results. This may be due to several 
factors such as the composition of the extracts, plant origin or even the diverse 
inflammation models. 
 
5. Toxicity 
With regard to in vivo studies, the literature is scarce and mostly oriented 
towards the essential oil. The toxicity of C. citratus hydroalcoholic extracts was 
evaluated in vivo, using albino rats. It was obtained a LD50 value of 460 mg/kg 
(Parra et al., 2001). On the other hand, using an infusion obtained from dried 
leaves, a dose about 20 times higher than normally used, administered orally for a 
period of 2 months to one group of rats which also included healthy pregnant 
females did not show any toxic effects (Formigoni et al., 1986). 
Clinical studies in humans involving the use of extracts are even scarcer. An 
infusion was administered orally for 2 weeks, in healthy volunteers, and after an 
evaluation of different blood and urine parameters was carried out. Only a slight 
increase was observed in direct bilirubin and amylase in some volunteers, without 
any clinic manifestation. However, these results do not assign any effect by 
administration directly of the infusion (Leite et al., 1986). 
There are also reports on the occurrence of dermatitis caused by contact 
with dry leaves of C. citratus, and this effect is usually attributed the constituents 
of the essential oil (Ross, 2010). In fact, citral, even diluted at 50%, can cause 
erythema when placed on the skin. In general, it should be avoided the contact of 
aldehydes with the mucous membranes (Buckle, 2001). 
 
 
 
 
CHAPTER I | INTRODUCTION 
 
23 
 
B. Phenolic Compounds 
1. Biosynthesis 
All plant constituents derive from the metabolism of carbohydrates 
synthesized during photosynthesis from CO2 and H2O. In the case of phenolic 
compounds, their synthesis takes place essentially in two pathways: shikimic acid 
and malonate (Vermerris and Nicholson, 2006) (Figure I.3). 
The shikimate pathway, common in plants and microorganisms, consists in 
the synthesis of 3-dehydroshikimic acid from the glycolysis of 
phosphoenolpyruvate and from erythrose 4-phosphate which comes from the 
pentose phosphate pathway. The 3-dehydroshikimic acid is then transformed into 
shikimic acid, which may also be converted into -glucagon, which in turn is 
converted into penta-O-galloylglucose, a key intermediate in the synthesis of 
gallotannins and ellagitannins (Niemetz and Gross, 2005). On the other hand, 
shikimic acid can lead to the synthesis of chorismate thus participates in the 
pathway of aromatic amino acids, like tryptophan, phenylalanine and tyrosine 
(Vermerris and Nicholson, 2006). Phenylalanine formed by the shikimate pathway 
originates another important biosynthetic pathway of phenolic compounds, 
specifically phenolic acids and flavonoids and derivatives: the phenylpropanoids 
pathway (Crozier et al., 2006; Grotewold, 2008; Vermerris and Nicholson, 2006). 
The phenylpropanoids pathway (Figure I.4) begins with phenylalanine 
deamination catalysed by the enzyme phenylalanine ammonia lyase (PAL), 
producing the cinnamic acid.  
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Figure I.3. Shikimate and malonate pathways (adapted from Vermerris and 
Nicholson, 2006). 
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Figure I.4. Phenylpropanoids pathway (PAL: phenylalanine ammonia lyase; C4H: 
cinnamate-4-hydroxylase; 4CL: 4-coumaroyl-CoA ligase; 2HAB: 2-hydroxylase 
benzoic acid) (adapted from Vermerris and Nicholson, 2006). 
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This is further hydroxylated in the 4 position by cinnamate-4-hydroxylase 
(C4H) to form p-coumaric acid. The complex 4-coumaroyl-CoA ligase (C4L) 
catalyses the conversion of p-coumaric acid and coenzyme A to coumaroyl-CoA 
and three molecules of malonyl-CoA (Ferrer et al., 2008). Alternatively, the 
cinnamic acid can also be metabolized to benzoic acid and then salicylic acid, the 
latter reaction being catalysed by the 2-hydroxylase benzoic acid (2HBA) 
(Vermerris and Nicholson, 2006). 
The p-coumaric acid, through a number of hydroxylation and methylation 
reactions may also give rise to caffeic, ferulic, 5-hydroxyferulic and synaptic acids 
(Vermerris and Nicholson, 2006). The ferulic and synaptic acids, together with the 
p-coumaroyl-CoA are the precursors of lignans and lignins (Ferrer et al., 2008). 
The flavonoid biosynthesis is catalysed by the enzyme chalcone synthase 
(CHS), and consists in the condensation of thioesters of p-coumaroyl-CoA with 
three units of malonyl-CoA, forming a chalcone. This, by intramolecular 
cyclization gives a flavanone, naringenin, a reversible reaction catalysed by 
chalcone isomerase (CHI) (Martens and Mithöfer, 2005) (Figure I.5). 
The oxidation of flavanones to di-hydroflavonols is catalysed by the enzyme 
flavanone 3-hydroxylase (F3H) while flavonol synthase (FLS) catalyses the 
oxidation of di-hydroflavonols to form flavonols (Vermerris and Nicholson, 2006). 
The enzyme di-hydroflavonol reductase (DFR) catalyses the reduction of di-
hydroflavonols to flavan-3,4-diols (leucoanthocyanidins), while the oxidation of 
cis-leucoanthocyanidin, catalysed by the enzyme leucoanthocyanidin oxidase 
(LDOX) or anthocyanidin synthase (ANS) gives way to anthocyanidins. These, in 
turn, are the precursor of anthocyanins by the action of 3-O-glycosyltransferases. 
The DFR is also involved in the formation of proanthocyanidins by the action of 
leucoanthocyanidin reductase (LAR), which catalyses the formation of catechins, 
that, by condensation, give rise to proanthocyanidins (Xie and Dixon, 2005). 
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Figure I.5. Flavonoids biosynthesis (CHS: chalcone synthase; CHI: chalcone 
isomerase; F3H: flavanone 3-hydroxylase; FLS: flavonol synthase; LDOX: 
leucoanthocyanidin oxidase; FS1: flavone synthase 1; FS2: flavone synthase 2; 
DFR: di-hydroflavonol reductase; LAR: leucoanthocyanidin reductase) (adapted 
from Crozier et al., 2006). 
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The synthesis of flavones is characterized by a great diversity of 
mechanisms. In one case, the flavone synthase 1 (FS1) removes two electrons of 
the carbons 2 and 3 of flavanone to form a flavone. Another possible mechanism 
depends on a mono-oxygenase, an enzyme from cytochrome P450, flavone 
synthase 2 (FS2), which catalyses the formation of an hypothetical 2-
hydroxylflavanone, that is subsequently dehydrated to flavone (Martens and 
Mithöfer, 2005). The heme-oxygenase cytochrome P450 enzymes catalyse the 
oxidation of A and B rings and the unsaturation in the flavanones. The 
hydroxylation pattern of the B ring depends on the phenylpropanoid precursor and 
hydroxylases belonging to the cytochrome P450. The most common enzymes 
involved in hydroxylation of the B ring are flavone 3'-hydroxylase (F3’H), which 
leads to hydroxylation in the 3’ carbon and flavone 3’,5’-hydroxylase (F3’5’H) 
which results in hydroxylation at carbons 3’ and 5’. These enzymes hydroxylate 
many flavonoids such as di-hydrokaempferol, kaempferol and apigenin (Ferrer et 
al., 2008). Other frequent substitutions in flavonoids are the methylation catalysed 
by O-methyltransferases (OMTS) and glycosylations. The glycosylated forms of 
flavonoids are the most commonly found in nature. This type of substitution 
usually occurs through oxygen atoms incorporated in hydroxyl groups, but also 
through carbon atoms. Reactions are catalysed by glycosyltransferases (GTs) that 
use activated sugars with nucleotides as donor substrates. A wide variety of sugars 
can be combined: mono-, di-, tri-glycosides, either heterogeneous or homogeneous 
(Vogt and Jones, 2000). The acylations with aliphatic and aromatic acids, 
especially acetic, malonic, p-coumaric and ferulic also constitute one of the final 
steps in the biosynthesis, being catalysed by acyltransferases and requiring acyl-
CoA as the acyl donor (Ferrer et al., 2008). 
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2. Classification and natural sources 
Phenolic compounds are a group of chemical substances, many of them 
present in, named phytochemicals, which comprise a large variety of structures. It 
is difficult to describe them chemically, however, hydroxylated aromatic rings 
(phenol rings) are structural units present in all phenolic compounds. Therefore, 
they are divided into several classes according to the number of phenol rings that 
they contain and to the structural elements binding these rings each other. The 
main classes of phenols are: phenol derivatives or simple phenols, phenolic acids, 
stilbenes, lignans, flavonoids, tannins, coumarins and anthraquinones (Figure I.6). 
 
2.1 Simple phenols 
Phenol derivatives are the most abundant phenols found in nature (Figure 
I.7). They are usually pyrogallol and phloroglucinol derivatives, but there are also 
di-hydroxylated derivatives, such as catechol, resorcinol and hydroquinone 
(Vermerris and Nicholson, 2006).  The antioxidant activity of simple phenols 
depends on the position of the hydroxyl groups. Studies showed that the catechol 
group is the one that has greater activity, followed by hydroquinone and resorcinol, 
which in turn, is much greater to that of phenol (carbolic acid) (Kancheva, 2009). 
Simple phenols also have anti-inflammatory activity, in particular by their 
action in the arachidonic acid cascade. The hydroxyl groups in ortho or para 
positions stimulate the synthesis of prostaglandin E2 (PGE2) and simultaneously 
inhibit the synthesis of leukotriene B4 (LTB4) (Alanko et al., 1993). 
 
2.2 Phenolic acids and derivatives 
Characterized by a phenol ring and a carboxylic function, phenolic acids can 
be subdivided in two classes: benzoic acid derivatives and cinnamic acid derivatives 
(C6-C1 and C6-C3 skeletons, respectively) (Figure I.8). The benzoic acids, such as 
gallic acid and protocatechuic acid (PCA), are found in very few plants, like 
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blackberries, raspberries and tea (Shahidi and Naczk, 1996). Although the very 
low concentration of PCA in plants, Vitaglione and co-workers (2007) verified that 
the PCA concentration increases in the serum of human healthy volunteers with an 
anthocyanin-rich diet. So, PCA could be considered the major anthocyanin 
metabolite in vivo.  
Hydroxycinnamic acids are trans-3-phenyl-2-propenoic acids differing in 
their ring substitution and that comprises coumaric, caffeic and ferulic acids and 
their derivatives. Generally, they appear in glycoside forms or as quinic, shikimic or 
tartaric esters. For example, caffeic and quinic acids could combine to form 
chlorogenic acid, which exists in artichoke, corn, wheat, rice and oat (Barnes et al., 
2007; Courts and Williamson, 2013). Ferulic acid is present in cereal grains and, 
in opposition to caffeic acid, is a less abundant phenolic acid (D’Archivio et al., 
2007). 
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Figure I.6. Main classes of phenolic compounds. 
CHAPTER I | INTRODUCTION 
 
32 
 
 
Figure I.7. Simple phenols (examples). 
 
 
Figure I.8. Phenolic acids (examples). 
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2.3 Stilbenoids 
Structurally, stilbenoids are hydrocarbons with a trans-ethene double bond 
substituted with a phenyl group on both carbon atoms of the double bond (Figure 
I.9). Stilbenes exist in low percentage in plants. Resveratrol and its isomer trans-
resveratrol, which are the most abundant molecules of this class, are mainly found 
in grapes and wine (Zhang et al., 2006), but also in Reynoutria japonica and 
Polygonatum multiflorum and in the heartwood of vascular plants such as Cassia 
garrettiana (Kimura et al., 1995). 
 
             Figure I.9. Stilbenoids (examples). 
 
2.4 Lignans 
Lignans possess a dibenzylbutane skeleton derived from phenylalanine via 
dimerization of substituted cinnamic alcohols (Figure I.10). Lignans are mostly 
found in their free form and the main sources of these molecules are Arctium 
lappa, Linum spp., Secale cereale, Triticum spp., Avena sativa and Hordeum 
vulgare (Barnes et al., 2007; D’Archivio et al., 2007). 
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               Figure I.10. Lignans (examples). 
 
2.5 Flavonoids 
Comprising more than 10,000 naturally occurring compounds, flavonoids 
are nearly ubiquitous in the kingdom of plants (in more than 9000 species) 
(Mouradov and Spangenberg, 2014). These molecules have a great structural 
diversity, but are all derived from a common biosynthetic pathway, the 
phenylpropanoid metabolic pathway, which incorporates precursors from both 
shikimic acid and acetate-malonate pathways, leading to the first flavonoid 
produced, the 2-hydroxychalcone. This basic compound serves as the central core 
for all other flavonoids, obtained by subsequent ring closure. The flavonoids 
derived from 2-hydroxychalcone are characterized by a common structure of two 
aromatic rings (A and B) bonded to each other by 3 carbon atoms and 1 oxygen 
atom to form a third 6-member heterocyclic ring (C) (Beecher, 2003). Considering 
the oxidation state and the functional group bonded to the C-ring, flavonoids are 
divided into subclasses (Figure I.11). Taking into account the oxidation state, the 
ring structure could be a heterocyclic pyran or a pyrone. The heterocyclic pyrans 
include flavans, flavan-3-ols, flavan-4-ols and flavan-3,4-diols which do not have 
unsaturated bonds on C-ring, or anthocyanidins, with 2 double bonds. The 
pyrones comprise  a carbonyl residue at C4,  with one double bond C2=C3 and a 
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hydroxyl group at C3 (flavonols), one double bond C2=C3 (flavones), without the 
double bond C2=C3 (flavanones), with one double bond C2=C3, but where the 
connection of the B-ring is through the C3 of C-ring instead of C2, as for other 
flavonoids (isoflavones), and the latter discovered neoflavonoids, which have some 
differences from the other C-ring pyrone flavonoids namely, the carbonyl group is 
on C2 instead of C4, the double bond is in C3=C4 and the connection of the B-
ring is through the C4 of C-ring (Gomes et al., 2008). Anthocyanidins like 
cyanidin, malvidin, delphinidin and pelargonidin are present in Rubus spp. 
Vaccinium spp. and Symplocarpus foetidus (Barnes et al., 2007), being responsible 
for their remarkable colour. Flavonols are wide spread in vegetables, cereals, spices 
and herbs. Quercetin, myricetin and kaempferol represent flavonoids significantly 
found in foods. Flavones, like apigenin and luteolin, may be found in vegetables, 
but also in spices and herbs. Flavonols and flavones are also widely spread among 
medicinal plants such as Hypericum spp., Pneumus boldus, Eupatorium 
perfoliatum and Sambucus nigra (Barnes et al., 2007). The most frequent 
flavanones are naringenin and hesperidin, which can be extracted from citrus fruits 
and juices (Manach et al., 2005). In general, flavonoids are also present in grassy 
plants, namely in grasses such as wheat, barley, rye, rice and sugarcane (Courts and 
Williamson, 2013). Finally, isoflavones are generally present in soy beans and 
other vegetables, being genistein and daidzein the most naturally occurring 
isoflavones. 
Within the various classes of flavonoids is common further differentiation, 
due to modifications of the flavonoids nucleus: additional or reduced 
hydroxylation; methylation of hydroxyl groups or of the aromatic core; 
isoprenylation of hydroxyl groups or of the flavonoids nucleus; methylenation of 
ortho-dihydroxyl groups; dimerization to produce biflavonoids and bisulfates; and, 
mainly the glycosylation of hydroxyl groups by hemiacetal bond to produce 
flavonoids O-glycosides or of the flavonoids core producing C-glycosides (Courts 
and Williamson, 2013).  
CHAPTER I | INTRODUCTION 
 
36 
 
C-glycosyl flavonoids are a less well studied sub-class of secondary plant 
metabolites in comparison to their more common and structurally diverse O-
glycosyl relatives. The defining feature and divergent characteristic of their 
formation and subsequent nature is a C-C covalent bond between the aglycone 
flavonoid backbone and a sugar moiety: generally monomer glucose or galactose. 
This linkage is found in plant species, such as C-glycosyl flavonoids at either the 6 
or 8 positions about the carbon backbone A-ring, and differs from O-glycosyl 
examples in the limited number of glycosylation positions, the form and range of 
attached saccharide polymerisation, and critically in the lack of an oxygen 
intermediate required for glycosidic linkage synthesis (Franz and Grün, 1983). 
Another less common sub-class are the O-glycosyl-C-glycosyl flavones, 
characterised by O-glycosylation at the same positions as described for mono-O-
glycosyl flavonoids in addition to C-glycosylation elsewhere on the flavone 
backbone, or O-glycosylation at one of the hydroxyl groups of a C-linked sugar 
moiety. The latter form of O-glycosylation occurs most usually at the 2 or less 
frequently at the 6 carbon of a C-linked hexose sugar (Ferreres et al., 2007). The 
significance of the C-glycosidic linkage to the overall flavonoid structure is higher 
than might be imagined at first in view of the seemingly relatively minor chemical 
divergence from the O-glycosidic linkage.  
The C-glycosidic bond between a sugar moiety and flavonoid carbon 
skeleton largely protects the flavonoid glycoside from the hydrolytic effect of both 
acidic and non-bacterial enzymatic treatments known to readily cleave O-glycosidic 
linkages, leading to fundamental differences in the analysis, degradation, 
pharmacokinetics and bioactivity of those flavonoids possessing a C-glycosyl group 
(Harborne, 1965). 
Most flavonoids do not occur in plants as aglycones, flavonoids O-glycosides 
being the most abundant. The exceptions are the flavan-3-ols like catechin, 
epicatechin and epigallocatechin gallate present in fruits, tea, red wine and cocoa 
products. 
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Figure I.11. Flavonoids (main classes and examples). 
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2.6 Tannins 
Tannins are a group of water-soluble polyphenols with high molecular 
weights (500 to 3000 Da) (Figure I.12). This class of phenolic compounds is 
mainly constituted by hydrolysable and condensed tannins, with structural units 
corresponding to phenolic acids or flavans, respectively.  
Hydrolysable tannins are formed by more or less complex conjugations of 
gallic acid (gallotannins) or ellagic acid (ellagitannins) or both. On the other hand, 
condensed tannins, also called proanthocyanidins, are built with flavanic units. 
They may be classified according to different criteria: the nature of the basic unit 
or the type of interflavanic linkage. The flavans that may constitute the condensed 
tannins are diverse: simple flavans (hydroxyl group is absent in the C-ring), flavan-
3-ols, flavan-4-ols and flavan-3,4-diols. In what concerns the interflavanic bond, 
proanthocyanidins may be grouped as A-, or B-type. B-type proanthocyanidins are 
characterized by a singly linked flavanyl units, usually between C4 of the chain-
extension unit and C6 or C8 of the chain-terminating moiety. In contrast, 
proanthocyanidins of the A-type possess an unusual second ether linkage to C2 of 
the terminating-unit. This feature introduces a high degree of conformational 
stability at the interflavanyl bonding axes of dimeric analogues.  
Mostly found in complexes with alkaloids, polysaccharides and proteins, 
tannins are generally present in plant barks and also in rhubarb (Rheum 
rhabarbarum) and cereals (Rangkadilok et al., 2007). 
 
2.7 Coumarins 
Coumarins are lactones obtained by cyclization of hydroxycinnamic acids, 
belonging to the phenolic compounds group with the basic skeleton of C6-C3 
(Figure I.13). Coumarins are present in plants in free and glycosylated forms. 
In general, coumarins are characterized by high chemical diversity, mainly 
differing in the degree of oxygenation of their benzopyrone moiety. The major 
coumarins include simple hydroxylcoumarins (e.g. esculetin and scopoletin), 
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furocoumarins and isofurocoumarins (e.g. psoralen and isopsoralen), 
pyranocoumarins (e.g. xanthyletin, xanthoxyletin, seselin and praeuptorin A), 
bicoumarins, dihydro-isocoumarins (e.g. bergenin) and others (e.g. wedelolactone). 
Herbaceous plants, tonka beans (Dipteryx odorata), vanilla grass (Hierochloe 
odorata) and sweet woodruff (Galium odoratum) are some sources of coumarins 
(Huang et al., 2010). 
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Figure I.12. Tannins (main classes and examples). 
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        Figure I.13. Coumarins (examples). 
 
2.8 Anthraquinones 
Also known as hydroxyanthracenic compounds, anthraquinones are a group 
of colourful dyes common in plants, being very unstable and existing not only in 
several oxidation states but also bonded to sugars, mainly glucose and rhamnose. 
The most abundant anthraquinones are chrysophanol, emodins, aloins, rheins and 
senidins (Figure I.14) (Vermerris and Nicholson, 2006). The reduced forms of 
anthraquinones (anthrones) may also dimerize to form dianthrones and these 
dimmers suit as molecular skeletons to synthesize naftodianthrones (e.g. hypericin 
from Hypericum perforatum). Generally, anthraquinones can be found in distinct 
plant families such as Polygonaceae, Fabaceae, Asphodelaceae and Rhamnaceae, 
among others (Vermerris and Nicholson, 2006). 
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       Figure I.14. Anthraquinones (examples). 
 
3. In vivo anti-inflammatory properties  
A lot of in vitro studies evidence the anti-inflammatory properties and 
mechanisms of action of phenolic compounds, however less in vivo studies have 
been published (Gonzalez-Paramas et al., 2011). In this review, some of the most 
representative compounds are referred (Table I.5). 
Different animal models and different routes of administration have been 
used for in vivo studies; consequently it is difficult to establish structure-activity 
relationships. Nonetheless, some studies have shown that C2-C3 double bound is 
essential for in vivo activity of flavonoids. Additionally, their potency is also 
related to the pattern and number of hydroxylation(s) on the A/B-ring (Pelzer et 
al., 1998), 5, 7-hydroxylation on the A-ring and 3’,4’-di-hydroxylation on the B-
ring, which is the most favourable (Gonzales et al., 2015). 
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Table I.5. In vivo anti-inflammatory properties of phenolic compounds (cont.). 
 
 
Phenolic 
Compounds 
Anti-inflammatory 
activity* 
In vivo model 
Route of 
administration 
Reference 
Phenolic Acids and Derivatives 
Verbascoside 
Colon damage, 
mediated by PPARα 
Dinitrobenzene sulfonic 
acid-induced 
experimental colitis 
Oral 
Esposito et 
al., 2010 
Curcumin 
Ear oedema 
TPA-induced ear 
oedema in mice 
- 
Huang et al., 
1991 
NF-κB binding 
activity 
Streptozotocin-induced 
diabetic rats 
Oral 
Kowluru and 
Kanwar, 
2007 
PPAR-γ is activated 
by induction of 
protein expression 
TNBS-induced colitis 
in rat 
Intraperitoneal 
injection 
Zhang et al., 
2006 
Colitis symptoms 
TNBS-induced colitis 
in mice 
Oral 
Camacho-
Barquero et 
al., 2007 
p38 MAPK activation 
NO production and 
iNOS expression 
iNOS mRNA levels in 
liver 
LPS-injected mice Oral Chan, 1995 
COX-2 expression TNBS-induced colitis 
in mice 
Oral 
Camacho-
Barquero et 
al., 2007 TNF-α levels 
IL-1β levels 
Streptozotocin-induced 
diabetic rats 
Oral 
Kowluru and 
Kanwar, 
2007 
Inflammatory 
responses in 
pancreatic beta-cells  
Streptozotocin-induced 
diabetic rats 
Intragastric 
Rashid and 
Sil, 2015 
Activates Nrf2 
NF-κB pathway 
Male C57BL/6 mice Intragastric 
Zeng et al., 
2015 
Stilbenes 
Resveratrol 
Endotoxemia 
symptoms 
LPS-injected mice 
Intraperitoneal 
injection 
Sebai et al., 
2009  
Plasma NO 
Colonic injury 
TNBS-induced colitis 
in rats 
Oral 
Martín et al., 
2004 
COX-2 expression and 
PGD2 levels 
IL-1β levels 
Atherosclerotic lesions 
ICAM-1 and VCAM-1 
expression 
Apo E-deficient (apo E-
/-) mice (Atherosclerosis 
model) 
Oral 
Do et al., 
2008 
Inflammasome 
activation 
Hypercholesterolemic 
rats 
Oral 
Deng et al., 
2015 
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Table I.5. In vivo anti-inflammatory properties of phenolic compounds (cont.). 
Phenolic 
Compounds 
Anti-inflammatory 
activity* 
In vivo model 
Route of 
administration 
Reference 
Flavonoids 
Apigenin 
Serum IgE levels Ovalbumin-sensitized 
mice 
Oral 
Yano et al., 
2007 Serum IL-4 levels 
Oxidative damage 
inflammatory 
responses 
Male CBA/CaJ mice 
Intraperitoneal 
injection 
Rithidech et 
al., 2012 
IL-6, IL-8, and ICAM-
1 expression 
Female BALB/c mice 
Intraperitoneal 
injection 
Wang et al., 
2012 
Severity of 
experimental 
autoimmune 
encephalomyelitis 
C57BL/6 and SJL/J 
mice 
Intraperitoneal 
injection 
Ginwala et 
al., 2015 
Luteolin 
Lethal endotoxin 
shock 
Leukocyte infiltration 
in the liver LPS-induced lethal 
toxicity in mice 
Intraperitoneal 
injection 
Kotanidou 
et al., 2002 
Serum TNF-α levels 
ICAM-1 expression in 
the liver 
Alveolar wall 
Thickness 
Oedema 
Inflammatory cell 
infiltrates 
Blood vessels damage 
LPS-induced mouse 
endotoxin 
shock model 
Intraperitoneal 
injection 
Chen et al., 
2014 
TNF-α-induced 
vascular inflammation 
C57BL/6 mice 
Intraperitoneal 
injection 
Jia et al., 
2015 
Clinical symptoms in 
DSS-induced colitis 
Female C57BL/6 CrSlc 
mice 
Intragastric  
Nishitani et 
al., 2013 
Isoorientin 
MPO activity 
Carrageenan-induced 
mice with pleurisy 
Intraperitoneal 
injection 
Zucolotto et 
al., 2009 
Hyperpermeability, 
expression of CAMs, 
and adhesion and 
migration of 
leukocytes 
Male C57BL/6 mice 
Intravenous 
injection 
Lee et al., 
2014 
Chrysin 
Serum IgE levels 
Serum IL-4 levels 
Ovalbumin-sensitized 
mice 
Oral 
Yano et al., 
2007 
Wogonin NO levels in serum 
LPS-treated Balb/c 
mice 
Intravenous 
injection 
Shen et al., 
2002 
Wogonin 
COX-2 protein 
expression and PGE2 
production TPA-treated mice 
Topical 
application in 
dorsal skin 
Park et al., 
2001 
Neutrophil 
infiltration 
Genistein 
Inflammation and 
joint destruction 
(histological analysis) 
Collagen induced 
arthritis in mice 
Subcutaneous 
injection 
Verdrengh 
et al., 2003 
CHAPTER I | INTRODUCTION 
 
45 
 
Table I.5. In vivo anti-inflammatory properties of phenolic compounds (cont.). 
Phenolic 
Compounds 
Anti-inflammatory 
activity* 
In vivo model 
Route of 
administration 
Reference 
Quercetin 
Lethal endotoxic 
shock 
LPS or LPS plus D-
galactosamine treated 
mice 
Intraperitoneal 
injection 
Takahashi 
et al., 2001 
Severity of adjuvant-
induced arthritis 
Chronic rat adjuvant-
induced arthritis 
Oral or intra-
cutaneous 
injection 
Mamani-
Matsuda et 
al., 2006 
Eosinophil number 
Ovalbumin-sensitized 
mice 
Oral 
Rogerio et 
al., 2007 
NO levels in serum 
LPS-treated Balb/c 
mice 
Intravenous 
injection 
Shen et al., 
2002 
COX-2 mRNA and 
PGE2 production Carrageenan-injected 
rats 
- 
Morikawa 
et al., 2003 TNF-α, RANTES, 
MIP-2 protein levels 
Isoquercetin 
COX-2 mRNA levels 
and PGE2 production 
Carrageenan-injected 
rats 
- 
Morikawa 
et al., 2003 
Cytokine production, 
namely TNF-α 
Chemokine 
production: CXCL2 
and CCL5 
Kaempferol 
Tyk2-STAT1/3 
signaling modulation 
Asthmatic mice Oral 
Gong et al., 
2013 
Src kinase activity 
UVB-induced COX-2 
expression 
Female ICR mice Topic 
Lee et al., 
2010 
Acute inflammatory 
and symptoms in 
gastritis and 
pancreatitis 
Male ICR and Balb/c 
mice 
Oral 
Kim et al., 
2015 
Rutin 
Lethal endotoxic 
shock 
LPS or LPS plus D-
galactosamine treated 
mice 
Intraperitoneal 
injection 
Takahashi 
et al., 2001 
Serum TNF-α levels 
NO levels in serum 
LPS-treated Balb/c 
mice 
Intravenous 
injection 
Shen et al., 
2002 
Morin 
Colonic damage 
TNBS-induced colitis 
in mice 
Oral 
Galvez et 
al., 2001 
NOS activity 
LTB4 levels 
IL-1β levels 
Icariin Paw oedema 
Carrageenan-induced 
paw oedema 
Oral 
Liu et al., 
2010 
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*inhibition of indicated events, unless where it is referred.
Table I.5. In vivo anti-inflammatory properties of phenolic compounds. 
Phenolic 
Compounds 
Anti-inflammatory 
activity* 
In vivo model 
Route of 
administration 
Reference 
Epigallocatechin 
gallate 
Polymorphonuclear 
leukocytes infiltration 
TPA-treated mice 
Topical 
application in 
dorsal skin 
Wei and 
Frenkel, 
1993 
Arthritis histological 
scores and  clinical 
symptoms 
Mice injected with 
monoclonal antibodies 
against collagen 
(arthritis model) 
Intraperitoneal 
injection 
Morinobu 
et al., 2008 
Colitis symptoms 
TNBS-induced colitis 
in mice 
Intraperitoneal 
injection 
Abboud et 
al., 2008 
NF-κB activation 
through: 
IκB phosphorylation 
and degradation 
p65 translocation to 
nucleus 
DNA binding 
TPA-treated mouse 
Ischemic-reperfused 
rat myocardium 
Oral and 
intravenous 
injection 
Aneja et al., 
2004; 
Kundu and 
Surh, 2007 
AP-1 activity through: 
c-Jun phosphorylation 
DNA binding 
TNBS-induced colitis 
in mice 
Ischemic-reperfused 
rat myocardium 
Intraperitoneal 
and 
intravenous 
injection 
Abboud et 
al., 2008; 
Aneja et al., 
2004 
Plasma IL-6 levels 
Ischemic-reperfused 
rat myocardium 
Intravenous 
injection 
Aneja et al., 
2004 
Pro-inflammatory 
responses in 
peripheral leukocytes 
Male GK and Wistar 
rats 
Oral 
Uchiyama 
et al., 2013 
Chrysophanol 
NF-κB p65 activation 
Dextran sulfate 
sodium-induced colitis 
in mice 
Oral 
Kim et al., 
2010 
COX-2 protein 
expression 
IL-6 production 
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Structure-activity relationships constitute valuable information to develop 
new anti-inflammatory drugs from natural sources. Accordingly, the correlation 
between structure and biological activity of phenolic compounds, in particular 
flavonoids, has been elucidated in the last years. In Table I.6 it is described the 
correlation between anti-inflammatory properties of flavonoids and the presence of 
specific functional groups. Flavonoids possess anti-inflammatory action in part due 
to their intrinsic antioxidant capacity. The scavenging of oxidizing species by 
flavonoids is related to the presence of the double bond between carbons 2 and 3 
in the C-ring of the flavonoid skeleton (Bonfili et al., 2008). The inhibition of 
nitric oxide (NO) production and enzymes involved in the production of 
prostaglandins (PGs) and leukotrienes (LTs), like phospholipase A2 (PLA2), 5- 
and 12-lipooxygenases (LOXs), is also dependent on double bond between C2 and 
C3 (Kim et al., 2004). It was demonstrated that flavones with this double bond 
were more potent than homologous flavanones, which have a single bond between 
C2 and C3 (Kim et al., 2004). It was also demonstrated that the presence of a C2-
C3 double bond in the C-ring is required for optimal inhibition of tumor necrosis 
factor (TNF)--induced intercellular adhesion molecule (ICAM)-1 expression by 
the luteolin (Benavente-García and Castillo, 2008). 
The hydroxylation of A-ring of flavonoids, in particular 5- and 7-
hydroxylation(s) is important in antioxidant capacity (Bonfili et al., 2008), 
inhibition of NO production (Kim et al., 1999, 2004) and cell adhesion molecules 
expression, such as ICAM-1 (Gerritsen et al., 1995; Suh et al., 2006). Furthermore, 
the presence of hydroxyl group at position 3 of the C-ring slightly blocks the 
inhibition of ICAM-1 expression by flavonoids (Suh et al., 2006). The inhibition 
of TNF- production seems to require a 5,7-hydroxyflavone structure, which is 
common to apigenin and luteolin (Ueda et al., 2004). Additionally, the presence of 
8-methoxyl group in the A-ring affected the inhibition of NO production favorably 
(Kim et al., 1999). 
The flavonoids bioavailability is correlated with their structure. In fact, the 
number of hydroxyl groups affects the affinity of flavonoids for the cellular 
membranes, influencing their structure, fluidity, permeability and the intestinal 
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absorption (Bonfili et al., 2008). The potency of anti-inflammatory activity of 
flavonoids in vivo depends on the patterns and number of hydroxyl groups on the 
B-ring. For example, 3',4'-dihydroxyl (catechol type) or 3',4'-hydroxyl/methoxyl 
(guaiacol type) groups were important for inhibiting granulomatous inflammation 
(Kim et al., 2004). The 4´-OH substitution in the B-ring increases the potency of 
flavonoids to inhibit lipopolysaccharide (LPS)-induced NO production and is 
important in ICAM-1 expression inhibitory properties of flavonoids (Benavente-
García and Castillo, 2008). Finally, TNF- inhibitory activity is promoted by the 
existence of hydroxyl group in the C3’ and C4’ (B-ring), and the absence of these 
groups may reverse the flavonoids action (Ueda et al., 2004). The presence of a 
carbonyl function at position 4 is required for the optimal inhibition of TNF--
induced ICAM-1 expression, such as it was shown for luteolin (Benavente-García 
and Castillo, 2008).  
Glycosylation also has an important role in biological action of flavonoids. 
For example, flavonoid aglycones are more potent than the corresponding 
glycosides (diosmetin vs diosmin) (Benavente-García and Castillo, 2008; Gerritsen 
et al., 1995). The flavonoid glycosides may not penetrate the cell membrane due to 
their hydrophilicity, or there might be steric impediment due to their large glycosyl 
residues (Kim et al., 1999). However, the glucoside acetylation may help in the 
availability of the compounds to suppress TNF- expression (Shie et al., 2010). 
Finally, the prenylated flavonoids that inhibit cyclooxygenase (COX)-2 activity all 
have a C3 isoprene residue in their structure (Kim et al., 2004). 
The inhibition of the proteasome activity by flavonoids is strictly correlated 
with the number of hydroxyl groups on the B-ring and their methylation reduces 
this activity (Bonfili et al., 2008; Wan et al., 2005). It is also important to note 
that C4 could be a site of nucleophilic attack by the hydroxyl group of N-terminal 
threonine of proteasome subunit and that C3 hydroxylation may modify the 
ability of flavonoids to inhibit the proteasome (Chen et al., 2005). 
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Table I.6. Anti-inflammatory structure-activity relationships of flavonoids. 
*inhibition of indicated enzymes and/or inflammatory mediators. 
 
4. In vivo bioavailability 
Phenolic compounds are currently receiving much attention due to their 
beneficial health effects related to their antioxidant (Xiao et al., 2013), anti-
inflammatory (Nichols and Katiyar, 2010), cardioprotective (Khurana et al., 
2013), cancer chemopreventive (Andrae-Marobela et al., 2013), and 
neuroprotective properties (Albarracin et al., 2012). Consequently, polyphenols 
can be considered healthy compounds, and claim to have health-promoting or 
Key 
functional 
group 
Structure 
Anti-
inflammatory 
activity* 
Reference 
C2-C3 
double 
bond 
O
 
NO production 
PLA2 activity 
5- and 12-LOXs 
activity 
ICAM-1 
expression 
Benavente-García and Castillo, 
2008; Bonfili et al., 2008; Kim et al., 
2004 
5,7-
dihydroxyl 
O
OH
OH
 
NO production 
TNF- 
production 
ICAM-1 
expression 
Bonfili et al., 2008; Chen et al., 
2004; Gerritsen et al., 1995; Kim et 
al., 1999, 2004; Ueda et al., 2004 
3’,4’-
dihydroxyl O
OH
OH
 
Proteasome 
activity 
Granulomatous 
inflammation 
TNF- 
production 
ICAM-1 
expression 
Benavente-García and Castillo, 
2008; Bonfili et al., 2008; Kim et al., 
2004; Shie et al., 2010; Ueda et al., 
2004 
4-carbonyl 
O
O  
Proteasome 
activity 
ICAM-1 
expression 
Benavente-García and Castillo, 
2008; Chen et al., 2005 
CHAPTER I | INTRODUCTION 
 
50 
 
disease-preventing properties. 
Significant advances have been achieved during the last decade, concerning 
the metabolism of polyphenols in vitro, but scarce data has been presented about 
what really happens in a completely different environment: the human body 
(Tarko et al., 2013). A purposed scheme for digestive metabolism of polyphenols 
in humans is depicted in Figure I.15. 
Bioavailability differs greatly from one polyphenol to another, so that the 
most abundant polyphenols are not necessarily those leading to the highest 
concentrations of active metabolites in target tissues. Knowledge of the 
bioavailability and metabolism of the various polyphenols is necessary to evaluate 
their biological activity within target tissues (Maqueda, 2012). However, most of 
the in vitro bioactivities of polyphenols remain uncharted in vivo (Li and 
Hagerman, 2013). Notwithstanding, some studies have reported the 
pharmacokinetics and tissue distribution of phenolics in liver, kidney, lung and 
heart (Wenzel and Somoza, 2005), but the plasma pharmacokinetics and tissue 
distribution of polyphenols and their metabolites have not yet been accounted in a 
satisfying manner (Lin et al., 2012). Although in vivo studies have been performed 
to verify the biological effects of polyphenols, reports of its bioavailability, 
pharmacokinetics and biological fate are few. Also, data indicating the circulating 
concentration, as well as their metabolites after oral administration is needed 
(Coni et al., 2000). 
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Figure I.15. Metabolism of polyphenols in human digestive system. 
 
The kinetics and extent of polyphenol absorption by measuring plasma 
concentrations and/or urinary excretion among adults after the ingestion of a single 
dose of polyphenol provided as pure compound, plant extract or whole 
food/beverage have been investigated (Manach et al., 2005). Such knowledge will 
allow evaluation of polyphenol intake and enable epidemiologic analysis that will 
in turn provide an understanding of the relation between the intake of these 
substances and the risk of development of several diseases. Furthermore, not all 
polyphenols are absorbed with equal efficacy. Some exhibit very low 
bioavailability, e.g. resveratrol (Santos et al., 2011), others show high plasmatic 
peaks, and a significant amount of polyphenols is converted in a wide range of 
metabolites. Polyphenols are metabolized by intestinal and hepatic enzymes and 
by the intestinal microflora (Manach et al., 2004). Many studies have focused on 
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the bioactivity of one specific molecule in aglycone form, frequently administrated 
at supraphysiological doses, whereas the plant extracts and foods contain complex 
and often poorly characterized mixtures with multiple additive or interfering 
activities (Steiner et al., 2008). Furthermore, recent human studies indicate that 
plasma concentrations and urinary excretions of gut microbial metabolites can 
exceed those of host origin, especially for polyphenols that are not easily absorbed 
in the upper gastrointestinal tract and persist untill the colon (van Dorsten et al., 
2010).  
Flavonoid glycosides are a particularly relevant group of polyphenols since 
they represent the majority of the bioactive constituents ingested by humans. 
Deglycosylation has often been referred to as a critical step in the “activation” of 
flavonoids following human consumption (Hollman and Katan, 1998; Walle et al., 
2005). This appears to be generally true for O-glycosylated compounds, because 
buccal, intestinal or colonic enzymatic hydrolysis results in improved 
bioavailability of the resulting aglycone (Hollman and Katan, 1998; Walle et al., 
2005). However, greater resistance of the C-glycosidic linkage to hydrolysis 
dictates that the bioavailability of C-linked flavonoid glycosides is somewhat 
different. Increasing evidence suggests that deglycosylation is not a prerequisite for 
C-glycosyl flavonoid absorption in the small intestine, resulting in the presence of 
the intact glycosyl flavonoid in human urine following oral consumption (Courts 
and Williamson, 2013). Generally, O-glycosylated structures are not detected in 
vivo due to first-pass intestinal and hepatic hydrolysis, presumably catalysed by 
broad-specificity of the β-glucosidases (Day and Williamson, 2007). C-Glycosyl 
flavonoids derivatives may survive to hepatic hydrolysis for reasons outlined 
previously, explaining their seemingly unusual presence in human urine, after oral 
ingesting (Courts and Williamson, 2009; Hasslauer et al., 2010). As such, it is very 
likely that C-glycosylation does not confer diffusive flavonoid absorption per se, 
rather that the C-glycosyl bond of these compounds has greater stability in vivo. 
While the C-glycosidic linkage appears to remain intact in the upper- and mid-
gastrointestinal tract, and no mammalian C-deglycosylating enzyme known with 
specificity toward flavonoid structures exists, increasing evidence suggests that 
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bacteria capable of cleaving the C-glycosidic linkage (putatively via expression of 
C-deglycosylating enzymes) are present in the colon, as outlined in Figure I.16 
(Courts and Williamson, 2013). 
Advances in the understanding of phenolic metabolism have been made 
possible by improvements in the analytical methods used, particularly the use of 
reverse phase HPLC-MS. Whereas most studies up to the late 1990s measured 
total aglycones in plasma and urine, after chemical or enzymatic deconjugation or 
both. Several recent works report the polyphenol conjugate composition of plasma, 
urine, faeces and/or tissues, after the administration of pure polyphenols or 
polyphenol-rich foods and beverages (Kroon et al., 2004). Analysing biological 
samples in the context of bioavailability and pharmacokinetic studies with natural 
compounds, one must be aware that extensive metabolism and biotransformation 
occurs. Different from other chemically active pharmaceutical compounds, 
polyphenols are often subject to metabolism by the intestinal microflora prior to 
absorption. Assessment of unknown metabolites might be achieved by monitoring 
all analytes, which show the plasma concentration time kinetics in studies for 
single dose (Bhattaram et al., 2002). The identification of metabolites is a 
challenge and requires more complex studies taking into account many possible 
influencing factors, such as age, gender, inter-individual bioavailability variation 
and also methodological approaches (Azorín-Ortuño et al., 2010; Maqueda, 2012). 
Studies of the mechanisms of the biological effects of polyphenols on human 
cell lines should use the metabolites produced in vivo (conjugates of the original 
aglycones or gut microbiota metabolites, such as methyl ethers, glucuronides and 
sulfates) and at the concentrations reached in biological fluids and tissues 
(nanomolar range) to provide real biological significance (Tomás-Barberán and 
Andrés-Lacueva, 2012). 
Animal models, as close to humans as monkeys and as simple as the worm 
Caenorhabditis elegans, have been successfully used in polyphenols and health 
research. These have been particularly useful in toxicological and in tissue 
distribution studies, which are essential to understand the metabolites that can be 
active in vivo. The model of C. elegans provides a smart methodology for testing 
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the activity of polyphenols in a simple and repetitive manner that can be very 
useful for screening studies (González-Manzano et al., 2012). 
Most published studies are based on animal models, with the majority using 
rodents and primates. Although polyphenol metabolism has been described in 
humans and several other species, little attention has been given to the interspecies 
differences, which could be crucial in explaining discrepancies in physiologic effects 
of phenols in different animal models compared with humans (Gu et al., 2006).   
Apart from the inherent differences between species, there are many factors that 
may influence in polyphenols’ different metabolic profiles among studies, as like 
administration procedure, sample preparation (Wenzel et al., 2005), extraction 
method (Wenzel et al., 2005), polyphenols vehicles (Azorín-Ortuño et al., 2010), 
dosage (Azorín-Ortuño et al., 2010), animal gender (Cassidy et al., 2006), 
polymorphisms (Miners et al., 2002), circadian variation of enterohepatic 
circulation (Almeida et al., 2009), anesthetic procedure, as well as the analytical 
procedure.   
The anesthetic procedure is important, namely when animal and human 
studies are compared, because animal handling requires anesthesia commonly, 
contrary to studies in humans. Anesthetic drugs can affect important aspects of 
metabolism, such as gastric emptying, induction and or/inhibition of phase I and 
phase II enzymes, intestinal motility and inhibition of intestinal transporters 
(BCRP and MRP) (Azorín-Ortuño et al., 2010). 
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Figure I.16. Metabolism of O- and C-glycosyl flavonoids in humans. 
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4.1 Pharmacokinetics 
Pharmacokinetics is a fundamental scientific discipline that underpins 
applied therapeutics. It provides a mathematical basis to assess the time course of 
drugs and their effects in the body. It enables to quantify the following processes: 
Absorption, distribution, metabolism and excretion (ADME). A variety of 
techniques is available for representing the pharmacokinetics of a drug. The most 
usual is to view the body as consisting of compartments between which drugs move 
and from which elimination occurs. The transfer of drugs between these 
compartments is represented by rate constants. Rate constants may be expressed 
by reactions of zero-order or first-order. Normally, all drugs are described to 
behaviour accordingly to a first-order reaction type. However, a continuous 
increase of the drug administered will change a first-order process to a zero-order 
process, such as occurs in an overdose situation (Dhillon and Gill, 2006). 
Pharmacokinetic models are hypothetical structures that are used to describe 
the fate of a drug in a biological system following its administration. In general, 
there are three kinds of pharmacokinetic models: one-compartimental, two-
compartimental and multicompartimental model. In one-compartimental models, 
following drug administration, the body is assumed as a kinetically homogeneous 
unit. This assumes that the drug achieves instantaneous distribution throughout 
the body and that the drug equilibrates instantaneously between tissues. The two-
compartment model resolves the body into a central compartment and a peripheral 
compartment. Although these compartments have no physiological or anatomical 
meaning, it is assumed that the central compartment comprises tissues that are 
highly perfused such as heart, lungs, kidneys, liver and brain. The peripheral 
compartment comprises less well-perfused tissues such as muscle, fat and skin. A 
two-compartment model assumes that, following drug administration into the 
central compartment, the drug distributes between that compartment and the 
peripheral compartment. However, the drug does not achieve instantaneous 
distribution, i.e. equilibration, between the two compartments. In a 
multicompartimental model the drug distributes into more than one compartment 
and the concentration–time profile shows more than one exponential. Each 
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exponential on the concentration–time profile describes a compartment (Dhillon 
and Gill, 2006). 
After the pharmacokinetic model is set, several useful parameters may be 
calculated: volume of distribution (Vd), maximal concentration (Cmax), time on 
which the concentrarion is maximal (tmax), half-life time (t1/2), clearance (CL), 
observed area under curve (AUC(0t)), area under curve from administration 
extrapolated to infinite time (AUC(0)) and mean residence time (MRT) (Dhillon 
and Gill, 2006).  
The volume of distribution (Vd) of a medication is an abstract parameter 
and is defined as the amount of drug in an organism divided by its plasma 
concentration. After distribution of the drug within the organism, the volume of 
distribution is computed as follows: Vd = m (total amount of drug [mg]) / C (drug 
plasma concentration [mg/L]). This formula can be easily understood if one 
considers that concentration (C) represents the quotient of the mass (m) and the 
volume (V). Only for a few medications, however, does the distribution volume 
correspond to a real physiological space, such as: the plasma volume (0.05 L/kg), 
the extracellular volume (0.2 L/kg) and the body water (0.66 L/kg). This is due on 
the one hand to the accumulation of many medications in various tissues, such as 
the adipose tissue or the bones (producing an increase in the numerator), and on 
the other hand to the avid binding with plasma proteins that prolongs the 
persistence of the agent within the vascular system (producing an increase in the 
denominator). Both are properties resulting from the solubility and the plasma-
protein binding of a medication and which are constant only for one particular 
patient. Interindividual differences depending on the amount of body fat or body 
water must also be taken into consideration (Brüggmann, 2008). The total 
clearance (CL) of a drug consists of the renal clearance and the extra-renal 
clearance. For most medications the latter can be equated with hepatic clearance. 
As a rule one can assume that renal insufficiency only reduces the renal clearance 
and that liver disease only impairs the extra-renal clearance. The renal portion of 
the total clearance results from the so-called renal dose fraction, i.e. from that 
portion of an administered dose that is eliminated unchanged via the kidneys 
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(Brüggmann, 2008). The AUC(0) represents the total drug exposure over time. 
Assuming linear pharmacodynamics with elimination rate constant k, one can 
show that AUC is proportional to the total amount of drug absorbed by the body 
(i.e. the total amount of drug that reaches the blood circulation). This is useful 
when trying to determine whether two formulations of the same dose (for example 
a capsule and a tablet) release the same dose of drug to the body. AUC becomes 
useful for knowing the average concentration over a time interval, AUC/t. Also, 
AUC is referenced when talking about elimination. The amount eliminated by the 
body (mass) = CL (volume / time) x AUC (mass x time / volume) (Lappin et al., 
2006). MRT refers to the time that a drug spends in the body. This is dependent 
on an individual body size, the rate at which the drug will move through and react 
within the person’s body, and the amount of the drug administered. The MRT of a 
drug deviates from the previous equations as it is based on a statistical derivation. 
This still runs off a steady-state volume assumption but then uses the area under a 
distribution curve to find the average drug dose clearance time. The distribution is 
determined by numerical data derived from either urinary or plasma data collected. 
Each drug will have a different residence time based on its chemical composition 
and route of administration. Some of these drug molecules will remain in the 
system for a very short time while others may remain for a lifetime. Since 
individual molecules are hard to trace, groups of molecules are tracked and their 
distribution is plotted to find a mean residence time (Rowland and Tozer, 1995). 
In the last fifteen years, substantial technological advances have been done 
in particle chemistry performance, improving detector design and in optimizing the 
system and data processors for chromatographic techniques. HPLC and GC 
analytical methods to determine polyphenols in different matrices have been 
reported. GC-MS, that is a commonly used technique and a method of choice in 
volatile polyphenols’ analysis by using derivatization of compounds, reveals 
limitations, namely the correct analysis of all possible samples’ compounds, 
including unconjugated fractions, due to its low limit of detection (LOD). 
Recovery yield is low and just a limited group of polyphenols can be analyzed. 
Many HPLC methods have been developed for the determination of polyphenols 
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in biological fluids, either alone or conjugated. Some of these methods were time-
consuming, expensive, or there was no internal standard, being not directly 
applicable. HPLC-UV was optimized for the separation and identification of major 
conjugate metabolites, with robustness to small changes in mobile phase, and being 
selective, precise, accurate robust and was, then, suitable for the quantitative 
determination of total compounds (free and conjugated) in urine samples.  
Moreover, UV detection did not allow the identification of some compounds and 
their conjugates due to fixed wavelength limitation. Hyphenating PDA and/or MS 
detectors to HPLC allowed the attainment of substantially good precision and 
accuracy values (usually higher than 90.0%). Its developing enabled the first 
identification of the entire profile of some polyphenols, without reducing the 
resolution of glucuronides, with an accurate index of exposure and detail of the 
polyphenols and its metabolites and conjugates (Santos et al., 2014). Beyond that, 
it was also possible to reduce time of analysis and ameliorate LOQ and LOD, the 
wide calibration range in comparison to other methods (e.g. GC) and to avoid need 
of enzymatic hydrolysis, simplifying the quantitative and qualitative analysis. It is 
considered to be an appropriate tool for further identification and quantification of 
polyphenols and its metabolites, in human pharmacokinetic studies. HPLC-ESI-
MS method has allowed the identification and quantification of polyphenols in 
biological samples, conferring lowest LOD. Taken together, HPLC-MS, NMR and 
HPLC-PDA analysis allowed to evaluate several polyphenolic compounds in 
plasma and urine and broadened the spectrum of identification and quantification 
of new metabolites. Finally, UPLC has revealed improved sensitivity, being much 
faster (within 5 minutes), requiring a much lower volume of biological sample, as 
well as a simple sample preparation procedure, good recoveries and minor matrix 
effect. Many studies started experiencing separation obstacles with it. This method 
is valuable for human clinical studies because large volume of blood sample is 
usually available in humans, which may be used to concentrate the analytes before 
analysis. 
Another important procedure in pharmacokinetic studies and its further 
analysis is sample preparation. When LODs and LOQs at ng/mL levels are 
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improved, occurs benefit in the resolution of conjugate metabolites. SPE approach 
is always used to gain cleaner samples and allows the LOD to be lowered 10 times, 
but it is time-consuming and is not economic when used to measure a large 
number of plasma samples in pharmacokinetic studies. So, a brand new SPE based 
methodology at a micro scale was developed over the classic solid-phase extraction 
technique. This method has shown a high specificity, a rapid isolation of analytes 
from complex matrices and much shorter analysis time. 
Trying to catalogue analytical methods for polyphenols with the present 
data can be inglorious. A strong suggestion lies on searching the best method for 
each polyphenols group, accordingly to their physical and chemical properties, and 
thus, to enable a close outlook of the most suitable method.   
 
4.1.1. Pharmacokinetic studies in rats 
The rat is still the most popular animal model used by researchers all over 
the world, as a plausible alternative to human studies. Moreover, the 
metabolic/pharmacokinetic approach in clinical studies must always be preceded by 
robust and reliable assays in rats. In recent years, a pronounced development has 
been achieved in the validation of several pharmacokinetic methods in this animal 
model (Table I.7). 
Carando et al. (1998) described the measurement of catechin in human 
plasma. Extraction with acetonitrile was followed by HPLC on a C18 column. 
Hollman and colleagues (1998) developed a method to analyze quercetin in 
human plasma and urine employing acid hydrolysis to liberate the aglycone, 
followed by HPLC on a C18 column and post-column derivatization with AlNO3 to 
generate a fluorescent complex. Variants of this method substituting acid 
hydrolysis for enzymatic (glucuronidase/sulfatase) were later reported (Morrice et 
al., 2000; Ader et al., 2000). Another recent work regarding resveratrol, and also 
emodin, was carried out by Lin and co-workers. In this study, plasma and tissue 
samples were assayed by HPLC-UV before and after hydrolysis with -
glucuronidase and sulfatase (Lin et al., 2012). 
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HPLC appears to be the most widely used method for quantifying plant 
constituents and metabolites. The solid-phase extraction (SPE) approach is always 
used to gain cleaner samples. This allows the LOD to be lowered 10 times, but it is 
time-consuming and is not economical when used to measure a large number of 
plasma samples in pharmacokinetic studies. The HPLC-UV method is a quick, 
precise and reliable method for the analysis of resveratrol in pharmacokinetic 
studies (He et al., 2006). 
Serra et al. presented a UPLC-MS validated method that can be used for 
epicatechin monitoring in vivo. One of the greatest advantages of the UPLC 
method developed is the possibility of quantifying the compound(s) studied at low 
concentrations within 5 minutes. This analysis time is between 2 and 5-times 
shorter than the methods reported in the literature for the analysis of the same 
kind of compounds by HPLC. Additionally, the UPLC system allowed the volume 
of the sample injected to be between 4 and 40 times lower than the other methods 
reported in the literature (Serra et al., 2009).  
An UPLC-MS method was properly validated by Wang and his team for the 
study of taxifolin kinetic behavior in rats. This method was linear over the 
concentration range of 6-6750 ng/mL. Intra- and inter-day precisions were all 
within 8% and accuracy ranged from 92.9% to 105.1%. The LOQ was 6 ng/mL. 
The present method was successfully applied to the estimation of the 
pharmacokinetic parameters of taxifolin following intravenous and oral 
administration to rats (Wang et al., 2009).  
Marti and co-workers (Martí et al., 2010) developed a rapid, simple and 
sensitive method to simultaneously extract and analyze procyanidins and 
anthocyanins, and their metabolites in plasma samples by microelution SPE 
(µSPE) plates and UPLC-ESI-MS, respectively. This extraction methodology allows 
to prepare 96 samples at one time and to increase sample throughput. On the 
other hand, Urpi-Sardà et al. (2009) used 96-well plates with millielution SPE 
(mSPE) to analyze procyanidins in rat plasma after cocoa intake. The main 
difference between these two designs is the capacity of the sorbent in SPE, which 
in the case of mSPE is from 5 to 60 mg and in µSPE plate is only 2 mg.  
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In the analysis of biological samples, such as plasma or serum, the quantity 
of sample available is a critical parameter in most cases. The µSPE plate can be a 
good approach because it allows the rapid isolation of the analytes from complex 
matrices because lower sample volume is loaded into the plate and lower elution 
solvent is necessary to elute the retained analytes. Moreover, in this design, the 
solvent evaporation and reconstitution steps are eliminated, and as a consequence 
the time for sample preparation is significantly reduced.  
In what concers HPLC-MS methodologies, Prasain and co-workers (2004) 
reported a remarkable LOD and a good calibration range, while He and colleagues 
(2006) using SPE technique improved the LOD, being 10 times better than 
previous studies. This method proved to be very precise. The method developed by 
Ma and collaborators (Ma et al., 2006), presented a remarkable calibration range 
and linearity, and it is very precise. Jan and colleagues (2009) reported a method 
with very good linearity, precision and accuracy, while the method from Wang and 
his team (2009) showed a very wide calibration range.  
Serra et al. (2009) introduced the UPLC methodology to improve the 
sensitivity, in addition for being much more rapid and to require a volume of 
biological sample 40 times lower. The type of columns used in this methodology is 
a substantial step forward to the pharmacokinetic studies of all analytes. 
Kapetanovic and co-workers (2011) presented recently a validated method with 
very good precision and accuracy, in a very wide range. Finally, the method 
developed by Lin and colleagues (2012) exhibited very good precision and accuracy 
values, but not so good extraction recoveries.  
Few studies have been performed on the absorption, tissue distribution, 
metabolism and excretion of flavone C-glycosides (Sheng et al., 2014; Xue et al., 
2014). Understanding the biodynamics of flavone C-glycosides after oral 
administration is fundamental to understand the existing structure-activity 
relationship and its potential use as preventive of some diseases. In addition to 
structural and physical-chemical attributes of the original compound, the 
absorption, pharmacokinetics and biotransformation to certain metabolites are 
crucial determinants of biological effects in organisms. However, the current 
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understanding of absorption and metabolism is limited to a small number of 
flavonoids and few studies refer to the metabolism of flavone C-glycosides (Zhang 
et al., 2007). Recently, the pharmacokinetic profile of vitexin glycosides has been 
studied (Ma et al., 2010; Zhang et al., 2010). Intact forms of vitexin O-glucoside 
and O-rhamnoside were detected in plasma, tissues, urine and bile after a single 
oral dose of a crude extract (Ma et al., 2010). This work also showed that 
deconjugation of C-glycosyl flavone is not a prerequisite for its absorption in rats. 
Puerarin, a C-glycosyl flavone, could be rapidly absorbed from the intestine 
without metabolism after oral administration (Prasain et al., 2004). High recovery 
of administered vitexin 4’’-O-glucoside and 2’’-O-rhamnoside in faeces indicated 
that the efficient absorption of these two molecules from the gastro-intestinal tract 
of rats was low. It was reported that vitexin 2’’-O-rhamnoside had limited 
gastrointestinal absorption with an oral bioavailability of about 3.57% (Liang et 
al., 2007). Another work investigated the pharmacokinetic behavior of six 
compounds: three secoiridoid glycosides and three flavonoid C-glycosides (Sheng 
et al., 2014). This study indicated that the bioavailability of the secoiridoid 
glycosides was much higher than that of flavonoid glycosides. The time to reach 
Cmax (Tmax) ranged from 10 to 40 minutes, and the elimination half-life (T1/2) 
ranged from 58.4 to 263.0 minutes. These results demonstrate that both the 
absorption and elimination processes of the six analytes were fast. This work also 
showed that the six analytes are mainly excreted by urine. The amounts of the six 
analytes excreted by bile, urine and faeces were very limited (<5.0%), suggesting 
that the six analytes were mainly excreted as metabolites.  
Two new metabolites (dihydrodaidzein and equol) of a C-glycoside flavone, 
the puerarin, as well as its mono- and dihydroxylated derivatives were investigated, 
using a HPLC-ESI-MS/MS validated method by Prasain et al. (2004). These 
metabolites were detected in both urine and faeces of rats after oral administration. 
However, the persistence of puerarin in the blood and urine as the principal 
metabolic form for the period of 4-72 hours after oral administration suggested 
that puerarin is rapidly absorbed from the intestine without being metabolized.  
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4.1.2. Pharmacokinetic studies in humans 
Human model gives the best approach for drug pharmacokinetic profile 
studies. In the last decade, the number of bioanalytical and pharmacokinetic 
studies with human plasma, blood and urine have been enhanced (Table I.8). This 
assumes the major importance, due to the possibility of the best dose prediction 
and polyphenols’ pharmacokinetic behavior following in vivo administration, in 
relation to other animal species used, and also in in vitro studies, such as in cell 
cultures. Compared with the effects of polyphenols in vitro, the results in vivo, 
although significant, are more limited (Serra et al., 2013). The reasons for this are: 
1) lack of validated in vivo biomarkers; 2) lack of long-term studies; and 3) lack of 
understanding or consideration of bioavailability in the in vitro studies, which are 
subsequently used for the design of in vivo experiments (Manach et al., 2005).  
The bioavailability and, consequently, bioactivity of polyphenols are 
strongly determined by the gut metabotype of each individual and personalized 
screenings, and applications are therefore highly recommended (Bolca et al., 2013; 
Schröder et al., 2013). The composition and metabolic activities of the human 
intestinal flora differs from that of experimental animals (Hirayama and Itoh, 
2005). Animals with human flora-associated (HFA) have been used for studying 
the metabolism of the human intestinal flora. Still, results with HFA animals 
suggest that the role of the human intestinal flora is somewhat different from the 
role of the animal flora in conventional experimental animals (Zeng et al., 2013). 
Analyses of blood, and even less so of plasma, may not be considered as 
representative for the whole organism, as soluble metabolites are bound to be 
enriched in the blood aqueous phase, while less hydrophilic ones or the parent 
compounds may associate more readily with other tissues, depending on 
characteristics such as lipid content and accessibility (Biasutto et al., 2010). In 
many cases, the assessment of levels in tissues has relied on the enzymatic 
conversion of conjugates to the aglycone before quantification. 
The concentrations of catechin, quercetin and resveratrol in samples such as 
blood serum, plasma, urine and whole blood have been measured following their 
oral and intragastric administration to humans. These compounds and their 
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conjugates were analyzed by GC analysis followed by MS detection employing two 
target ions and one qualifier ion for each compound. Excellent resolution and 
linearity was obtained for all three polyphenols in all biological fluids sampled 
(Soleas et al., 2001).  
In a study about curcumin, Ireson and colleagues developed an HPLC-MS 
method to characterize its metabolites ex vivo. The major metabolites in 
suspensions of human hepatocytes were identified as hexahydrocurcumin and 
hexahydrocurcuminol (Ireson et al., 2001). 
In another study with volunteers, they were fed with a diet containing 
catechin, catechin, 3'-O-methylcatechin, and metabolites of microbial origin were 
identified in urine. Catechin and its 3'-O-methylated derivative formed in the small 
intestine and liver were the most abundant compounds excreted and accounted for 
25.7% of the catechin ingested. This finding agrees with recoveries of 20.0–40.0% 
reported in previous studies and confirms the good absorption level of catechin by 
the small intestine. On the other hand, aromatic acids formed from catechin 
accounted for 10.6% of the catechin ingested (Gonthier et al., 2003).  
A solid-phase extraction reversed-phase HPLC-UV assay for the 
simultaneous determination of hesperetin and naringenin in human urine was 
developed and validated. Urine samples were incubated with 
glucuronidase/sulphatase. Stability studies showed urine quality control samples to 
be stable for both hesperetin and naringenin through three freeze–thaw cycles and 
at room temperature for 24 hours (error ≤ 3.6%). This method was selective, 
precise, accurate and robust, and seemed to be suitable for the quantitative 
determination of total (free and conjugated) hesperitin in urine samples obtained 
in pharmacokinetic studies in humans, after oral administration of the dietary 
flavanone glycosides, hesperidin and naringin, either as pure substances or in citrus 
fruits that contain them. The determination of urinary flavanone aglycone 
hesperitin may be an useful biomarker for flavonoids intake (Kanaze et al., 2004). 
A sensitive, precise and selective analytical method has been developed for 
the identification and quantification of resveratrol metabolites in human low-
density lipoprotein (LDL) after moderate consumption of red wine, using HPLC-
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ESI-MS/MS. Results to date indicate that resveratrol metabolites were 
incorporated into LDL after a moderate intake of red wine. The metabolites 
identified in LDL were trans-resveratrol-3-O-glucuronide, cis-resveratrol-3-O-
glucuronide and cis-resveratrol-3-O-glucoside, as well as free trans-resveratrol 
(Urpí-Sardà et al., 2005). 
A rapid, sensitive and accurate protein precipitation procedure and sensitive 
HPLC separation coupled to UV detection was described allowing quantification 
of resveratrol and separation and identification of at least six major conjugate 
metabolites in human plasma and urine. The fast and non-intensive sample 
preparation method by protein precipitation simplifies large sample processing for 
clinical trials, having better or similar LOQ for resveratrol (5 ng/mL), and resolving 
the major conjugate metabolites (Boocock et al., 2007). 
Urpí-Sarda et al. (2007) described an HPLC-MS method to characterize the 
metabolic profile of resveratrol in human urine and LDL after sample clean-up 
with SPE, to study resveratrol and its metabolites bioavailability. This method 
enabled the determination of resveratrol metabolic profile in 10 minutes for 
different types of matrices. To improve the resolution of the sulfates, acetone was 
incorporated into the mobile phase. Acetone allows better resolution of sulfates by 
improving the peak shape and reducing the relative retention time. The 
incorporation of a shorter chromatographic column also reduced the 
chromatographic time to 10 min. The use of a 96-well SPE plate helped to avoid 
laborious sample preparation, requiring ~3 hours of preparation per plate. The use 
of HPLC-MS/MS avoids the need to perform enzymatic hydrolysis, thus 
simplifying the qualitative and quantitative profiling of the resveratrol metabolites. 
Another highlight of the present method is the ability to differentiate between the 
trans and cis isomers of resveratrol-4-O-glucuronide, resveratrol-3-O-glucuronide, 
resveratrol-4-sulfate and resveratrol-3-sulfate. This method is the first to identify 
the entire profile of resveratrol sulfates in human LDL and urine, and furthermore, 
without reducing the resolution of glucuronides (Urpi-Sarda et al., 2007). 
The soy isoflavone, daidzein, was studied in a human trial after oral 
administration of both aglycone and glucoside forms. Isoflavonoid trimethylsilyl 
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ether derivatives were separated and quantified by GC-MS analysis. The limits of 
detection were between 8 and 70 fmol. The recoveries ranged between 93% and 
105% obtained after spiking plasma samples with reference compounds and 
subtracting the basal values from the blank plasma. The intra- and inter-assay 
coefficients were always <5% for all quantified isoflavonoids. This area ratio was 
then interpolated against calibration curves in the linear range between 0 and 25 
pmol constructed for known amounts of the individual isoflavonoids. It was not 
possible to determine the unconjugated fractions of the oxidative metabolites in 
plasma because the free plasma concentrations were below the limit of detection 
(Rüfer et al., 2008). 
Before questions about polyphenols’ bioavailability can be addressed, 
ultrasensitive methods are necessary to study their pharmacokinetics, which is not 
yet linear. In fact, these studies involve several parameters, like the dose and 
nature of the phenolic compound, and procedures capable of influencing final 
results and conclusions. Additionally, the lack of analytical parameters and 
characteristics in published papers with analytical validation of the procedure is 
frequent, hindering viable comparisons between studies. Bioavailability and 
pharmacokinetics studies of polyphenols have been assessed mostly through 
human and animal models, particularly rodents and primates, and more recently, 
the nematode Caenorhabditis elegans has been successfully used in toxicological 
and in tissue distribution studies. It is recommended to increase the length of 
human intervention studies, to more closely reflect the long-term consumption of 
polyphenols. Together with validated in vivo biomarkers, these issues will 
contribute to achieve a better in vitro/in vivo bioavailability correlation.  
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C. Aims 
Infusion of C. citratus leaves is used in traditional medicine for the 
treatment of inflammatory-related pathologies. However, little is known about its 
pharmacological activity, in particular its anti-inflammatory properties, as well as 
the mechanisms of action and its bioactive compounds. On the other hand, the 
development of new anti-inflammatory drugs is of utmost importance, since 
inflammation has been associated with several pathologies, including Alzheimer, 
diabetes, cardiovascular diseases, atherosclerosis and cancer, but current anti-
inflammatory drugs are not totally safe and effective. During the last decade, 
developments have been achieved on the phytochemical characterization 
(Figueirinha et al., 2010, 2008) and the disclosure of the anti-inflammatory 
mechanisms of lemongrass infusion in vitro (Francisco et al., 2014, 2013, 2011). 
In contrary, little attention has been paid to the in vivo approach. 
 
Therefore, the aims of the present study are to: 
 Develop and validate an analytic method to quantify the phenolic 
compounds in C. citratus extracts; 
 Investigate the influence of harvest time and plant quality on C. 
citratus infusion phenolic compounds profile; 
 Further elucidate C. citratus phenolic compounds chemistry, 
particularly of the tannins; 
 Evaluate the potential of C. citratus infusion as source of new anti-
ulcer and/or anti-inflammatory drugs, using in vivo bioguided assays; 
 Assess the contribution of phenolic compounds - flavonoids and 
tannins - to the overall C. citratus activity; 
 Incorporate C. citratus infusion and polyphenol-enriched fractions in 
a pharmaceutical formulation with anti-inflammatory activity; 
 Study the pharmacokinetics in an in vivo model of phenolic 
compounds from C. citratus infusion. 
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Abstract 
Cymbopogon citratus (lemongrass) leaves and/or infusion are commonly 
consumed as a beverage or as an herb in several cuisines worldwide. It is also used 
in traditional medicine for the treatment of several pathologic conditions, such as 
peptic ulcers, inflammatory conditions and cancer. Recent studies revealed the 
crucial role of the phenolic compounds of the infusion bioactivity as anti-
inflammatory and antineoplasic, particularly attributed to flavonoids. A high-
performance liquid chromatography – diode-array detector (HPLC-DAD) method 
was developed, for the first time, for the simultaneous quantification of phenolic 
compounds in Cymbopogon citratus polar extracts, which seem to be the main 
contributors to the antioxidant effects of this herb. The separation was performed 
on a Spherisorb S5 ODS-2 column (250 x 4.6 mm i.d.; particle size, 5 µm), using a 
methanol: aqueous formic acid (5%, v/v) gradient as the mobile phase, with a flow 
of 1 mL min-1. The detection was achieved with a DAD detector and the 
chromatographic profiles were registered at 280 nm. The developed method was 
validated according to the Food and Drug Administration (FDA) 
recommendations. Good linearity was observed within a wide concentration range.  
The developed method is simple, precise at the intra-day and inter-day levels and 
accurate with very good recovery percentages. Phenolic acids and flavonoids, 
including luteolin 6-C-glucosyl-8-C-arabinoside, luteolin 6-C-glucoside, luteolin 7-
O-glucoside, luteolin 7-O-neohesperidoside, luteolin 6-C-arabinosyl-2’’-O-
rhamnoside and luteolin 2″-O-rhamnosyl-C-(6-deoxy-ribo-hexos-3-ulosyl) were 
successfully quantified in leaves infusion of C. citratus using the developed HPLC 
method. This data may be of great interest for the food supplement and 
pharmaceutical industries. 
 
Keywords: Lemongrass, polyphenols, flavonoids, HPLC. 
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1. Introduction 
Cymbopogon citratus (DC.) Stapf, Poaceae, commonly known as 
lemongrass, is a spontaneous perennial graminoid, largely distributed in tropical 
and subtropical countries. The lemon-like flavour of the plant is responsible for its 
use in tropical countries cuisines being its leaves a common ingredient in Asian 
cuisine in teas, soups and curries, being also suitable for fish, seafood and poultry 
(Adeneye and Agbaje, 2007). In African and Latin American countries, this herb is 
highly consumed as an aromatic and pleasant-tasting herbal drink (Francisco et al., 
2014). In traditional medicine, aqueous extracts of lemongrass leaves are also used 
for the treatment of several inflammation-based pathologies (Shah et al., 2011), 
cardiovascular diseases (Runnie et al., 2004), cancer (Puatanachokchai et al., 
2002), digestive disorders (Bergonzelli et al., 2003), nervous system disorders 
(Linck et al., 2010), infections (Barbosa et al., 2008), among other health 
problems.  
Preliminary results obtained by our group (Figueirinha et al., 2010) proved 
that an essential oil-free infusion from C. citratus leaves induced a reduction of 
nitric oxide (NO) production in dendritic cells co-incubated with an inflammatory 
stimulus (lipopolysaccharide - LPS), allowing cell viability under the assayed 
conditions. In another recent work, we have demonstrated that C. citratus leaves 
extract has a potent anti-inflammatory activity that is related to its polyphenolic 
content (Figueirinha et al., 2008). In addition, we verified that this extract and its 
polyphenolic fractions inhibit LPS-induced iNOS expression in fetal skin-derived 
dendritic cell line (FSDC) (Figueirinha et al., 2010), stressing the use of C. citratus 
extract as a potential new anti-inflammatory drug. Moreover, we have previously 
demonstrated that C. citratus and its polyphenols inhibited NO production, in 
dendritic cells and mouse macrophages, through modulation of p38 mitogen-
activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK) 1/2 and NF-κB 
signaling pathways (Francisco et al., 2013; Francisco et al., 2011). More recently, 
the analgesic and anti-inflammatory activities of lemongrass infusion were 
validated in rats (Garcia et al., 2015). 
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Studies considering chemical composition of lemongrass have shown a wide 
variety of phenolic compounds such as phenolic acids, condensed tannins and 
flavonoids, such as luteolin and apigenin derivatives (Campos et al., 2014; 
Figueirinha et al., 2008; Tavares et al., 2015). Luteolin and its glycosides have 
been described by numerous authors by their antioxidant (Cheel et al., 2005; 
Orrego et al., 2009; Tapia et al., 2007) and anti-inflammatory properties (Chen et 
al., 2004; Costa et al., 2012; Francisco et al., 2014; Xagorari et al., 2002). On the 
other hand, although there has been a few works, in the literature, regarding the 
quantification of the phenolic compounds of lemongrass extracts (Figueirinha et 
al., 2008; Roriz et al., 2014), there are no reports about the validation of analytical 
methods for the quantification of any phenolic constituents found in Cymbopogon 
citratus polar extracts.  
The aim of the present study was to develop and validate a simple and 
sensitive reversed phase-high performance liquid chromatography (RP-HPLC) 
method with UV detection for the simultaneous determination of the phenolic 
compounds present in three different extracts from Cymbopogon citratus leaves. 
 
2. Materials and Methods 
2.1 Plant material and Chemicals 
Cymbopogon citratus dried leaves were purchased from ERVITAL (Castro 
d’Aire, Portugal). The plant was cultivated in the region of Mezio, Castro d’Aire 
(Portugal). A voucher specimen was deposited in the Herbarium of Aromatic and 
Medicinal Plants of the Faculty of Pharmacy – University of Coimbra (A. 
Figueirinha 0109). The identity of the plant was confirmed by J. Paiva (Life 
Sciences Department, University of Coimbra, Portugal). A lipid- and essential oil-
free infusion (CCI) was prepared as previously described (Figueirinha et al., 2008). 
CCI was prepared by adding boiling water to the plant material, the mixture being 
kept hot and left to stand for 15 min. Two hydro-alcoholic extracts were also 
prepared. A maceration process was applied to 5g of dried leaves, by adding 150 
mL of 50% ethanol and absolute ethanol (CCM50 and CCM100, respectively), 
and left to stand for 10 days, in the dark at room temperature. All extracts were 
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then filtered under vacuum, concentrated and freeze-dried. The freeze-dried 
extracts were kept at -20ºC until use. Caffeic acid (>99%) and p-coumaric acid 
(>99%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Isoorientin 
(>99%) and isovitexin (>99%) were purchased from Extrasynthese (Genay, 
France). All other reagents and solvents were of HPLC grade and were purchased 
from Merck (Darmstadt, Germany). Water for HPLC was purified with the 
Millipore Simplicity System (Bedford, MA, USA).  
 
2.2 Preparation of stock and standard solutions  
Caffeic and p-coumaric acids stock solutions were prepared at a 
concentration of 10.00 g mL-1, in 50% methanol. Five standard solutions of each 
standard were prepared by appropriate dilution of the stock solution with mobile 
phase (methanol-5% (v/v) aqueous formic acid, 5:95, v/v): 5.00, 2.50, 1.00, 0.50 
and 0.25 g mL-1. Isoorientin and isovitexin stock solutions were prepared at a 
concentration of 250.00 g mL-1, in 50% methanol. Five standard solutions of each 
standard were prepared by appropriate dilution of the stock solution with mobile 
phase (methanol-5% (v/v) aqueous formic acid, 5:95, v/v): 125.00, 62.50, 31.25, 
15.63 and 7.81 g mL-1. Standard solutions were freshly prepared each day and 
stored at 4 ºC.  
 
2.3 Instrumentation and chromatographic conditions 
HPLC analyses were performed in a chromatograph GILSON equipped with 
a diode-array detector (DAD) (Gilson Electronics SA, Villiers le Bel, France). The 
studies were carried out on a Spherisorb S5 ODS-2 column (250 x 4.6 mm i.d.; 
particle size, 5 µm; Waters Corp., Milford, MA, USA) and a Nucleosil C18 guard 
cartridge (30 x 4 mm i.d.; particle size, 5 µm; Macherey-Nagel, Düren, Germany) 
at 25ºC. A mobile phase of 5% (v/v) aqueous formic acid (A) and methanol (B) 
was used with a discontinuous gradient: 5–15% B (0–10 min.), 15–30% B (10–15 
min.), 30–35% B (15–25 min.), 35–50% B (25–35 min.) and 50–80% B (35–40 
min.), followed by an isocratic elution for 20 min, at a flow rate of 1mL min-1. An 
injection volume of 100 L was used for all standards and samples. 
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Chromatographic profiles were acquired in the wavelength range 200–600 nm, and 
recorded at 280 nm. Data treatment was carried out with Unipoint 2.10 software 
(Gilson).  
 
2.4 Method validation  
The HPLC-DAD method was validated according to the US Food and Drug 
Administration (FDA) regulations (FDA, 2013), including also some 
complementary aspects taken in the guidelines from the International Conference 
on Harmonization (ICH) (ICH, 2005). The parameters considered for the 
validation included linearity, accuracy, precision, limits of detection and 
quantification. 
 
2.4.1. Linearity 
Calibration curves were constructed with six standard solutions, containing 
caffeic acid, p-coumaric acid, isoorientin and isovitexin. Linearity was determined 
through the calculation of a regression line by the method of least squares, 
representing the peak area as a function of the standard concentration. The F-test 
was used to evaluate the linear relationship (Araujo, 2009). The Fisher variance 
ratio or F-test (Fcalculated) was calculated by the equation: 
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where: σlof
 2 is the lack-of-fit variance; σε2 is the purely experimental variance; 
SSlof
 is the lack-of-fit sum squares; DFlof is the lack-of-fit degrees of freedom; SSε is 
the purely experimental sum squares; DFε is the purely experimental degrees of 
freedom; I is the number of i concentration levels; ȳi is the average response for the 
level i; ŷi is the estimated experimental response for the level i; J is the total number 
of j injections per i concentration levels. The value of Fcalculated was compared against 
the critical value of F found in statistical tables (Ftabulated). Data collected were 
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analyzed using the Analysis ToolPak of Microsoft Excel (Microsoft Corp., 
Redmond, WA, USA). 
 
2.4.2. Limits of detection and quantification 
The limits of quantification (LOQ) and detection (LOD) were calculated 
experimentally, using lowering spiking assays, with LOQ and LOD being the 
amount of compound that can be quantified with a signal-noise ratio of 10, and 
3.3, respectively (ICH, 2005). 
 
2.4.3. Precision and accuracy 
The precision of an analytical method describes the closeness of individual 
measures of an analyte when the procedure is applied repeatedly to multiple 
aliquots of a single homogeneous volume of matrix (FDA, 2013). Repeatability 
(intra-day precision) was determined by calculating the percentage of relative 
standard deviation (% R.S.D.) for three independent determinations at three 
concentrations (0.50, 2.50 and 10.00 g mL-1, for caffeic acid and p-coumaric acid; 
7.81, 62.50 and 250.00 g mL-1, for isoorientin and isovitexin). Three independent 
samples were spiked with caffeic acid, p-coumaric acid and isoorientin and the 
analyte was quantified within the same day. To determine the intermediate 
precision the same method was applied and the samples were analyzed at the first, 
the third and the fifth day. The accuracy of an analytical method describes the 
closeness of mean test results obtained by the method to the actual value 
(concentration) of the analyte (FDA, 2013). Intra-day accuracy was assessed by 
calculating the percentage of recovery according to the following equation: 
%accuracy = (measured concentration/nominal concentration) x 100. Intermediate 
precision and accuracy were assessed by assaying three standard sample levels in 
triplicate on three separate occasions. The %RSD should not exceed 15%, with the 
exception of LOQ, where it should not deviate more than 20% (FDA, 2013). 
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2.5 Method applicability 
The developed and validated method was applied to the quantification of 
phenolic acids and flavonoids, namely carlinoside, isoorientin, cynaroside, luteolin 
7-O-neohesperidoside, kurilensin A and cassiaoccidentalin B, in three different 
extracts of C. citratus leaves. It should be emphasized that it is the first time that 
these flavonoids are quantified by a validated method in this species. On the other 
hand, the simultaneous quantification and validation of these analytes, within only 
one run, is of remarkable importance from a time-saving and quality control 
perspective. For that, three independent sample solutions at 3 mg mL-1 of CCI, 
CCM50 and CCM100 were prepared from the freeze-dried extract, in 50% 
methanol. Calibration curves were prepared by injecting different concentrations of 
standard samples, recording their peak areas and plotting peak areas vs. 
concentration of the standard.  For interpretation of results, the calibration curves 
were used to quantify the phenolic acids and flavonoids previously identified by 
HPLC-MSn (Figueirinha et al., 2008) in lemongrass infusion. 
 
3. Results and Discussion 
3.1 Method validation  
3.1.1. Linearity 
Linearity was evaluated over the concentration range of 0.50 – 10.00 g mL-
1 for caffeic and p-coumaric acids and over the concentration range of 7.81 – 
250.00 g mL-1 for isoorientin, estimating the regression equations (caffeic acid: y 
= 9957547x - 1980541; p-coumaric acid: y = 65289976x + 522431; isoorientin: 
y = 1939071x – 4248388; isovitexin: y = 19173001x + 1904129) and the 
determination coefficient (R2 = 1.00) from the least squares method, for all 
standards (Table II.1). Although the coefficient of determination for the 
calibration curve had been higher than 0.999, only an appropriate statistical 
method can evaluate the acceptability of the linear model (Araujo, 2009). In this 
work, the F-test was used to evaluate the linearity. The comparison between the 
calculated and tabulated Fisher ratio (Fcalculated and Ftabulated, respectively) indicates 
that Fcalculated is lowest than the Ftabulated (3.26 (tabulated at the 95% with 4 and 12 
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degrees of freedom)), which is considered an evidence of an acceptable fit of the 
data to the regression line and indicating a good linearity over the concentration 
range proposed. 
 
3.1.2. Limits of detection and quantification 
The experimentally determined limit of detection (LOD) and limit of 
quantification (LOQ) for all standards are presented in Table II.1. 
 
3.1.3. Precision and accuracy 
The method showed very good precision and accuracy. Repeatability, 
intermediate precision and accuracy are presented in Table II.2. These results 
suggested that the procedures described above were satisfactory with respect to 
both accuracy and precision. All precisions and accuracies results were acceptable. 
 
Table II.1. Linearity, LOD and LOQ values for caffeic acid, p-coumaric acid, 
isoorientin and isovitexin. 
Standard 
Concentration 
range 
(g mL-1) 
Calibration 
curve 
R2 Fcalculated* 
LOD 
(g mL-1) 
LOQ 
(g mL-1) 
Caffeic acid 0.50 – 10.00 
y = 9957547x –  
1980541 
1 1.37 0.65 1.97 
p-Coumaric 
acid 
0.50 – 10.00 
y = 65289976x 
+  
522431 
1 3.19 0.11 0.32 
Isoorientin 7.81 – 250.00 
y = 1939071x –  
4248388 
1 2.87 0.13 0.40 
Isovitexin 7.81 – 250.00 
y = 19173001x 
+ 1904129 
1 3.15 0.11 0.33 
*Fcalculated should be lower than 3.26 (Ftabulated at 95% with 4 and 12 degrees of freedom). 
 
3.2 Method applicability: flavonoids quantification 
The phenolic acids and flavonoids previously identified by HPLC-MSn 
(Figueirinha et al., 2008) were quantified by HPLC-DAD: 3-feroylquinic acid (1), 
neochlorogenic acid (2), chlorogenic acid (3), p-coumaric acid (4), carlinoside (5), 
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isoschaftoside (6), isoorientin (7), cynaroside (8), veronicastroside (9), luteolin 7-
O-neohesperidoside (10), kurilensin A (11) and cassiaoccidentalin B (12). The 
chromatogram of CCI is representative of all three extracts and is depicted in 
Figure II.1. The concentration of each compound was determined by linear 
regression of the previously validated calibration curves and the results are 
expressed in the respective standard equivalents (Table II.3). The found amounts 
of each compound in the lemongrass extracts suggest that the most abundant 
phenolic compounds are 3-feroylquinic acid, chlorogenic acid, p-coumaric acid, 
isoorientin, kurilensin A and cynaroside. Moreover, all flavonoids are extracted in 
greater amounts when the polarity of the extraction solvent diminishes. These 
flavonoids have already been reported for their medicinal properties, such as 
antioxidant, anti-inflammatory and anticancer (Choi et al., 2014; Hwang et al., 
2013; Kundu et al., 2011; Park and Song, 2013; Yuan et al., 2014). Nevertheless, 
carlinoside, cassiaocidentalin B and luteolin 7-O-neohesperidoside may also have 
some relevant roles in the therapeutic applications of lemongrass, since they have 
been described as anti-inflammatory, antioxidant and hepatoprotective (Abdel-
Kader et al., 2009; Pham et al., 2013; Tomaino et al., 2010).  
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Figure II.1. HPLC-DAD profile of CCI (3mg mL-1), recorded at 280 nm. 
 
Table II.3. Phenolic compounds quantification by HPLC-DAD. 
Peak Compound 
Measured concentration 
mean ± SD (g mL-1) 
CCI CCM50 CCM100 
1 3-Feroylquinic acida 3.82 ± 0.04 3.75 ± 0.05 3.72 ± 0.08 
2 Neochlorogenic acida 2.16 ± 0.18 2.32 ± 0.12 2.46 ± 0.12 
3 Chlorogenic acida 4.40 ± 0.30 4.39 ± 0.14 4.53 ± 0.31 
4 p-Coumaric acidb 8.01± 0.21 8.21 ± 0.05 8.12 ± 0.08 
5 Carlinosidec 8.60 ± 0.11 16.30 ± 0.30 33.05 ± 0.17 
6 Isoschaftosided 11.35 ± 0.23 21.05 ± 0.14 45.06 ± 0.08 
7 Isoorientinc 52.02 ± 0.54 100.14 ± 0.09 210.14 ± 0.27 
8 Cynarosidec 23.45 ± 0.26 45.75 ± 0.19 87.09 ± 0.31 
9 Veronicastrosided 3.26 ± 0.09 6.76 ± 0.28 11.96 ± 0.07 
10 Luteolin 7-O-neohesperidosidec 11.12 ± 0.13 24.02 ± 0.17 43.72 ± 0.19 
11 Kurilensin Ac 26.48 ± 0.29 54.70 ± 0.05 104.48 ± 0.14 
12 Cassiaoccidentalin Bc 13.78 ± 0.16 27.06 ± 0.17 52.30 ± 0.18 
aConcentration expressed in g equivalents of caffeic acid per mL; bConcentration 
expressed in g equivalents of p-coumaric acid per mL; cConcentration expressed in g 
equivalents of isoorientin per mL; dConcentration expressed in g equivalents of isovitexin 
per mL. 
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4. Conclusions 
A simple and efficient reversed-phase HPLC-DAD method was successfully 
validated for simultaneous identification and quantification of phenolic 
compounds in Cymbopogon citratus, for the first time. The developed HPLC 
method was validated according to ICH and FDA guidelines. The method is 
simple, precise and accurate, presenting good LOD and LOQ values. It can be used 
for phenolic compounds quantification in other polar extracts and in different 
plants as well as in quality control of herbal formulations, with promising use in 
pharmaceutical and food supplement industries. 
 
 
 
 
 
 
 
 
 
 

  
 
 
 
 
 
 
 
B. Influence of harvest time and material quality on phenolic 
content and antioxidant activity of Cymbopogon citratus infusion 
Gustavo Costa, Helena Grangeia, Artur Figueirinha, Isabel Vitória 
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Abstract 
Cymbopogon citratus (Cc) leaves are a product of high economic value 
because of its use in perfumery, cosmetic, pharmaceutical and agriculture 
industries. Polyphenols are most frequently present in combined form, and their 
structure and contents are often dependent of several factors like: plant varieties, 
culture conditions, maturation and processing. In this study, we aimed to evaluate 
the effect of the harvesting date and the quality of the plant material on the 
phenolic composition and the antioxidant activity of C. citratus leaves.  
The plant material was classified accordingly to its harvest month for the 
same year: April to September and also accordingly to its quality (leaves ageing 
state): high, medium and low. A lipid-free infusion was prepared. Total 
hydroxycinnamic acids, flavonoids and tannins were evaluated by 
spectrophotometric methods and polyphenolic profile was attained by HPLC-
DAD. Antioxidant capacity was assessed using DPPH, ABTS and FRAP assays. 
Regarding the harvest date influence, total phenols were fairly constant from 
April to August, with a little decrease in September. Higher concentration of 
hydroxycinnamic acids was found in April and June, but much lower on the 
following months. With exception of August, almost the same percentage of 
flavonoids was registered for all months. On the other hand, we found that the 
best months for tannins biosynthesis were June, July and August. The samples 
collected in April and June were the most effective against all the oxidant species 
tested, suggesting a correlation between this parameter and amount of 
hydroxycinnamic acids.  
In what concerns the contents of each polyphenol, evaluated by HPLC-
DAD, some significant differences were observed for the hydroxycinnamic acids, 
which seem to be more influenced by the conditions studied (harvest month and 
material quality). 
In conclusion, for Cymbopogon citratus leaves, both harvest date and plant 
quality are key criteria that have to be taken into account when selecting the 
material for human consuming, in order to receive benefits that have been 
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associated with phenolic compounds, namely to those who are present in this 
plant. 
 
Keywords: Cymbopogon citratus; lemongrass; polyphenols; flavonoids; tannins; 
antioxidant; HPLC-DAD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II | RESULTS and DISCUSSION 
 
99 
 
1. Introduction 
Medicinal plants are commonly used to obtain phytotherapeutic medicines, 
food and cosmetics (Martinazzo et al., 2009). However, their use is limited by 
several factors including: cultivation, harvest period, climatic factors, humidity, 
brightness, part of the plant, transportation method, storage, drying process and 
extraction process, which may all modify the composition of the products, directly 
affecting its safety and efficiency (Calixto, 2000).  
Phenolic compounds are ubiquitous in the plant kingdom exerting several 
functions on plant. Many factors influence phenolic accumulation in plants 
although some are more significant than others. The hydric stress and other 
exogenous growth factors, exposure to various light sources and the presence of 
fungal or predatory pressures are shown to alter plant biosynthesis (Cohen and 
Kennedy, 2010). During plant growth, phenolic compounds protect fruits and 
vegetables from microbial damage, ultraviolet (UV) radiation, and predation 
among other environmental stresses. The sun exposure is credited with being a 
major element relating to plant metabolism. It is now a well-established knowledge 
that sunlight itself directly influence the phenolic compounds biosynthesis 
(Zucker, 1965). The major challenge on studying sun exposure and plants is the 
dual effect of radiation. As the amount of sun exposure increases there is a 
concomitant rise in temperature (Spayd et al., 2002). Both flavonoids and 
proanthocyanidins showed significant increases with sun exposure (Spayd et al., 
2002). Also phenolic acids are affected by UV radiation (Booij-James et al., 2000). 
As seen in sun exposure, temperature can also be correlated to phenolic 
composition (e.g. anthocyanins) but breaching a critical limit (high and low) has 
detrimental effects. It is likely that all plants exhibit temperature thresholds 
(Bradfield and Stamp, 2004). Furthermore, the phenolic composition, the degree 
of hydroxylation and acylation, is also sensitive to temperature shifts and likely 
reflects different sensitivity of various genes or enzymes in the flavonoid pathway 
(Cohen et al., 2008). The phase of postharvest, more precisely the drying process, 
requires special attention; therefore, the choice of dryer, drying system, air 
composition, height of layers of leaves in the dryer, and temperature and relative 
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humidity of the room air can provide plants with better quality after harvesting. 
The rate at which water is removed from the medicinal plant during drying is very 
important because a rapid process can degrade active ingredients (Coradi et al., 
2014). 
Cymbopogon citratus (DC.) Stapf, Poaceae, is an aromatic herb known as 
lemongrass, native from India and tropical Asia and currently it grows worldwide. 
Lemongrass is a crop of high economic value because of its use in the perfumery, 
cosmetic, pharmaceutical and food industries (Oyedele et al., 2002; Saddiq and 
Khayyat, 2010). C. citratus is commercially cultivated in the Democratic Republic 
of Congo, Angola, Madagascar and Comoros Island. However, the leading exporter 
of this plant is Guatemala, trading about 250,000 kg per year, while the USA 
imports about 70,000 kg per year (Department of Agriculture, Forestry and 
Fisheries, 2012). The commercial value of lemongrass species is further enhanced 
by their ability to grow in moderate and extremely harsh climatic conditions 
(Padalia et al., 2011). C. citratus is commonly used in folk medicine for treatment 
of nervous and gastrointestinal disturbances, and as antispasmodic, analgesic, anti-
inflammatory, anti-pyretic, diuretic and sedative (Santin et al., 2009). Recently, 
our group has been involved in the identification of functional compounds from 
lemongrass. We demonstrated that flavonoids, such as luteolin and apigenin 
glycosides, and proanthocyanidins strongly contributed to antioxidant and anti-
inflammatory properties of an essential oil-free infusion from lemongrass (Costa et 
al., 2015a; Figueirinha et al., 2010, 2008; Francisco et al., 2014, 2013, 2011). 
Factors such as harvest season and quality grades are usually not taken into 
account for this plant, since it is harvest along the whole year, except for the winter 
(Department of Agriculture, Forestry and Fisheries, 2012). Hence, the chemical 
composition of the plant may vary from one month to another, leading to different 
industrial final products. Quality grading, performed by expert graders from 
industry, entails evaluating the appearance of the fresh and/or dry leaves. A 
literature search was undertaken on the effect of different methods of drying on 
chemical composition and content of the essential oil. The results showed that 
drying method had a significant effect on oil content and composition of aromatic 
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plants (Okoh et al., 2008). However, to our knowledge, there are no reports of 
those effects on the polyphenolic content of lemongrass. 
Therefore, the aim of this study was to investigate the effect of the harvest 
time and plant quality on the qualitative and quantitative phenolic composition of 
C. citratus infusion. 
 
2. Materials and Methods 
2.1 Plant material 
Dry leaves of Cymbopogon citratus were acquired from ERVITAL (Mezio, 
Castro Daire, Portugal). Cymbopogon citratus was bred in the region of Mezio, 
Castro Daire (Portugal), located in a greenhouse located 1000 m above sea level. A 
voucher specimen is deposited in the Herbarium of Aromatic and Medicinal Plants 
of the Faculty of Pharmacy – University of Coimbra (A. Figueirinha 0109). The 
identity of the plant was confirmed by J. Paiva (Life Sciences Department, 
University of Coimbra, Portugal). The plant material was harvest within the year 
of 2011, and classified accordingly to two parameters: its harvest date - April 
(Apr), June (Jun), July (Jul), August (Aug) and September (Sep) - and its quality 
grade, by leaves ageing state - high (H), medium (M) and low (L) quality, where 
high quality corresponds to young fully-grown green leaves and low quality 
corresponds to aged brownish leaves. This criterion to classify the plant material 
according to its quality was set by the producer. A lipid- and essential oil-free 
infusion (extract) was prepared from each sample as previously described 
(Figueirinha et al., 2008). Briefly, the infusion was prepared by adding boiling 
water to the plant material, the mixture being kept hot and left to stand for 15 
min. The extract was then filtered under vacuum, concentrated and freeze-dried. 
The freeze-dried extract was kept at -20ºC until use. 
 
2.2 Polyphenols quantification 
2.2.1. Total phenols 
A modified version of the Folin-Ciocalteu method (Wang, C., Lee, W., Peng 
et al., 1997) was used. Briefly, the sample (100 L) was mixed with 1 mL of Folin-
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Ciocalteau reagent (Merck, Darmstadt, Germany) and 5 mL of sodium carbonate 
(20%, w/v) (Merck, Darmstadt, Germany), and the final volume was completed 
with MilliQ water. The absorbance was measured at 700 and 735 nm and the 
results expressed as grams of gallic acid equivalents by 100 g freeze-dried extracts. 
The extracts of all samples were analyzed in triplicate. 
 
2.2.2. Total hydroxycinnamic acids 
The method described by Lamaison and co-workers (Lamaison et al., 1991) 
was used. Briefly, Arnow reagent (1 mL) was added to the extracts in 50% ethanol 
(1 mL), previously mixed with HCl 0.5N (1 mL). Then, 1 mL of NaOH 1N was 
added to the mixture and the final volume was completed with MilliQ water. The 
absorbance was measured immediately at 505 nm, and the results were expressed 
in grams caffeic acid equivalents by 100 g of freeze-dried extracts. The extracts of 
all samples were analyzed in triplicate. 
 
2.2.3. Total flavonoids 
Reagent [AlCl3·6H2O 2% in methanol (w/v), 2 mL] was added to the 
extracts in ethanol (2 mL). The absorbance was measured after 10 min, at 430 nm 
(Lamaison and Carnat, 1990), and the results were expressed in grams rutin 
equivalents by 100 g of freeze-dried extracts. The extracts of all samples were 
analyzed in triplicate. 
 
2.2.4. Total tannins 
The European Pharmacopeia official method was used. Briefly, the extracts 
were solubilized in MilliQ water (500 mg / 2 mL), and then mixed with 1 mL of 
Folin-Ciocalteau reagent (Merck, Darmstadt, Germany) and 10 mL of MilliQ 
water, and the final volume was completed with sodium carbonate (20%, w/v) 
(Merck, Darmstadt, Germany). The same procedure was applied to the extract 
solutions, previously treated with skin powder (1%, w/v) for 1 hour. The 
absorbance of both solutions was measured at 760 nm after 30 min, and the 
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results expressed as grams of pyrogallol equivalents by 100 g freeze-dried extracts. 
The extracts of all samples were analyzed in triplicate. 
 
2.2.5. HPLC-DAD analyses 
HPLC analyses were performed in a chromatograph GILSON equipped with 
a diode-array detector (DAD) (Gilson Electronics SA, Villiers le Bel, France). The 
studies were carried out on a Spherisorb S5 ODS-2 column (250 x 4.6 mm i.d.; 
particle size, 5 µm; Waters Corp., Milford, MA, USA) and a Nucleosil C18 guard 
cartridge (30 x 4 mm i.d.; particle size, 5 µm; Macherey-Nagel, Düren, Germany) 
at 25ºC. A mobile phase of 5% (v/v) aqueous formic acid (A) and methanol (B) 
was used with a discontinuous gradient: 5–15% B (0–10 min.), 15–30% B (10–15 
min.), 30–35% B (15–25 min.), 35–50% B (25–35 min.) and 50–80% B (35–40 
min.), followed by an isocratic elution for 20 min., at a flow rate of 1 mL/min. An 
injection volume of 100 L was used for all standards and samples. 
Chromatographic profiles were acquired in the wavelength range 200–600 nm, and 
recorded at 280 nm. Data treatment was carried out with Unipoint 2.10 software 
(Gilson). For the quantitative analysis of phenolic compounds, a calibration curve 
was obtained by injection of known concentrations (0.25–10 g/mL for caffeic acid 
and p-coumaric acid; 0.08-3.30g/mL for isovitexin and isoorientin) of the 
different standards: caffeic acid (y = 9957547x - 1980541; R2 = 0.9978); p-
coumaric acid (y = 65289976x + 522431; R2 = 0.9999); isovitexin (y = 
19173001x + 1904129; R2 = 0.9994); isoorientin (y = 11857477x + 1553624; 
R2 = 0.9992). The results were expressed in percentage, g of respective standard 
equivalent per 100 g of extract, as mean ± standard deviation of three 
independent analyses. 
 
2.3 Antioxidant activity 
2.3.1. DPPH radical assay 
Free radical-scavenging activity was evaluated according to the method 
described by Blois and colleagues (Blois, 1958). Aliquots of extract methanolic 
solution (100 µL) were assessed by their reactivity with a methanolic solution of 
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500 µM 2,2-diphenyl-1-picrylhydrazyl (DPPH) (500 µL) (Sigma-Aldrich, Química 
S.A., Portugal) in the presence of 100 mM acetate buffer, pH=6.0 (1 mL). 
Reaction mixtures (3 mL) were kept for 30 min at room temperature and in the 
dark. The decreases in the absorbance were measured at 517 nm. Different 
dilutions of each of the test compounds were assayed and the results were obtained 
by interpolating the absorbance on a calibration curve obtained with Trolox 
(62.5-1000 µM) (Sigma-Aldrich, Química S.A., Portugal). Two independent 
experiments in triplicate were performed for each extract. Results were expressed as 
Trolox equivalent antioxidant capacity (TEAC), defined as the concentration of 
the extract whose antioxidant capacity is equivalent to a 1.0 mM of Trolox 
(Antolovich et al., 2002).  
 
2.3.2. ABTS (pH=4) radical assay 
The assay was carried out according to Cano and co-workers (Cano et al., 
1998) with minor modifications made by Villaño and colleagues (Villaño et al., 
2004). Free radicals were generated by an enzymatic system consisting of 
horseradish peroxidase enzyme, its oxidant substrate (hydrogen peroxide) and the 
2,2’-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS•+) chromophore. The 
radical was generated by a reaction between 1.5 mM ABTS (Sigma-Aldrich, 
Spain), 15 µM hydrogen peroxide (Sigma-Aldrich, Spain) and 0.25 µM peroxidase 
(Sigma-Aldrich, Spain) in 50 mM glycine-HCl buffer (pH=4). The final volume 
was 60 mL, yielding a final concentration of 30 µM of the ABTS•+ radical cation. 
The blank reference cuvette contained glycine–HCl buffer. Once the radical was 
formed, the extract was added and the decrease in absorbance was evaluated. The 
assay was carried out at room temperature. The reaction started by adding 100 µL 
of test extract to 2 mL of ABTS•+ solution, the mixture was vortexed for 10 s, and 
the absorbance at 414 nm was measured after 2 min of reaction. Two independent 
experiments in triplicate were performed for each extract, six different dilutions 
being prepared in 50% aqueous methanol and submitted to the reaction. TEAC 
values were obtained by interpolating the decrease in absorbance on the calibration 
curve obtained using Trolox solutions from 62.5 to 500 µM.  
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2.3.3. ABTS (pH=7) radical assay 
In this assay, the ABTS•+ radical was produced by the oxidation of 7 mM 
ABTS with potassium persulphate (2.45 mM, final concentration) (Merck, 
Darmstadt, Germany) in water. The mixture was allowed to stand in the dark at 
room temperature for 12–16 h before use, and then the ABTS•+ solution was 
diluted with phosphate buffered saline (PBS) at pH=7 and equilibrated at 30 ºC 
to give an absorbance of 0.7±0.02 at 734 nm. Aliquots (50 µL) of 50% aqueous 
methanol of the test extract were mixed with 2 mL of the ABTS•+ preparation, 
vortexed for 10 s, and the absorbance measured at 734 nm after 4 min of reaction 
at 30 ºC. Different dilutions of each extract were assayed and the results were 
obtained by interpolating the absorbance on a calibration curve obtained with 
Trolox (62.5–500 µM). The results were expressed as TEAC values. Two 
independent experiments in triplicate were performed for each extract. 
 
2.3.4. Ferric reducing power assay 
Ferric reducing ability was evaluated according to Benzie and Strain (Benzie 
and Strain, 1996) with minor modifications. The FRAP reagent contained 10 mM 
of TPTZ (Sigma-Aldrich, Spain) solution in 40 mM HCl, 20 mM FeCl3·6H2O 
(Merck, Darmstadt, Germany) and acetate buffer (300 mM, pH=3.6) (1:1:10, 
v/v/v). Aliquots (100 µL) of 50% aqueous methanol of the test extract were added 
to 3 mL of the FRAP reagent, and the absorbance was measured at 593 nm after 
incubation at room temperature for 6 min, using the FRAP reagent as blank. 
Different dilutions of each extract were assayed and the results were obtained by 
interpolating the absorbance on a calibration curve obtained with Trolox (31.25-
1000 µM). The results were expressed as TEAC values. Two independent 
experiments in triplicate were performed for each extract. 
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3. Results 
3.1 Polyphenols quantification 
3.1.1. Evaluation by spectroscopic methods 
Figure II.2 displays the amount of total phenols, hydroxycinnamic acids, 
flavonoids and tannins in each harvest moth. For this assay only high-quality 
samples were used. Total phenols contents seem to be quite stable in April 
(5.67%), June (5.55%) and July (5.35%), followed by an increase in August 
(6.14%) and a decrease to minimum levels in September (4.58%). The 
hydroxycinnamic acids present their maximum values in April (4.96%) and June 
(5.08%), but suffer a 2% fall in the following months. Total flavonoids were the 
phenolic compounds which have the most significant decrease in a given harvest 
date, August (4.81%), exhibiting their maximum values in June (6.63%) and 
September (6.62%). Total tannins increase from April (2.89%) to August (3.96%), 
followed by a decrease to minimum levels in September (2.97%). 
 
Figure II.2. Phenolic compounds amount (%, g of respective 
standard equivalents per 100 g of extract) quantified in 
lemongrass infusion of samples harvested from April to 
September.  
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Figure II.3 shows the phenolic content of four lemongrass samples: high- 
and low-quality, harvested in April; and medium- and high-quality, harvested in 
June. In all studied samples the amount of all groups of phenolic compounds is 
higher in high-quality samples and lower in low-quality samples. A correlation 
between phenolic compounds content and sample quality was markedly observed.  
 
Figure II.3. Phenolic compounds amount (%, g of respective 
standard equivalents per 100 g of extract) quantified in 
lemongrass infusion of high-quality (H) and low-quality (L) 
samples harvested in April, and in the infusion of medium-
quality (M) and high-quality (H) samples harvest in June. 
 
3.1.2 HPLC-DAD analyses 
HPLC-DAD phenolic profiles from C. citratus infusions were very similar for 
all analysed samples, exhibiting only slight quantitative differences. The 
chromatographic profile of high-quality April-harvested lemongrass infusion was 
found to be representative of all samples (Figure II.4). The following compounds 
were identified: 3-O-feruloylquinic acid (1), 5-O-caffeoylquinic acid 
(neochlorogenic acid) (2), 3-O-caffeoylquinic acid (chlorogenic acid) (3), p-
coumaric acid (4), luteolin 6-C-glucosyl-8-C-arabinoside (carlinoside) (5), apigenin 
6-C-arabinosyl-8-C-glucoside (isoschaftoside) (6), luteolin 6-C-glucoside 
(isoorientin) (7), isoorientin 2’’-O-rhamnoside (8), luteolin 7-O-neohesperidoside 
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(9), luteolin 6-C-arabinosyl-2’’-O-rhamnoside (kurilensin A) (10), luteolin 6-C-
pentoside (11) and luteolin 2″-O-rhamnosyl-6-C-(6-deoxy-ribo-hexos-3-ulosyl) 
(cassiaoccidentalin B) (12). Compounds identification was achieved by HPLC-
PDA-ESI/MSn  as previously described  (Figueirinha et al., 2008; Francisco et al., 
2014; Tavares et al., 2015). 
 
 
Figure II.4. HPLC-DAD profile of high quality lemongrass infusion (harvested in 
April), recorded at 280 nm. 
 
In Figure II.5 and Table II.4, it may be observed the percentage variation 
of each compound identified in lemongrass infusion over spring-summer months. 
Only high-quality samples were used. Hydroxycinnamic acids seem to be the group 
of compounds that suffers the most variability. Compound 1 increased from April 
(0.11%) to September (0.19%), with a smooth breakdown in July (0.14%). 
Compound 2 exhibited its highest amount in June (0.22%), followed by a 
substantial breakdown in the rest of the summer. Compound 3 showed a 
consistent increase over all tested months, exhibiting its highest amount in 
September (0.16%). Compound 4 kept almost the same percentage over time 
(0.03-0.04%).  
In what concern the quantified flavonoids, there were no significant changes 
on all months tested, with the exception of compound 7, which exhibited its 
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maximum amount in April (0.13%), and then a constant decrease in the following 
months until reaching a stable plateau in August and September (0.09%).  
 
 
Figure II.5. Phenolic compounds (1-12) quantified by HPLC-DAD in lemongrass 
infusion of samples harvested from April to September. The results are expressed 
in percentage, g of respective standard equivalent per 100 g of extract (compounds 
1-3 in caffeic acid equivalents; compound 4 in p-coumaric acid; compounds 5 and 
7-12 in isoorientin equivalents; compound 6 in isovitexin equivalents). 
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Figure II.6 illustrates the amount of each quantified phenolic compound in 
lemongrass infusion, extracted from four lemongrass samples: high- and low-
quality, harvested in April; and medium- and high-quality, harvested in June. As 
observed for the quantified phenolic compounds (see section 3.1.1), all detected 
polyphenols decrease with the degradation of the vegetable material, presenting 
their maximum values in high-quality samples and their minimum percentages in 
the low-quality sample.  
 
 
Figure II.6. Phenolic compounds (1-12) quantified by HPLC-DAD in lemongrass 
infusion of high-quality (H) and low-quality (L) samples harvested in April, and in 
the infusion of medium-quality (M) and high-quality (H) samples harvest in June. 
The results are expressed in percentage, g of respective standard equivalent per 100 
g of extract. 
 
3.2 Antioxidant activity 
Figure II.7 displays the antioxidant capacity against the different tested 
oxidant species for each harvest moth. Only high-quality samples were used. Both 
DPPH, ABTS (pH=7) and FRAP assays showed that the plant extracts possess 
very similar antioxidant activities over the months, with a swift decrease in 
September. In contrast, the tested samples from April to July exhibited a drastic 
decrease in the antiradical effect for the ABTS (pH=4) assay, maintaining the 
antioxidant levels afterwards. Furthermore, the present data show that the 
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lemongrass infusion is more effective against ABTS (pH=7) and DPPH, in 
comparison against the other evaluated species. 
 
 
Figure II.7. Antioxidant activity (expressed in TEAC value) of 
lemongrass extracts harvested from April to September. 
 
Figure II.8 shows the antioxidant capacity against the different tested 
oxidant species of samples with distinct quality levels. In all studied samples the 
antioxidant activity against all tested oxidant species is directly related to the 
quality level. 
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Figure II.8. Antioxidant activity (expressed in TEAC value) of 
lemongrass extracts from high-quality (H) and low-quality (L) 
samples harvested in April, and of medium-quality (M) and 
high-quality (H) samples harvest in June. 
 
4. Discussion 
Results obtained in this work suggest that phenolic compounds contents can 
be related to the harvest date. The total phenols assay showed a substantial loss 
from August to September, suggesting that the biosynthesis of these compounds is 
affected by the sunlight, such was suggested by Eichholz et al. (2011) and Namlı et 
al. (2014) in Vaccinium corymbosum and Hypericum retusum, respectively, or 
temperature, decreasing with the arrival of autumn. In contrast, the total 
flavonoids show a great increase in the same period. Therefore, the climatic 
conditions such as sunlight intensity and period, temperature, air composition and 
wind dynamics, during that time of the year seem to favour the biosynthesis of 
these phenolic compounds, as referred by other authors (Martínez-Lüscher et al., 
2014; Vidović et al., 2015). Hydroxycinnamic acids, another relevant group of 
phenolic compounds on lemongrass infusion, are more affected by the beginning of 
the summer, as observed in the remarkable breakdown from June to July.  
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Nevertheless, the best month to harvest lemongrass depends on which group 
of phenolic compounds is more relevant for its use. For tannins, summer months 
(June, July and August) must be selected. In what concern hydroxycinnamic acids, 
they are more abundant in April and June. Flavonoids should be better extracted 
from plant material collected either in June or in September. This data is also 
extremely important if one wants to take advantage of a biological beneficial effect 
of a single phenolic compounds group. For instance, lemongrass hydroxycinnamic 
acids and flavonoids have showed to possess a significant anti-inflammatory 
potential (Figueirinha et al., 2010, 2008; Francisco et al., 2014, 2013, 2011), 
while tannins have a greater effect against oxidant species (Costa et al., 2015a). 
Regarding the influence of plant quality on the composition of lemongrass 
extract, it is clear the correlation between these two parameters. Regardless the 
group of phenolic compound addressed, its content was always inversely 
proportional to the degree of leaves ageing, and therefore, to the time of sunlight 
and/or UV light exposition. These data are corroborated by other authors (Joubert 
et al., 2012; Stanimirova et al., 2013). Nevertheless, a recent work proved that 
UV-B supplementation, in low doses at physiological conditions, increases the 
amount of phenolic compounds biosynthesized by this plant (Kumari and Agrawal, 
2010). 
Antioxidant assays showed that all samples exhibited reasonably good TEAC 
values, with the exception for the ABTS (pH=4) assay. In that case, lemongrass 
infusion anti-radical power is tightly dependent on the harvest month, since it 
decreases drastically from April to July. This radical at pH=4 could be a significant 
marker for antioxidant activity monitoring. For other three oxidant species tested, 
the relationship between the harvest date and antioxidant potential is not very 
straight, with the exception of the sample collected in September, to which the 
antioxidant capacity decreased slightly. Nevertheless, it is clear the influence of 
harvest season on the antioxidant activity of lemongrass, as described by Zhu and 
co-workers for the phenolic acids and flavonoids from blueberries (Vaccinium 
ashei) (Zhu et al., 2013). Among the different groups of phenolic compounds, the 
phenolic acids seem to be the most decisive in the overall antioxidant activity of 
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the extract. For instance, in April and June, which are the months when the highest 
amount of phenolic acids is synthesized, the antioxidant potential is at its highest. 
Curiously, this data is corroborated by a recent review (Razzaghi-Asl et al., 2013). 
In what concerns the quality of the harvested material and its antioxidant 
capacity, the relationship could not be more explicit. For all tested oxidant species, 
the high-quality samples exhibited the best antioxidant results, and samples 
collected at the same month, but with low-quality presented the poorest potential. 
These results are corroborated by recent works (Klavsen and Madsen, 2008; 
Nantitanon et al., 2010). The difference is more pronounced for ABTS radical (at 
pH=4) and for ferric reducing power. On the other hand, all samples showed a 
better activity against ABTS (at pH=7) and DPPH radicals.  
The phenolic compounds quantification allowed investigating the variation 
of each particular phenolic compound for the different types of samples. Ferulic 
and caffeic acid derivatives (1-3) seem to be more sensitive to environment 
changes. These findings agree with those reported by Kotilainen and colleagues 
(Kotilainen et al., 2008), in which a decrease in some phenolic acids occurred upon 
irradiance with UV-B or UV-B + UV-A. On the other hand, p-coumaric acid (4) 
showed no substantial differences in the period of time tested, as described by 
Agati and co-workers in Ligustrum vulgare (Agati et al., 2011). Flavonoids seem to 
be more stable on their individual amounts, exception made to isoorientin. This 
flavonoid, besides being the most abundant flavonoid in lemongrass infusion, is 
also the most variable through the harvesting season. This point is crucial to 
consider when the bioactivity of this compound is at stake. In fact, isoorientin has 
been associated with significant biological activities such as antioxidant and anti-
inflammatory (Francisco et al., 2014; Orrego et al., 2009). Several authors suggest 
that this particular group of phenolic compounds act as a response to UV stress, 
that is regarded as an oxidative stress, and also as “sunscreen compounds” aiming 
at countering the UV-B-induced oxidative damage (Agati et al., 2011; Xu et al., 
2008). Moreover, increased UV-B induces the rapid synthesis of antioxidant 
enzymes (superoxide dismutase, catalase, and glutathione peroxidase) to cope with 
the free superoxide radicals. It is supposed that peroxidases under UV-B stress can 
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use flavonoids as substrates to detoxify hydrogen peroxide (Zlatev et al., 2012). 
The classical model proposed by Yamasaki et al. (1997), in which B-ring ortho-
dihydroxylated flavonoids are effective substrates for class III peroxidases to 
reducing H2O2 may be corroborated in light of the data presented here, since this 
specific type of flavonoids are the most abundant in lemongrass infusion. 
The effect of material quality on the amount of each phenolic compound 
was again disclosed. Once again, the percentage of all compounds is greater as the 
quality of the harvested vegetable material increases. 
 
5. Conclusions 
Our results indicate that the content on polyphenols and the antioxidant 
capacity of Cymbopogon citratus infusion is strongly related with the quality of 
the plant at the moment it is harvested. The effects of UV irradiance on the 
biosynthesis of flavonoids with potentially effective antioxidant activities lead to 
the hypothesis that light-induced changes in flavonoid metabolism are aimed at 
equipping the leaves with effective antioxidant metabolites, namely tannins. 
Therefore, it is not indifferent to extract the phenolic compounds from this plant 
with different quality grades or harvested on different months of the year. 
However, antioxidant activity and flavonoid concentrations were evaluated only at 
five consecutive months and with only one medium-quality and one low-quality 
samples, making it difficult to correlate the extent of environmental factors with 
polyphenolic content. This interesting issue may merit further investigations in 
which the composition on all phenolic compounds and in every month of the year 
are studied. 
In conclusion, both harvest date and plant quality are key criteria that have 
to be taken into account when selecting the material for human consuming, in 
order to receive benefits that have been allocated to phenolic compounds, namely 
to those who are present in this plant. 
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Abstract 
Cymbopogon citratus (lemongrass) leaves infusion, a commonly used 
ingredient in Asian, African and Latin America cuisines, is also used in traditional 
medicine for the treatment of several pathologic conditions, however little is 
known about their bioactive compounds. Recent studies revealed the crucial role of 
the phenolic compounds on the infusion bioactivity, namely flavonoids and 
tannins. Flavonoids have already been characterized; however the tannin fraction 
of lemongrass infusion is still uncharted. The aim of the present work is to 
characterize this fraction, and to evaluate its contribution to the antioxidant 
potential of this plant. Chemical characterization was achieved by HPLC-DAD-
ESI/tandem MS and antioxidant activity was evaluated using DPPH, ABTS and 
FRAP assays. Hetero-dimeric flavan structures have been described for the first 
time in lemongrass consisting of apigeniflavan or luteoliflavan units linked to a 
flavanone, either naringenin or eriodictyol, which may occur as aglycone or 
glycosylated forms. The antioxidant capacity of the fraction containing these 
compounds was significantly higher than the infusion, indicating its potential as a 
source of natural antioxidants. 
 
Keywords: Cymbopogon citratus; lemongrass; Poaceae; polyflavans; polyphenols; 
tannins; antioxidant. 
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1. Introduction 
Cymbopogon citratus (DC.) Stapf, commonly known as lemongrass, 
belongs to the Poaceae family and is a tropical perennial shrub originated 
from Southeast Asia. The lemon-like flavour of the plant is responsible for its 
use in tropical countries cuisines being its leaves a common ingredient in 
Asian cuisine in teas, soups and curries, being also suitable for fish, seafood 
and poultry (Adeneye and Agbaje, 2007). In African and Latin American 
countries, this herb is highly consumed as an aromatic and pleasant-tasting 
herbal drink. Furthermore, this plant is reported to possess antifungal, 
mosquito repellent, insecticidal, anti-diabetic, anti-septic, anti-mutagenic 
and anti-carcinogenic activity. The tea prepared from its leaves is medicinally 
used in Japan and Brazil (Masuda et al., 2008), and aqueous extracts of 
dried leaves are used in folk medicine for the treatment of several 
inflammation-based pathologies (Shah et al., 2011). The antioxidant and 
radical scavenging activities of hydrophilic extracts of Cymbopogon citratus 
have been reported by several authors and related to its polyphenolic 
components (Cheel et al., 2005; Khadri et al., 2008; Yoo et al., 2008). A 
recent work also revealed the high capacity of an aqueous extract from 
lemongrass to protect against the hydrogen peroxide-induced oxidative stress 
(Rahim et al., 2013).  
Previous studies suggested that lemongrass contains tannins, namely 
proanthocyanidins, based on the observation that acid cleavage of a fraction 
isolated from its lipid-free infusion yielded anthocyanidin-type products, 
although the precise nature of the compounds was not established 
(Figueirinha et al., 2010). Proanthocyanidins are oligomeric and polymeric 
flavonoids composed of flavan-3-ol subunits linked by C-C bonds. They are 
widespread throughout the plant kingdom, where they accumulate in many 
different organs and tissues, providing protection (Quijada-Morín et al., 
2012). Much of the earlier research on proanthocyanidins refers to flavan-3-
ol and flavan-3,4-diols  oligo/polymers, although other structures able to 
release anthocyanidins upon heating in acidic alcohol solutions have also 
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been described. Thus, in sorghum, also belonging to the Poaceae family, 
Gujer and co-workers (Gujer et al., 1986)  identified unique hetero-dimers 
and trimers consisting of a flavanone, either eriodictyol or eriodictyol 5-O-
glucoside, as the terminal unit linked to one or two glucosylated luteoliflavan 
(i.e. 5,7,3’,4’-tetrahydroxyflavan-5-O-glucosyl) extending units. The presence 
in sorghum of that type of oligomers containing either luteoliflavan or 
apigeniflavan extending units (i.e. releasing the 3-deoxyanthocyanidins 
luteoliflavan and apigeniflavan upon acid cleavage) up to the heptamer was 
further confirmed by Krueger and colleagues (Krueger et al., 2003). 
The present work aims to characterize phytoconstituents of the tannin 
fraction from Cymbopogon citratus infusion, and to evaluate its contribution 
to the antioxidant potential of this plant. 
 
2. Materials and Methods 
2.1 Plant material, extract preparation and fractioning 
Dry leaves of Cymbopogon citratus were purchased from ERVITAL 
(Mezio, Castro Daire, Portugal). The plant was cultivated in the region of 
Mezio, Castro Daire (Portugal). A voucher specimen was deposited in the 
Herbarium of Aromatic and Medicinal Plants of the Faculty of Pharmacy – 
University of Coimbra (A. Figueirinha 0109). The identity of the plant was 
confirmed by J. Paiva (Life Sciences Department, University of Coimbra, 
Portugal). A lipid- and essential oil-free infusion was prepared (CcI) as 
previously described (Figueirinha et al., 2008). Afterwards, the extract was 
fractionated on a reverse phase preparative Flash Chromatography® C18 
column Buchi® (150 × 40 mm; particle size 40 - 63 μm) (Flawil, 
Switzerland), eluted with aqueous methanol, in a discontinuous gradient: 5% 
(0-40 min), 5-10% (40-55 min), 10% (55-85 min), 10-15% (85-90 min), 15-
25% (90-110 min), 25-50% (110-140 min), 50% (140-160 min), 50-80% 
(160-180 min), 80-100% (180-200 min) and 100% (200-220 min) at a flow 
rate of 3 mL/min. The chromatographic profile was registered at 280 and 
320 nm by the UV detector C-640 Buchi® (Flawil, Switzerland), and the 
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data was acquired using the software ECOMAC® 0.238 (Prague, Czech 
Republic). Two fractions were obtained: F1 (0-120 min), containing 
phenolic acids and flavonoids and F2 (120-220 min), with flavonoids and 
tannins. F2 was then sub-fractionated by gel chromatography on a 
Sephadex LH-20 (Sigma-Aldrich, Amersham, Sweden) column (35 x 4 cm) 
using ethanol as mobile phase. All fractionation processes were monitored by 
high-performance liquid chromatography (HPLC) and thin layer 
chromatography (TLC) for polyphenols, providing two major fractions: 
flavonoids fraction, FF (yield 31.5%) and tannins fraction, TF (yield 14.2%). 
TF was analyzed by HPLC-DAD-ESI/tandem MS. 
 
2.2 HPLC-DAD-MS 
Analyses were carried out in a Hewlett-Packard 1100 chromatograph 
(Agilent Technologies, Waldbronn, Germany) with a quaternary pump and 
a diode array detector (DAD) coupled to an HP Chem Station (rev. A.05.04) 
data-processing station. An Agilent Poroshell 120 EC-C18, 2.7 µm (4.6 x 
150 mm) column thermostatted at 35°C was used. The solvents used were: 
(A) 0.1% formic acid, and (B) acetonitrile. The elution gradient established 
was from 8% B to 10% B in 5 min, to 25% B in 20 min, to 40% B in 20 
min, to 60% B in 5 min and steady at 60% B for more 5 min and re-
equilibration of the column using a flow rate of 0.5 mL/min. Double online 
detection was carried out in the DAD at 280, 320 and 370 nm as preferred 
wavelengths and in a mass spectrometer (MS) connected to HPLC system 
via the DAD cell outlet. 
MS detection was performed in an API 3200 Qtrap (Applied 
Biosystems, Darmstadt, Germany) equipped with an ESI source and a triple 
quadrupole-ion trap mass analyzer, which was controlled by the Analyst 5.1 
software. Zero grade air served as the nebulizer gas (30 psi) and as turbo gas 
(400 ºC) for solvent drying (40 psi). Nitrogen served as the curtain (20 psi) 
and collision gas (medium). Both quadrupols were set at unit resolution. The 
ion spray voltage was operated at -4500 V in the negative mode. Method 
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settings were: declustering potential (DP), -40 V; entrance potential (EP), -
10 V; collision energy (CE), -50 V; and cell exit potential (CXP) -3 V. In 
order to obtain the fragmentation pattern of the parent ion, enhanced 
product ion (EPI) mode was also applied using the following settings: 
declustering potential (DP), -50 V; entrance potential (EP), -6 V; collision 
energy (CE), -25 V; and collision energy spread (CES) 0 V.  
 
2.3 Acid-catalyzed hydrolysis 
In order to confirm the nature of the compounds from TF, an acid-
catalyzed hydrolysis was performed according to Porter et al.(Porter et al., 
1986) Briefly, an aliquot of TF dissolved in methanol was mixed with 
sulphuric acid in buthanol (5%, v/v) and iron-amonium sulfate 
dodecahydrate in hydrochloric acid 2N (2%, w/v). The mixture was sealed 
inside a glass vial and heated at 95ºC for 40 min. Then, the product of the 
hydrolysis was microfiltered and analysed by HPLC-DAD-MS. 
 
2.4 Antioxidant activity 
For the antioxidant activity assays, the adequate amount of freeze-
dried sample was solubilised in the referred solvent for each test.    
 
2.4.1 DPPH radical assay 
Free radical-scavenging activity was evaluated according to the method 
described by Blois et al. (1958). Aliquots of samples (100 µL) were assessed 
by their reactivity with a methanolic solution of 500 µM DPPH (500 µL) 
(Sigma-Aldrich, Quimica S.A., Portugal) in the presence of 100 mM acetate 
buffer, pH 6.0 (1 mL). Reaction mixtures (3 mL) were kept for 30 min at 
room temperature and in the dark. The decreases in the absorbance were 
measured at 517 nm. Different dilutions of each of the test compounds were 
assayed and the results were obtained by interpolating the absorbance on a 
calibration curve obtained with Trolox (62.5-1000 µM) (Sigma-Aldrich, 
Quimica S.A., Portugal). Two independent experiments in triplicate were 
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performed for each of the assayed compounds. Results were expressed as 
Trolox equivalent antioxidant capacity (TEAC), defined as the 
concentration of the sample solution whose antioxidant capacity is 
equivalent to a 1.0 mM solution of Trolox (Antolovich et al., 2002).  
 
2.4.2 ABTS (pH=4) radical assay 
The assay was carried out according to Cano (Cano et al., 1998) with 
minor modifications made by Villaño(Villaño et al., 2004). Free radicals 
were generated by an enzymatic system consisting of horseradish peroxidase 
enzyme, its oxidant substrate (hydrogen peroxide) and the 2,2’-azinobis-3-
ethylbenzothiazoline-6-sulfonic acid (ABTS•+) chromophore. The radical 
was generated by a reaction between 1.5 mM ABTS (Sigma-Aldrich, Spain), 
15 µM hydrogen peroxide (Sigma-Aldrich, Spain) and 0.25 µM peroxidase 
(Sigma-Aldrich, Spain) in 50 mM glycine-HCl buffer (pH 4.5). The final 
volume was 60 mL, yielding a final concentration of 30 µM of the ABTS•+ 
radical cation. The blank reference cuvette contained glycine–HCl buffer. 
Once the radical was formed, the sample was added and the decrease in 
absorbance was monitored. The assay was carried out at room temperature. 
The reaction started by adding 100 µL of test sample to 2 mL of ABTS•+ 
solution, the samples were vortexed for 10 s, and the absorbance at 414 nm 
was measured after 2 min of reaction. Two independent experiments in 
triplicate were performed for each of the assayed compounds. In each case, 
six different dilutions were prepared in 50% aqueous methanol and 
submitted to the reaction. TEAC values were obtained by interpolating the 
decrease in absorbance on the calibration curve obtained using Trolox 
solutions from 62.5 to 500 µM.  
 
2.4.3 ABTS (pH=7) radical assay 
In this assay, the ABTS•+ radical was produced by the oxidation of 7 
mM ABTS with potassium persulphate (2.45 mM, final concentration) 
(Merck, Darmstadt, Germany) in water. The mixture was allowed to stand in 
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the dark at room temperature for 12–16 h before use, and then the ABTS•+ 
solution was diluted with phosphate buffered saline (PBS) at pH 7.4 and 
equilibrated at 30 ºC to give an absorbance of 0.7±0.02 at 734 nm. Aliquots 
(50 µL) of 50% aqueous methanol of the test compound were mixed with 2 
mL of the ABTS•+ preparation, vortexed for 10 s, and the absorbance 
measured at 734 nm after 4 min of reaction at 30 ºC. Different dilutions of 
each of the test compounds were assayed and the results were obtained by 
interpolating the absorbance on a calibration curve obtained with Trolox 
(62.5–500 µM). The results were expressed as TEAC values. Two 
independent experiments in triplicate were performed for each of the assayed 
compounds. 
 
2.4.4 Ferric reducing power assay 
Ferric reducing ability was evaluated according to Benzie and 
Strain(Benzie and Strain, 1996) with minor modifications. The FRAP 
reagent contained 10 mM of TPTZ (Sigma-Aldrich, Spain) solution in 40 
mM HCl, 20 mM FeCl3·6H2O (Merck, Darmstadt, Germany) and acetate 
buffer (300 mM, pH 3.6) (1:1:10, v/v/v). Aliquots (100 µL) of 50% aqueous 
methanol of the test compounds were added to 3 mL of the FRAP reagent, 
and the absorbance was measured at 593 nm after incubation at room 
temperature for 6 min, using the FRAP reagent as blank. Different dilutions 
of each of the test compounds were assayed and the results were obtained by 
interpolating the absorbance on a calibration curve obtained with Trolox 
(31.25-1000 µM). The results were expressed as TEAC values. Two 
independent experiments in triplicate were performed for each of the assayed 
compounds. 
 
3.Results and Discussion 
3.1 HPLC-DAD-MS analyses  
The HPLC-DAD chromatogram of the tannin-rich fraction obtained 
from an oil-free infusion of C. citratus (TF) is shown in Figure II.9. The 
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tentative identities, retention times, UV maxima, and recorded molecular 
and MS2 fragment ions for individual components are presented in Table 
II.5.  A total of 15 compounds were tentatively identified including two 
distinct types of flavonoids: flavan-3-ols and flavan-flavanone hetero-dimers, 
these latter being the most abundant ones.  
Compounds 1-4 showed a UV spectral shape characteristic of flavan-3-
ols with a single maximum at 278 nm. Compound 2 ([M-H]− at m/z 289) 
was identified as catechin as confirmed by comparison with a commercial 
standard. Compounds 1, 3 and 4 were identified as dimeric procyanidins 
based on their molecular ion ([M-H]− at m/z 577) and MS2 fragmentation 
pattern showing the typical retro Diels-Alder fission (RDA; -152 amu, m/z at 
425), RDA + water loss (-170 amu, m/z at 407), heterocyclic ring fission (-
126 amu, m/z at 451), and cleavage of the interflavanic bond following the 
quinone-methide mechanism (QM; -288 amu, m/z at 289). By comparison 
with the relative retention times of procyanidins previously identified in the 
laboratory, it was possible to identify compounds 1, 3 and 4 as the 
procyanidin dimers B3, B4 and B2, respectively.  
Figure II.9. HPLC-DAD profile of tannin-rich fraction from Cymbopogon 
citratus leaves, registered at 280 nm. 
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Compounds 5-15 exhibited a different profile of UV spectrum, 
showing maximum absorbance at 278-280 nm but also an inflexion between 
331 and 349 nm, and their mass spectra suggest that they could correspond 
to flavan-flavanone hetero-dimers similar to those reported in sorghum 
(Gujer et al., 1986; Krueger et al., 2003). 
The detected compounds belonged to a series of dimers differing in 
masses of ±16 amu and ±162 amu depending on the number of hydroxy 
groups on ring-B and/or hexosyl residues, respectively, and their identities 
were assigned based on their molecular ions and MS2 fragmentation 
patterns. It has been indicated that the position of elementary units in 
proanthocyanidin oligomers could be deduced through the analysis of the 
product ions derived from the quinone methide (QM) cleavage of the 
interflavan bond, where lower (terminal) units would be released as such, 
while the upper (extension) units suffer a structural rearrangement yielding 
ions 2 Da lower than the original flavan constituents (Friedrich and 
Eberhardt, 2000; Gu et al., 2003). Thus, for instance, terminal eriodyctiol 
(MW 288) and narigenin (MW 272) would be expected to produce negative 
ions at m/z 287 and 271, respectively, whilst extension luteoliflavan and 
apigeniflavan units could be expected to produce them at m/z 272 and 256, 
respectively.  
Tentative identities for compounds 5-15 were assigned based on those 
assumptions and are indicated in Table II.5 and their structures depicted in 
Figure II.10. 
Compound 12 presented a molecular ion [M-H]− at m/z 543 releasing  
MS2 fragment ions at m/z 423 (-120 amu) and 407 (-136 amu) from the 
RDA fission of mono- and di-hydroxylated B-ring units, respectively; the 
higher abundance of the ion at m/z 407 suggested that it was produced from 
the cleavage of the upper (extension) unit of a di-hydroxylated B-ring, which 
was, therefore, associated to a luteoliflavan. The other two product ions at 
m/z 272 and 271 would derive from the interflavan cleavage and could be 
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attributed to the upper luteoliflavan unit and a terminal naringenin, 
respectively. Thus, the compound was tentatively identified as the dimer 
luteoliflavan-naringenin. Similar reasoning was applied to assign compounds 
14 and 15 as the dimers apigeniflavan-naringenin and luteoliflavan-
eriodictyol, respectively. The other hetero-dimers contained one or two 
hexosyl substituents linked to the aglycone(s) through an oxygen bridge, as 
deduced from the observation of losses of 162 amu in their MS2 
fragmentation spectra. Compound 9 ([M-H]− at m/z 705) showed a majority 
product ion at m/z 543 (-162 amu, loss of a hexosyl residue); the ion at m/z 
287 would be due to further QM cleavage of the previous ion, suggesting 
that eriodictyol hexoside would be the terminal unit. 
The other hetero-dimers contained one or two hexosyl substituents 
linked to the aglycone(s) through an oxygen bridge, as deduced from the 
observation of losses of 162 amu in their MS2 fragmentation spectra. 
Compound 9 ([M-H]− at m/z 705) showed a majority product ion at m/z 
543 (-162 amu, loss of a hexosyl residue); the ion at m/z 287 would be due 
to further QM cleavage of the previous ion, suggesting that eriodictyol 
hexoside would be the terminal unit. The other two fragment at m/z 585 (-
120 amu) and 569 (-136 amu) could be attributed to RDA fissions of the 
upper and lower units, respectively, taking into account relative abundances, 
which suggested an apigeniflavan nature for the extension unit. Therefore, 
the compound was tentatively assigned as apigeniflavan-eriodictyol-O-
hexoside. Based on similar considerations, compounds 10, 11 and 13 were 
respectively identified as luteoliflavan-eriodictyol-O-hexoside, luteoliflavan-
naringenin-O-hexoside and apigeniflavan-naringenin-O-hexoside. 
Compound 8 ([M-H]− at m/z 851) showed major fragment ions at m/z 
689 and 527 from the consecutive loss of two hexosyl residues, whereas 
another ion at m/z 731 (-120 amu) pointed to the existence of an upper 
apigeniflavan unit, so it could be tentatively identified as apigeniflavan-O-
hexosyl-naringenin-O-hexoside. Similarly, according to its molecular ion, 
compound 5 was assigned as luteoliflavan-O-hexosyl-eriodictyol-O-hexoside. 
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Compounds 6 and 7 presented the same molecular ion at m/z 867 and 
similar fragmentation pattern with two main fragments ions at m/z 705 and 
543 from the consecutive loss of two hexosyl residues, and other two at m/z 
747 (-120 amu) and 731 (-136 amu) attributable to RDA cleavages. 
These compounds were tentatively assigned based on the relative 
abundances of these latter ions. 
  
Table II.5. Phenolic characterization of tannin-rich fraction from 
Cymbopogon citratus infusion, by HPLC-DAD-tandem MS. 
 
Peak Tentative Identification 
Rt 
(min) 
λmaxima 
(nm) 
[M-
H]- 
(m/z) 
MS2 (m/z) 
1 Procyanidin B3* 8.25 278 577 
451(13), 425(46), 407(100), 
289(54) 
2 Catechin* 9.59 278 289 
245(100), 221(28), 203(50), 
163(45), 137(22), 125(66) 
3 Procyanidin B4* 13.78 278 577 
451(30), 425(65), 407(91), 
289(100) 
4 Procyanidin B2* 14.85 278 577 
451(33), 425(72), 407(94), 
289(100) 
5 
Luteoliflavan-O-hexosyl-
eriodictyol-O-hexoside 
16.34 280, 338 883 747(11), 721(100), 559(77) 
6 
Apigeniflavan-O-hexosyl-
eriodictyol-O-hexoside 
17.34 280, 338 867 
747(5), 731(2), 705(100), 
543(86) 
7 
Luteoliflavan-O-hexosyl-
naringenin-O-hexoside 
18.85 280, 342 867 
747(2), 731(3), 705(100), 
543(74) 
8 
Apigeniflavan-O-hexosyl-
naringenin-O-hexoside 
19.95 280, 339 851 731(3), 689(100), 527(80) 
9 
Apigeniflavan-eriodictyol-O-
hexoside 
20.61 280, 331 705 
585(16), 569(5), 543(100), 
287(2) 
10 
Luteoliflavan-eriodictyol-O-
hexoside 
21.58 280, 349 721 585(13), 559(100), 287(3) 
11 
Luteoliflavan-naringenin-O-
hexoside 
23.60 279, 344 705 
585(2), 569(4), 543(100), 
271(2) 
12 Luteoliflavan-naringenin 25.09 280, 342 543 
423(31), 407(100), 272(3), 
271(15) 
13 
Apigeniflavan-naringenin-O-
hexoside 
25.71 278, 335sh 689 569(5), 527(100), 271(2) 
14 Apigeniflavan-naringenin 26.30 279, 336 527 407(100), 271(11), 256(2) 
15 Luteoliflavan-eriodictyol 28.77 278, 341 559 423(100), 287(13), 272(3) 
sh: shoulder; *confirmed by a commercial standard 
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Figure II.10. Proposed structures for compounds 5-
15 identified in tannin-rich fraction from 
Cymbopogon citratus leaves. 
 
Thus, the ion at m/z 747 was more abundant in compound 6 which 
might suggest an upper apigeniflavan unit, so that it could be identified as 
apigeniflavan-O-hexosyl-eriodictyol-O-hexoside. In contrast the ion at m/z 
731 was more abundant in compound 7 pointing to an upper luteoliflavan 
unit, allowing its tentative identification as luteoliflavan-O-hexosyl-
naringenin-O-hexoside. The nature and substitution position of the hexosyl 
residues on the different aglycones cannot be established from the available 
data, although they might be speculated to be glucose probably linked to the 
hydroxyl group at C5 of the corresponding flavan unit, according to the 
previous identifications made by Gujer (Gujer et al., 1986) and 
Krueger(Krueger et al., 2003) in sorghum.  
 
 
3.2 Acid-catalyzed hydrolysis 
The product from TF acid hydrolysis was characterized by HPLC-
DAD-MS and apigenidin and luteolinidin molecules were detected (data not 
shown). These results confirm the presence of apigeniflavan and luteoliflavan 
residues in the structure of the tannin oligomers present in TF, respectively. 
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3.3 Antioxidant activity  
Table II.6 shows the TEAC values for the lipid-free infusion (CcI) and 
tannin fraction (TF) of C. citratus obtained by different assays. In all assays, 
TF exhibited higher antioxidant capacity (lower TEAC values). In the DPPH 
assay, the TEAC value for TF was 0.61, 2.33 times more potent than CcI. 
 
Table II.6. Antioxidant activity of CcI and TF from Cymbopogon citratus. 
Sample 
TEAC* 
DPPH• ABTS• (pH=4) ABTS• (pH=7) Fe3+ 
CcI 1.40 ± 0.06 2.29 ± 0.02 0.83 ± 0.04 2.63 ± 0.10 
TF 0.61 ± 0.07 1.59 ± 0.05 0.65 ± 0.06 0.38 ± 0.07 
*TEAC (Trolox-Equivalent Antioxidant Capacity): Amount of the samples (mg/mL) that 
has the same anti-radical activity of Trolox 1 mM. The results are expressed as mean±SD 
of three independent experiments.  
 
Nevertheless, the TEAC value of CcI, which corresponds to an EC50 of 
28.99g/mL, is substantially better than another lemongrass infusion 
previously mentioned in the literature, which presents an EC50 of 
41.72g/mL(Tavares et al., 2015). In the ABTS (pH=4) method, TF and 
CcI showed TEAC values of 1.59 and 2.29, respectively; whereas in the 
ABTS (pH=7) assay, the samples gave TEAC values of 0.65 and 0.83, 
respectively. In both cases, TF was about 1.3 times more efficient in 
neutralizing the ABTS• radical than CcI. However, the two samples 
happened to be significantly more potent at pH=7 than in an acidic 
environment, which might be important when considering physiological 
conditions. In the FRAP assay, TF (TEAC value of 0.38) was almost 7 times 
more efficient than CcI (2.63). In the case of CcI, the antioxidant capacity 
increases as follows: Fe3+ < ABTS (pH=4) < DPPH < ABTS (pH=7), while 
TF antioxidant power increases: ABTS (pH=4) < ABTS (pH=7) < DPPH 
< Fe3+. This may be explained by the fractionation process, leading to a 
different matrix and composition with a distinct chemical behaviour against 
the tested oxidant species. Nevertheless, the tannin fraction proved to be 
fairly more active in inactivating the potentially harmful oxidant entities 
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than the crude extract obtained by infusion. This data seems to be supported 
by previous studies in Sorghum bicolor, which showed that this type of 
condensed tannins has a very important contribution to the antioxidant 
activity of the whole plant (Bors et al., 2000; Choi et al., 2007). 
 
4. Conclusions 
The present work allowed the identification of hetero-dimeric flavan 
structures for the first time in Cymbopogon citratus. These flavonoid 
oligomers consist of apigeniflavan or luteoliflavan units linked to a 
flavanone, either naringenin or eriodictyol, and occur as aglycone and 
glycosylated forms. The detected proanthocyanidin hetero-dimers, along 
with some common procyanidin dimers, constitute the main compounds in 
the tannin fraction of C. citratus infusion. The findings of this study support 
the antioxidant potential of this plant and emphasize the contribution of the 
tannin fraction to this activity.  
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Abstract 
Ethnopharmacological relevance: Treatment of gastric ulcers with 
medicinal plants is quite common in traditional medicine worldwide. Cymbopogon 
citratus (DC.) Stapf leaves infusion has been used in folk medicine of many 
tropical and subtropical regions to treat gastric disturbances. 
Aim of the study: The aim of this study was to assess the potential 
gastroprotective activity of an essential oil-free infusion from C. citratus leaves in 
acute gastric lesions induced by ethanol in rat. 
Materials and Methods: The study was performed on adult male Wistar 
rats (234.0 ± 22.7 g) fasted for 24 hours but with free access to water. The extract 
was given orally before (prevention) or after (treatment) intragastric administration 
of absolute ethanol. Effects of dose (28 or 56 mg/kg of body weight) and time of 
contact of the extract with gastric mucosa (1 or 2 hours) were also assessed. 
Animals were sacrificed, being the stomachs removed and the lesions were assessed 
by macroscopic observation and histopathology. 
Results: C. citratus extract, given orally before or after ethanol, significantly 
(P<0.01) reduced gastric mucosal injury compared with control group (vehicle + 
ethanol). The effect does not appear to be dose-dependent. Results also suggested 
that the extract is more effective when the time of contact with gastric mucosa 
increases. 
Conclusions: The results of this assay confirm the gastroprotective activity 
of C. citratus extract on experimental gastric lesions induced by ethanol, 
contributing for the pharmacological validation of its traditional use. 
Keywords: Cymbopogon citratus; lemongrass; infusion; gastric ulcer; 
gastroprotective. 
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1. Introduction 
Peptic ulcer disease is a serious gastrointestinal disease that affects a 
considerable number of people in the world and has a significant impact on the 
quality of life (Yuan et al., 2006). Many drugs currently available for the treatment 
of peptic ulcers have decreased the morbidity rates, but limitations still exist, such 
as incidence of relapses and adverse effects (Borrelli and Izzo, 2000; Schmeda-
Hirschmann and Yesilada, 2005). Cymbopogon citratus (DC.) Stapf (Poaceae), 
also known as lemongrass, is a perennial herb native to India and widely cultivated 
in other tropical and subtropical regions. Infusions and decoctions of C. citratus 
leaves have been used in popular medicine to treat a wide variety of health 
problems such as feverish conditions, nervous and gastrointestinal disorders 
(Carlini et al., 1986). It is also recommended in folk medicine to treat gastric 
disturbances, stomachache, gastritis and ulcers (de Albuquerque et al., 2007; 
Novais et al., 2004; Tene et al., 2007). Studies on C. citratus leaves infusions and 
decoctions have shown antioxidant and anti-inflammatory activities (Cápiro et al., 
2001; Carbajal et al., 1989; Cheel et al., 2005; Figueirinha et al., 2010, 2008; 
Francisco et al., 2013, 2011; Pereira et al., 2009) and revealed the presence of 
several polyphenols, including tannins, phenolic acids and flavonoids (Cheel et al., 
2005; Figueirinha et al., 2008; Francisco et al., 2014; Marques and Farah, 2009; 
Pereira et al., 2009). Those properties may be indicative of the potential benefit in 
the gastrointestinal tract, mainly on gastric mucosal injury generated by oxidative 
damage. However, to our knowledge there are no pharmacological studies 
regarding the potential gastroprotective activity of this medicinal plant in 
literature. 
This study was therefore carried out in order to assess the gastroprotective 
activity of an essential oil-free infusion from C. citratus dry leaves in acute gastric 
lesions experimentally induced by ethanol in rats. 
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2. Materials and methods 
2.1 Plant material and extract preparation 
Dry leaves of Cymbopogon citratus (DC.) Stapf were acquired from Ervital® 
(Mezio, Castro Daire, Portugal). The plant was cultivated in the region of Mezio, 
Castro Daire (Portugal), in a greenhouse located 1000 m above sea level. The 
identity of the plant was confirmed by Prof. Dr. J. Paiva (Department of Botany, 
University of Coimbra, Portugal). A voucher specimen is deposited in the 
herbarium of the Faculty of Pharmacy, University of Coimbra (A. Figueirinha 
0109). 
The extract was prepared as previously described by Figueirinha and co-
workers (Figueirinha et al., 2008). Briefly, an infusion was obtained by adding 150 
mL of boiling water to 5 g of the powdered plant material and left to stand at room 
temperature for 15 minutes. The infusion was filtered under vacuum and the 
volume was made up to 150 mL with the same solvent. Afterwards, an essential 
oil-free infusion was obtained by repeatedly washing the infusion with n-hexane to 
remove the less polar compounds; the aqueous phase was concentrated in a 
rotavapor and then freeze-dried (extraction yield: 14%). Before the experiment, the 
extract was solubilized in water (vehicle) and given to rats, by gavage, at a dose of 
28 mg/kg of body weight (d1) or 56 mg/kg of body weight (d2). These doses were 
calculated by extrapolation from the human dose recommended in traditional 
medicine (2 g of dried leaf/150 mL of water) (Carlini et al., 1986). 
 
2.2 Animals 
Adult male Wistar rats (234.0±22.7 g) were purchased from Charles River 
Laboratories (Barcelona, Spain). The rats were housed at least for 7 days before 
experiments in the local bioterium under standard laboratory conditions, which 
include a temperature of 22±1ºC, relative humidity of about 50-60% and a 
controlled 12-h light cycle beginning early in the morning. Rats were deprived of 
food for 24 hours prior to experiments, but allowed free access to water. During 
the period of starvation animals were housed in wire-bottom cages to prevent 
coprophagy. Animal experimentation in this study was conducted in accordance 
CHAPTER II | RESULTS and DISCUSSION 
 
141 
 
with the European guidelines for laboratory animal use and care (86/609/EEC) and 
the project was approved by the Portuguese Veterinary General Division 
(Reference no. 99 – 0420/000/000, 9/11/2009). 
 
2.3 Ethanol-induced gastric lesions assay 
Rats were divided into nine experimental groups (n = 6-9). Absolute ethanol 
administered orally by gavage at a single dose of 1 mL/rat was used as ulcerogenic 
agent. Group I received vehicle (water) orally one hour before ethanol (positive 
control). The animals were sacrificed one hour after ulcer induction. Animals from 
group II received orally only vehicle, and one hour later they were sacrificed 
(negative control). Animals from group III received orally only extract, and one 
hour later they were sacrificed (negative control). Animals from groups IV, V and 
VI were given extract orally prior to ulcer induction (prevention groups). Animals 
from group IV received dose d1 of the extract one hour before ethanol 
administration. Animals from group V received dose d2 of the extract one hour 
before ethanol administration. Animals from group VI received dose d1 of the 
extract two hours before ethanol administration. One hour after ulcer induction 
the animals from groups IV-VI were sacrificed. Animals from groups VII, VIII and 
IX received extract orally after ulcer induction by ethanol (treatment groups). One 
hour after ethanol administration, the animals received a dose d1 (groups VII and 
IX) or d2 (group VIII) of the extract. They were sacrificed one hour (groups VII 
and VIII) or two hours (group IX) after extract administration. After the animals 
were sacrificed, each stomach was removed, opened along the greater curvature, 
rinsed with physiological saline and photographed. The gastric mucosa was 
carefully examined, macroscopically and by histopathology, and scored. 
 
2.4 Macroscopic assessment of gastric mucosal lesions 
Gastric mucosa was examined macroscopically and each lesion was graded 
and scored based on its incidence and severity according to an arbitrary grading 
system. The grade of severity was attributed differently in each parameter: loss of 
mucosal folds (0, 1, 2, 3); haemorrhagic areas (0, 1, 2, 3); necrotic areas/ulcers (0, 
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2, 4, 6); perforation (0, 10). The ulcer index (U.I.) for each stomach was the sum 
of scores of all lesions. The U.I. for each experimental group was reported as 
median (minimum – maximum). The significance of differences between groups 
was assessed by Kruskal-Wallis test, followed by Mann-Whitney U test, when 
appropriate. P<0.05 versus control was taken as significant. 
 
2.5 Microscopic assessment of gastric mucosal lesions 
After macroscopic examination of the stomach, gastric tissue samples from 
the lesion sites were prepared for histopathological studies. The fragments were 
fixed in 4% neutral phosphate-buffered formalin, embedded in paraffin blocks, cut 
in 3 µm thick sections and stained with hematoxylin and eosin. The slides were 
examined under microscope and assessed for histopathological changes such as 
congestion, oedema, haemorrhage and necrosis. 
 
3. Results 
The severity of gastric mucosal damage in the experimental groups, as 
measured by U.I., is listed in Table II.7. Rats treated only with vehicle and C. 
citratus extract (groups II and III) showed a normal morphology of the gastric 
mucosa. In the positive control group, treated orally with vehicle and absolute 
ethanol, severe and widespread damage of the glandular mucosa was observed 
macroscopically and the U.I. was found to be very high (median: 9.0). Ethanol 
administration produced the expected characteristic haemorrhagic and necrotic 
mucosal lesions, consisting of elongated bands usually parallel to the long axis of 
the stomach, submucosal oedema and loss of epithelial cells (Figure II.11a). In 
accordance with the macroscopic assessment, the histological examination of the 
gastric tissue samples revealed haemorrhagic areas, mucosal atrophy and presence 
of inflammatory infiltrate (Figure II.11b). 
In the prevention groups, treated orally with C. citratus extract prior to 
ethanol, an important reduction in both number and severity of gastric lesions was 
observed (Figure II.12). The U.I. significantly decreased in all prevention groups 
(P<0.01) compared to the positive control group. Similarly, when administered 
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after ethanol administration (treatment groups), C. citratus extract also produced a 
significant reduction in the U.I. (P<0.01) compared to the positive control group. 
However, the protective effect of the extract does not seem to be dose-dependent, 
as no significant differences in the U.I. were found across the doses used, both in 
prevention (group IV versus V; P=0.143) and treatment groups (group VII versus 
VIII; P=0.154). Although not statistically significant, the gastroprotective effects 
of the extract were more pronounced when time of contact with gastric mucosa 
increased to 2 hours (group VI and IX) compared to 1 hour (groups IV and VII). 
 
Table II.7. Effect of essential oil-free infusion from Cymbopogon citratus leaves 
on gastric lesions induced by ethanol in rats. 
Experimental group 
Administered 
product(s) 
Dose 
(mg/kg) 
Time of 
contact 
(h) 
Ulcer Index (U.I.) 
[median (min-
max)] 
Control groups:     
Group I Vehicle, ethanol - - 9.0 (5 – 12) 
Group II Vehicle - - 0.0 
Group III Extract 28 1 0.0 
Prevention groups:     
Group IV Extract, ethanol 28 1 3.5 (2 – 4)* 
Group V Extract, ethanol 56 1 4.0 (3 – 5)* 
Group VI Extract, ethanol 28 2 2.5 (1 – 4)* 
Treatment groups:     
Group VII Ethanol, extract 28 1 4.0 (3 – 5)* 
Group VIII Ethanol, extract 56 1 4.0 (3 – 6)* 
Group IX Ethanol, extract 28 2 3.0 (1 – 4)* 
* P<0.01, compared to positive control (group I) (Kruskal-Wallis test, followed by Mann-Whitney 
U test). 
 
Figure II.11. Ethanol-induced gastric injury in rats. (a) Representative 
macroscopic aspect of the stomach, showing severe and widespread damage of the 
glandular mucosa one hour after ethanol administration. (b) Histological section of 
gastric mucosa, showing haemorrhagic areas, mucosal atrophy and presence of 
inflammatory infiltrate (HE staining). 
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Figure II.12. Representative macroscopic aspect of the effects of Cymbopogon 
citratus extract on ethanol-induced gastric lesions in rats. (a) Stomach treated with 
extract, dose 28 mg/kg, one hour before ethanol (group IV). (b) Stomach treated 
with extract, dose 56 mg/kg, one hour before ethanol (group V). (c) Stomach 
treated with extract, dose 28 mg/kg, two hours before ethanol (group VI). (d) 
Stomach treated for one hour with extract, dose 28 mg/kg, after ethanol 
administration (group VII). (e) Stomach treated for one hour with extract, dose 56 
mg/kg, after ethanol administration (group VIII). (f) Stomach treated for two 
hours with extract, dose 28 mg/kg, after ethanol administration (group IX). 
 
4. Discussion 
The formation of gastric mucosal lesions following ethanol administration 
seems to occur both directly and indirectly through several mechanisms. Gastric 
mucosal damage induced by ethanol has been reported to involve a depletion of 
gastric defensive mechanisms, including disruption of the mucosal barrier, gastric 
mucus depletion, reduced gastric blood flow and alterations in permeability, that 
contribute to the development of the haemorrhagic and necrotic aspects of tissue 
injury (Glavin and Szabo, 1992). Furthermore, some studies suggest that oxygen-
derived reactive species and lipid peroxidation are associated with gastric damage 
induced by ethanol. This data suggest that antioxidant compounds could be active 
in this experimental model, producing gastroprotective effects (Glavin and Szabo, 
1992; La Casa et al., 2000). 
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Essential-oil free infusion from Cymbopogon citratus leaves, administered 
before (prevention) or after (treatment) ethanol, reduced significantly the 
incidence and severity of gastric lesions and consequently the U.I.. These results 
indicate that C. citratus extract, at doses equivalent to the human dose 
recommended in traditional medicine, display a gastroprotective effect against 
ethanol-induced ulcer. 
A previous phytochemical study of the essential oil-free infusion from C. 
citratus used in this study has indicated the presence of tannins, phenolic acids 
(caffeic and p-coumaric acid derivatives) and flavonoids (Figueirinha et al., 2008). 
In the flavonoid fraction, representing 6.1% of the extract, several O- and C-
glycosylflavones of apigenin and luteolin were identified (Francisco et al., 2014). 
Many compounds from these chemical classes have been shown to possess anti-
ulcer properties (Borrelli and Izzo, 2000). Tannins have radical-scavenger 
properties and, at low concentrations, are known to create a layer in the mucosa 
and to increase the resistance to chemical and mechanical injury or irritation 
(Borrelli and Izzo, 2000). Recently, a different group of flavanic dimmers have 
been identified in lemongrass infusion, which have been correlated with a 
pronounced anti-radical activity (Costa et al., 2015a). Phenolic acids, such as 
caffeic, p-coumaric, ferulic and hydroxycinnamic acids, display anti-ulcer activity in 
several acute gastric ulcer models (Barros et al., 2008). It is well known that many 
flavonoids have antisecretory and cytoprotective properties in different 
experimental models of gastric ulcer (La Casa et al., 2000; Mota et al., 2009). In 
particular, several plants with anti-ulcer activity which contain luteolin and 
luteolin O- and C-glycosides have been reported (Batista et al., 2004; Coelho et al., 
2009, 2006; Min et al., 2006; Yesilada et al., 2000). Therefore, the polyphenolic 
chemical composition of the extract may contribute, at least in part, to the 
gastroprotective effects observed in this study. 
Literature reports that many polyphenols have antiulcer activity probably 
because of their antioxidant properties, which could prevent the formation of free 
radicals in the body and also minimize injuries by oxidative reactions (La Casa et 
al., 2000; Repetto et al., 2002). In previous studies our group demonstrated the in 
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vitro antioxidant and anti-inflammatory activity of the essential oil-free infusion 
from C. citratus used in this study and of different fractions obtained from it 
(Figueirinha et al., 2010, 2008), providing a possible mechanism to explain the 
protection produced by the plant extract against ethanol-induced gastric lesions. 
 
5. Conclusions 
In conclusion, the results of this study suggest a gastroprotective activity of 
C. citratus extract against ethanol-induced gastric lesions, contributing to the 
pharmacological validation of its traditional use. In the future, further 
pharmacological evaluations are required to identify and isolate the active 
gastroprotective compounds in the plant as well as elucidating their mechanisms of 
action. 
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Abstract 
Cymbopogon citratus is one of the most common herbs used in folk 
medicine due to its anti-inflammatory and antioxidant properties. Taking into 
account these properties showed on in vitro assays, the aim of this work was to 
evaluate the anti-inflammatory and analgesic activities of C. citratus leaves 
infusion (CcE), and its flavonoid-rich (CcF) and tannin-rich (CcT) fractions. The 
evaluation of the anti-inflammatory activity was performed in the carrageenan-
induced rat paw oedema model. Both central and peripheral analgesic activities 
were evaluated in mice through the hot plate test and the acetic acid-induced 
writhing test, respectively.  
In the acute inflammation model, the statistically significant results 
obtained in percentage of oedema inhibition were 70.80% and 82.30% for CcE 
(34.12 mg/kg and 68.24 mg/kg, respectively), 59.00% for CcF (7.42 mg/kg), 
61.00% for CcT (5.96 mg/kg) and 84.00% for positive control group (10 mg/kg). 
For the peripheral pain evaluation, statistically significant results showed a pain 
reduction of 57.00% for CcE (136.48 mg/kg), 54.60% for CcF (14.8 mg/kg), 
52.20% for CcT (11.92 mg/kg) and 83.00% for positive control group.  
This study demonstrates that C. citratus infusion compounds are able to 
reduce inflammation and peripheral pain in vivo, with polyphenols showing a 
significant contribution for these activities.   
 
Keywords: Cymbopogon citratus, lemongrass, in vivo, inflammation, pain, 
phenolic compounds. 
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1. Introduction 
Cymbopogon citratus (DC.) Stapf, commonly known as lemongrass, is an 
Indian native herb belonging to the Poaceae, which comprises approximately 500 
genus and 8000 herb species (Barbosa et al., 2008). C. citratus is used in folk 
medicine with a wide range of indications, such as digestive and nervous disorders, 
inflammation, pain, fever and diabetes (Lorenzetti et al., 1991). It is also 
consumed as an aromatic drink and is widely used in traditional cuisine due to its 
lemon flavor (Figueirinha et al., 2008). Moreover, C. citratus leaves are a source of 
essential oil used both in the flavor and fragrance industries and for the production 
of insect repellents and disinfectants (Negrelle and Gomes, 2007; Rauber et al., 
2005).  
Because of its economic impact, most phytochemical studies are centered in 
the volatile compounds of C. citratus leaves and only essential oil chemical 
composition is well known (Kasali et al., 2001). However, many of the suggested 
therapeutic activities of lemongrass have been attributed to the non-volatile 
phenolic compounds present in leaves, which have gained attention especially by 
their antioxidant and radical-scavenging activities. This fact has increased both 
industrial and academic interest on the non-volatile composition of the plant (Arce 
et al., 2004; Figueirinha et al., 2008). Presently, it has been proven the presence of 
a great variety of constituents in C. citratus leaves, such as phenolic acids, 
alkaloids, alcohols and, more important, flavonoids and tannins, which may be 
responsible for some therapeutic activities such as anti-inflammatory activity 
(Figueirinha et al., 2010; Negrelle and Gomes, 2007; Vendruscolo et al., 2005).  
Considering that inflammation may lead to various diseases – such as 
rheumatoid arthritis, inflammatory bowel disease or psoriasis – and current 
steroidal and non-steroidal anti-inflammatory drugs used to treat inflammatory 
disorders can develop many adverse effects, the discovery of new and safer anti-
inflammatory agents continue to be an issue of high interest. In this field, plants 
used in folk medicine become excellent research candidates for their potential 
content in compounds to lead to effective herbal formulations from standardized 
active extracts. 
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To our knowledge, there are no pharmacological studies that evaluate the 
anti-inflammatory potential of C. citratus leaves infusion and its phenolic 
compounds on in vivo models, even if in a previous study of our group it has been 
reported that, under inflammatory conditions, an essential oil-free infusion of C. 
citratus leaves allowed cell viability and conferred significant reduction of nitric 
oxide production in dendritic cells stimulated with lipopolysaccharide (Figueirinha 
et al., 2010). More recently, our group found more evidence of the anti-
inflammatory mechanisms behind the beneficial effects of this plant, and mainly 
due to its phenolic compounds in vitro (Francisco et al., 2014, 2013, 2011). 
Based on these findings, the aim of the present work was to evaluate the 
anti-inflammatory and analgesic activities of an essential oil-free infusion (CcE), a 
flavonoid-rich fraction (CcF) and a tannin-rich fraction (CcT) of C. citratus leaves 
on animal models of acute inflammation and pain. 
 
2. Materials and methods 
2.1.  Plant material and infusion preparation 
Dry leaves of C. citratus (DC.) Stapf were purchased from ERVITAL® 
(Mezio, Castro D’Aire, Portugal). The plant was cultivated in the region of Mezio, 
Castro d’Aire (Portugal), in a greenhouse at 1000 m above sea level and was 
collected in September 2007. A voucher specimen was deposited in the Herbarium 
of Aromatic and Medicinal Plants of the Faculty of Pharmacy - University of 
Coimbra (A. Figueirinha 0109). The plant identification was confirmed by Dr. J. 
Paiva (Department of Life Sciences, University of Coimbra, Portugal).  
CcE was obtained as previously described by Figueirinha et al. (Figueirinha 
et al., 2008). Briefly, the infusion was prepared by adding boiling water to the 
plant material (30:1 v/w) and left for 15 min. After the extraction, the mixture was 
filtered under vacuum and it was washed three times with n-hexane to remove the 
less polar compounds. The aqueous phase was concentrated using a rotary 
evaporator to a small volume, freeze-dried, and kept at -20ºC, in N2 atmosphere, 
until use. All subsequent study was performed with this essential oil-free infusion 
(CcE). For in vivo experiments the infusion was dissolved in distilled water. 
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Administrated doses were calculated based on the traditionally used doses, taking 
into consideration the yield of the extraction process and the conversion into 
animal doses, according to the FDA (Food and Drug Administration) guidelines. In 
order to examine a possible dose-dependent effect, two different doses were used: 
D’1 and D’2 (dose and double dose for the anti-inflammatory assay), and D’’1 and 
D’’2 (dose and double dose for the analgesic assay), according to the animal model 
used. 
 
2.2.  Infusion fractionation 
The flavonoid and tannin-rich fractions were obtained using a reverse phase 
semipreparative column Lichroprep RP-18 (310 mm x 25 mm, particle sizes 40-
63 m), Merck (Darmstadt, Germany), eluted with water and aqueous methanol 
solutions. Tannin-rich fraction (CcT), phenolic acids fraction and a mixture of 
phenolic acids and flavonoids were obtained. Dry residue of that mixture was 
recovered in 50% aqueous ethanol and fractionated by gel chromatography on a 
Sephadex® LH-20 (Sigma–Aldrich-Amersham, Sweden) column (85cm×2.5 cm), 
using ethanol as mobile phase, as previously described (Figueirinha et al., 2010). A 
flavonoid-rich fraction (CcF) was obtained. All the fractioning processes described 
above were monitored by HPLC and thin-layer chromatography. 
The tannin and flavonoid-rich fractions were concentrated under reduced 
pressure at 40°C and freeze-dried. Again, before the in vivo experiments, the 
fractions were dissolved in distilled water and the doses administrated were 
calculated taking into consideration the yield of the fractioning process, according 
to Figueirinha et al. (Figueirinha et al., 2010), and converted into animal doses. 
 
2.3.  Reagents and drugs 
n-Hexane was purchased from Carlo Erba Reagenti SpA (Milan, Italy). 
Acetic acid was purchased from J.T. Baker (Deventer, Holand). Ketamine (Ketalar, 
7.7 mg/kg) was purchased from Parke-Davis, Pfizer (Seixal, Portugal) 
Chlorpromazine (Largatil, 2.3 mg/kg) was purchased from Rhône-Poulenc Rores, 
Laboratório Vitória SA (Amadora, Portugal). Diclofenac sodium (Voltaren 75 
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mg/3mL) was purchased from Novartis Pharmaceuticals SA (Barcelona, Spain). 
Morphine hydrochloride and carrageenan-κ were purchased from Sigma Chemical 
Co. (St. Louis, MO, USA). All other reagents were purchased from Merck 
(Darmstadt, Germany).   
 
2.4.  Animals 
Male Wistar rats weighing 120-220 g and male mice weighing 20-30 g were 
obtained from Charles River (Barcelona, Spain). The animals were maintained 
with food and water ad libitum and kept at 22 ± 1ºC with controlled 12-hour 
light/dark cycle at the Faculty of Pharmacy (University of Coimbra). The animals 
were allowed to adapt to the laboratory for 7 days before testing.  
For evaluation of C. citratus anti-inflammatory activity, male Wistar rats 
were fasted with free access to water at least 24 h prior to experiments, and to 
study the analgesic activities, male mice were fasted with free access to water at 
least 18 h prior to experiments. The research was conducted in accordance with the 
internationally accepted principles for laboratory animal use and care as found in 
Directive 2010/63/EU. 
 
2.5.  Pharmacological assays 
2.5.1. The carrageenan-induced rat paw oedema test 
The carrageenan-induced rat paw oedema test (Green and Green, 1971) was 
used to evaluate the in vivo acute anti-inflammatory activity of the samples of C. 
citratus. Diclofenac sodium was used as reference drug. The animals were divided 
into eight groups (n = 6): carrageenan control group received water 0.5 µL/g p.o., 
positive control group received diclofenac sodium 10 mg/kg i.p. and test groups 
received orally the extract at the doses of 34.12 mg/kg (CcE D’1) and 68.24 mg/kg 
(CcE D’2), the flavonoid-rich fraction at the doses of 3.71 mg/kg (CcF D’1) and 
7.42 mg/kg (CcF D’2), and the tannin-rich fraction at the doses of 2.98 mg/kg 
(CcT D’1) and 5.96 mg/kg (CcT D’2).  
Carrageenan control and test groups were dosed 1 h and positive control 
group was dosed 30 min before a subplantar injection of 0.1 mL of 1% solution of 
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carrageenan in saline, administered to the right hind footpad of each animal. The 
paw oedema volume was measured with a digital plethysmometer (model LE7500, 
Panlab, Barcelona, Spain) after carrageenan injection and then every hour during 
six hours. The anti-inflammatory effect was calculated 4 h after carrageenan 
administration and was expressed as percentage of oedema inhibition for the 
treated animals with respect to the carrageenan control group. The percentage of 
oedema inhibition was calculated according to the following equation: 
% oedema inhibition = 1 - (Vt/Vc) x 100 
where Vt is the mean variation of the paw volume in rats treated with the sample 
or diclofenac sodium and Vc is the mean variation of the paw volume in the 
carrageenan control group. 
 
2.5.2. The hot plate test 
The hot plate test was used to evaluate the central analgesic activity of the 
samples by measuring the reaction time according to the method described by 
Eddy & Leimbach (Eddy and Leimbach, 1953). Morphine was used as reference 
drug. Mice were placed individually on a hot plate set at 55±1°C (model LE7406, 
PanLab, Barcelona, Spain). Reaction time was recorded when the animals licked 
their forepaws, shaked or jumped. The baseline was considered as being the 
reaction time before treatment. Then, the animals were divided into seven groups 
(n = 6-8): positive control group received morphine 10 mg/kg i.p. and test groups 
received orally the extract at the doses of 68.24 mg/kg (CcE D’’1) and 136.48 
mg/kg (CcE D’’2), the flavonoid-rich fraction at the doses of 7.42 mg/kg (CcF D’’1) 
and 14.84 mg/kg (CcF D’’2), and the tannin-rich fraction at the doses of 5.96 
mg/kg (CcT D’’1) and 11.92 mg/kg (CcT D’’2). Test groups were dosed 1 h and 
positive control group was dosed 30 min before placement of the animals on the 
hot plate for new recording of reaction time to temperature. Analgesic capacity was 
calculated by using the formula:  
% analgesic capacity = 1 - (Tb/Tt) x 100 
where Tb is the mean reaction time recorded as baseline and Tt is the mean 
reaction time recorded after treatment with morphine or the samples. 
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2.5.3. The acetic acid-induced writhing test  
The acetic acid-induced writhing test was carried out according to the 
method previously described by Collier et al. (Collier et al., 1968). The test was 
used to evaluate the peripheral analgesic activity of the samples, employing 
diclofenac sodium as reference drug. Acetic acid 0.6% in saline was administered 
i.p., 0.1 mL/10 g b.w. The number of writhes – a response consisting of abdominal 
wall contractions followed by hind limb extension – was counted during 
continuous observation of the animals for 30 min, starting to count 5 min after the 
injection. The animals were divided into eight groups  (n = 6-8): negative control 
group received water 0.5 µL/g p.o., positive control group received diclofenac 
sodium 10 mg/kg i.p. and test groups received orally the extract at the doses of 
68.24 mg/kg (CcE D’’1) and 136.48 mg/kg (CcE D’’2), the flavonoid-rich fraction 
at the doses of 7.42 mg/kg (CcF D’’1) and 14.84 mg/kg (CcF D’’2), and the 
tannin-rich fraction at the doses of 5.96 mg/kg (CcT D’’1) and 11.92 mg/kg (CcT 
D’’2). Negative control and test groups were dosed 1 h and positive control group 
was dosed 30 min before the acetic acid injection. A significant reduction in the 
number of writhes by any drug was considered as a positive analgesic response. 
Analgesic capacity was calculated by using the formula:  
% analgesic capacity = 1 - (Wt/Wc) x 100 
where Wt is the average number of writhes in test and positive control groups and 
Wc is the average number of writhes in the negative control group. 
 
2.6. Histological analysis 
A histological analysis was carried out in order to evaluate the toxicity of the 
C. citratus leaves essential oil-free infusion (CcE). The animals used in the 
carrageenan paw oedema test were sacrificed and the livers were collected, cut into 
transverse fragments (5 mm) and immersed in a 10% solution of formaldehyde for 
24 h. The pieces were processed into paraffin and stored at -20°C. The fragments 
were cut in 4 µm pieces in a SHANDON (AS 325) microtome and stained with 
hematoxylin and eosin. The resulting images were obtained and observed using a 
NIKON (Eclipse E600) microscope.  
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2.7. Transmission electron microscopy (TEM) 
Samples (2-3 mm) of liver collected from the untreated rats (control) and 
the rats treated with CcE at 34.12 mg/Kg (CcE D’1) and 68.24 mg/kg (CcE D’2) 
were fixed for 3 h at 4ºC in 2.5% glutaraldehyde in 0.1 M sodium cacodylate 
buffer (pH 7.2) supplemented with 1 mM calcium chloride. Following rinsing in 
the same buffer, the samples were postfixed in 1% buffered osmium tetroxide for 
1.5 h at 4 ºC and then in 1% aqueous uranyl acetate for 1h at room temperature. 
The samples were further dehydrated in a graded ethanol series (70%-100%) and 
embedded in Spurr’s resin. Thin sections were obtained with a LKB Ultratome 
NOVA, ultramicrotome equipped with a diamond knife, conventionally stained 
with uranyl acetate and lead citrate and observed in a JEOL JEM-100 SX at 80 kV. 
 
2.8. Statistical analysis 
Data obtained from animal experiments were expressed as mean and 
standard error of the mean (mean±S.E.M.). Comparison between groups was done 
by One-way ANOVA followed by Bonferroni’s multiple comparison test. Values of 
p<0.05 were considered to be significant. 
 
3. Results 
3.1. Carrageenan-induced rat paw oedema test 
Subplantar injection of the carrageenan solution into the right hind footpad 
of each rat led to a time-dependent increase in the paw volume. This increase was 
observed at 1 h and it was maximal at 4 h after administration. 
Carrageenan-induced paw oedema volume was significantly reduced at the 
fourth hour by the administration of CcE D’1 and CcE D’2, CcF D’2, CcT D’2 
and diclofenac sodium. The percentage of oedema reduction was 70.80% and 
82.30% for CcE D’1 and CcE D’2, respectively, 59.00% for CcF D’2, 61.00% for 
CcT D’2 and 84.00% for positive control group. There was no significant 
difference between CcF D’1 or CcT D’1 and the negative control group (Figure 
II.13).     
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3.2. Hot plate test 
Mice treated with morphine showed a marked increase in the reaction time 
with a maximum protective effect of 75.9%. However, the results reveal that mice 
treated with any of the samples did not show any significant increase in the 
baseline (Figure II.14).  
 
 
Figure II.13. Results from the carrageenan-induced rat paw oedema test were 
obtained after administering water 0.5 µL/g p.o. (negative control), diclofenac 
sodium 10 mg/kg i.p. (positive control) and C. citratus aqueous extract 34.12 
mg/kg (CcE D’1) and 68.24 mg/kg (CcE D’2), C. citratus flavonoid-rich fraction 
3.71 mg/kg (CcF D’1) and 7.42 mg/kg (CcF D’2) and C. citratus tannin-rich 
fraction 2.98 mg/kg (CcT D’1) and 5.96 mg/kg (CcT D’2) p.o. Each value is the 
mean±S.E.M. of 6 rats. Statistical differences between the treated and the negative 
control groups were determined by ANOVA followed by Bonferroni test. * P < 
0.05. 
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Figure II.14. Results from the hot plate test were obtained before and after 
administering morphine 10 mg/kg i.p. (positive control) and C. citratus aqueous 
extract 68.24 mg/kg (CcE D’’1) and 136.48 mg/kg (CcE D’’2), C. citratus 
flavonoid-rich fraction 7.42 mg/kg (CcF D’’1) and 14.84 mg/kg (CcF D’’2) and C. 
citratus tannin-rich fraction 5.96 mg/kg (CcT D’’1) and 11.92 mg/kg (CcT D’’2) 
p.o. Each value is the mean±S.E.M. of 6-8 mice/group. Statistical differences 
between the treated and the control groups were determined by ANOVA followed 
by Bonferroni test. * P < 0.05. 
 
3.3.  Acetic acid-induced writhing test  
Mice treated with CcE D’’2 showed a significant inhibition of the writhing 
response induced by acetic acid. The percent analgesic capacity was 27.5% (34.8 ± 
8.1 writhes) and 57.0% (20.6 ± 9.7 writhes) for CcE D’’1 and CcE D’’2, 
respectively. Diclofenac sodium showed an analgesic capacity of 83.0% (13.0 ± 
3.4 writhes). An important inhibition of the writhing response was also found for 
CcF D’’2 and CcT D’’2, with a percent analgesic capacity of 54.6% (21.8 ± 14.9 
writhes) and 52.1% (23.0 ± 9.9 writhes), respectively. There was no significant 
difference between the lowest dose of flavonoids and tannins-rich fractions and the 
negative control group (48.0 ± 1.8 writhes), corresponding to 22.1% (37.4 ± 11.2 
writhes) and 18.55% (39.1 ± 8.9 writhes) of percent analgesic capacity, 
respectively (Figure II.15). 
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3.4. Histological analysis  
In Figures II.16A, B and C are represented the histological images of liver 
for control animals, animals treated with CcE single dosage (D’1) and double 
dosage (D’2), respectively, of the animals used in the carrageenan-induced rat paw 
oedema test. No differences were observed between the control and test groups, in 
both tested dosages. The images showed well shaped hepatic cells, with no signs of 
blood stasis in the extracellular medium or necrotic cells, revealing the absence of 
toxicity of the C. citratus leaves essential oil-free infusion.  
 
 
 
 
Figure II.15. Results from the acetic acid-induced writhing test were obtained 
after administering water 0.5 µL/g p.o. (negative control), diclofenac sodium 10 
mg/kg i.p. (positive control) and C. citratus aqueous extract 68.24 mg/kg (CcE 
D’’1) and 136.48 mg/kg (CcE D’’2), C. citratus flavonoid-rich fraction 7.42 mg/kg 
(CcF D’’1) and 14.84 mg/kg (CcF D’’2) and C. citratus tannin-rich fraction 5.96 
mg/kg (CcT D’’1) and 11.92 mg/kg (CcT D’’2) p.o. Each value is the 
mean±S.E.M. of 6-8 mice/group. Statistical differences between the treated and 
the control groups were determined by ANOVA followed by Bonferroni test. * P < 
0.05. 
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Figure II.16. Histological study of liver. Staining with hematoxylin (cell nuclei - 
blue) and eosin (cytoplasm - pink / red); 20x magnification in the original. (A) 
Negative control group; (B) Animals treated with CcE single dosage D’1(34.12 
mg/kg); (C) Animals treated with CcE double dosage D’2 (68.24 mg/kg). Bar = 50 
µm. 
 
3.5. Liver cell ultrastructure  
A general view of the ultrastructural organization of the rat liver 
parenchymal cells (hepatocytes) is shown in Figure II.17A. Briefly, hepatocytes 
are polygonal in shape with one, or sometimes two, large rounded nuclei 
containing one or two prominent nucleoli and a few dense masses of 
heterochromatin. In the whole cytoplasm, the most characteristic feature was the 
presence of a very high number of mitochondria showing a moderate electron-
dense matrix and a reasonable number of electron-dense cristae (Figures II.17A, 
B). Both the smooth (SER) and rough endoplasmic reticulum (RER) were also 
abundant, the former appearing as irregularly shaped vesicular structures or short, 
branching tubules, and the latter as single or small groups of flattened cisternae 
often surrounding closely the mitochondria (Figure II.17B). A few lipid bodies of 
relatively small size, and a reasonable high number of peroxisomes with a 
homogeneous electron-dense matrix, generally containing a finely granular or 
crystalline core (nucleoid), were also frequently present (Figures II.17A, B). 
Secondary lysosomes, Golgi bodies and vesicles, and glycogen granules were 
sometimes seen. Adjacent hepatocytes were separated one from each other by a 
small intercellular space in which junctional complexes were present (Figure 
II.17A). The ultrastructure of hepatocytes in rats treated with both CcE D’1 
(Figure II.17C) and CcE D’2 (Figure II.17D) did not differ significantly from 
that of hepatocytes in control rats (Figure II.17A). In general, the integrity of 
organelles, plasma membrane and junctional complexes remained intact and the 
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organelles retained the features characteristic of the control liver. Only in a few 
hepatocytes the mitochondria matrix sometimes appeared more electron-
transparent (Figure II.17C) and with a more reduced number of cristae, and the 
lipid bodies could be larger (Figure II.17D) and more numerous in the cytosol. 
 
 
Figure II.17. Transmission electron micrographs of hepatocytes in control rats (A 
and B) and in rats treated with CcE D'1 (C) and with CcE D'2 (D). N - nucleus, 
nu - nucleolus, m - mitochondria, px - peroxisomes, rer - rough endoplasmic 
reticulum, ser - smooth endoplasmic reticulum, li - lipid bodies, arrow - rer cistern 
surrounding a mitochondria, arrowhead - plasma membranes of two adjacent 
hepatocytes. Bar = 1 µm. 
 
4. Discussion and Conclusions 
Anti-inflammatory and analgesic effects of many herbs have been related to 
their polyphenolic composition, mostly to flavonoids and tannins. Also, it has been 
reported that flavonoids such as luteolin produce significant antinociceptive and/or 
anti-inflammatory activities (Hosseinzadeh and Younesi, 2002). In regard to C. 
citratus, we have previously demonstrated (Figueirinha et al., 2010) that the most 
active polyphenolic fractions of an essential oil-free infusion are those which held 
flavonoids and tannins and, when tested in vitro, CcE showed high anti-
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inflammatory activity, inhibiting the NO production in dendritic cells. In the 
present study, anti-inflammatory and analgesic activities of an essential oil-free 
infusion of C. citratus leaves were evaluated to verify the claims made by folk 
medicine. Additionally, its flavonoid and tannin-rich fractions were tested, trying 
to better characterize their contribution for the pharmacological effects and also to 
deeper identify the responsible components of C. citratus for its traditional uses.  
The carrageenan-induced rat paw oedema assay was performed to study the 
anti-inflammatory effect. This experimental model is commonly used for 
determining the acute phase of the inflammation because it is related with 
neutrophil infiltration, as well as the neutrophil-derived free radicals, 
prostaglandins and cytokines production (Cardoso et al., 2003; Tanas et al., 2010). 
Diclofenac sodium is widely used as a reference non-steroidal anti-inflammatory 
drug (NSAID), being commonly prescribed due to its anti-inflammatory and 
analgesic effects. This drug has the ability to reduce inflammation, swelling and 
pain by inhibiting either the release of arachidonic acid or the prostaglandin 
synthesis in vivo and in vitro, as well as by influencing the function of 
polymorphonuclear leukocytes in vitro, decreasing chemotaxis and free radical 
formation (Mahgoub, 2002; Ojewole, 2004). 
Our present results indicate that the C. citratus infusion has anti-
inflammatory activity, corroborating its traditional use. The observed effect for the 
highest dose was similar to that obtained by the reference NSAID used. The 
flavonoid and the tannin-rich fractions also exhibited anti-inflammatory activity at 
their highest dose, but when compared to the standard and the infusion, a lower 
inflammation inhibition was observed. Synergistic effects between the different 
phenolic compounds and/or the presence of other compounds in the extract can 
probably contribute for the CcE activity.  
However, regarding the low doses that were used in the assay with the 
polyphenols, we may conclude about an important contribution of both flavonoids 
and tannins for the anti-inflammatory effect. This fact suggests that these 
polyphenols are significantly responsible for the overall effect observed with CcE.  
The mechanism behind these results is still unclear, but previous works point that 
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one of the major anti-inflammatory pathways modulated by these compounds 
might be the inhibition of NF-κB-regulated cytokines expression, probably from 
the scavenging capacity of reactive oxygen species, which modulates the activation 
of NF-κB pathway (Francisco et al., 2011; Morgan and Liu, 2011). On the other 
hand, the same reactive species-scavenging ability may be related to the inhibition 
of polymorphonuclear leukocytes’ action, such as neutrophils (Ojewole, 2004; 
Tanas et al., 2010).  
For the potential analgesic activity two different models were used to study 
both central and peripheral mechanisms of nociception. The hot plate test allows 
us to verify central analgesic effects while the acetic acid-induced writhing test 
evaluates peripheral analgesic effects of drugs (Queiroz et al., 2010; Shang et al., 
2010).  
The hot plate test is based on the animal behavior resulting from activation 
of the primary nociceptors by high temperature and, therefore, it is an excellent 
indicator of potential pharmacological drug effects. In the present study, morphine 
hydrochloride, a central-acting analgesic drug, which acts by activating opioid 
receptors (Eddy and Leimbach, 1953; Queiroz et al., 2010; Ruangsang et al., 
2010), produced a pronounced inhibitory effect on the nociceptive response 
showed by the increase in mice reaction time; in contrast, the C. citratus infusion, 
its flavonoid- and tannin-rich fractions showed no antinociceptive activity in this 
test. 
As mentioned above, the acetic acid-induced writhing test is useful to 
evaluate drugs with analgesic activity at a peripheral level of nociception. It is 
known that acetic acid acts indirectly by inducing the release of endogenous pro-
inflammatory mediators such as histamine, serotonin, bradykinin, acetylcholine, P 
substance and prostaglandins involved in visceral inflammatory pain, by causing an 
increased vascular permeability (Queiroz et al., 2010; Ruangsang et al., 2010). 
This model is, therefore, sensitive to the action of NSAIDs (Dandawate et al., 
2012; Queiroz et al., 2010). In this study, diclofenac sodium caused the inhibition 
of pain induced by acetic acid, and CcE, CcF and CcT showed also a significant 
reduction of the writhing response at the highest dose used. There were no relevant 
CHAPTER II | RESULTS and DISCUSSION 
 
165 
 
differences in the inhibition of the number of writhes for the three samples, which 
leads us to conclude that flavonoids and tannins are the compounds that almost 
exclusively contribute for the C. citratus peripheral analgesic activity. This fact 
corroborates the published data about phenolic compounds exerting an 
antinociceptive effect in vivo, namely for tannins (DalBó et al., 2005; Subarnas 
and Wagner, 2000) and flavonoids (Gorzalczany et al., 2011; Valério et al., 2009; 
Vidyalakshmi et al., 2010). 
This study reveals that CcE and its flavonoids and tannins are able to reduce 
paw oedema induced by carrageenan and the peripheral mechanism of pain, 
suggesting that their anti-inflammatory and analgesic effects may be related to the 
inhibition of the synthesis and release of various inflammatory mediators and to its 
antioxidant activity.  
These results suggest that the CcE acts as anti-inflammatory and peripheral 
analgesic agent, still does not exhibit intrinsic central analgesic activity. Together, 
it can be inferred that the observed analgesic effect is likely associated with the 
inflammatory process, flavonoids and tannins having a significant contribution for 
these activities. 
Liver plays a crucial role in the detoxification, modification and excretion of 
both endogenous and exogenous substances, including a variety of toxic 
substances. When exposed to toxic substances, hepatocytes show extensive 
alterations in the number, morphology and/or ultrastructure of organelles, such as 
mitochondria, endoplasmic reticulum, peroxisomes and lipid bodies (Lüde et al., 
2007). To investigate the potential for hepatotoxicity of C. citratus extracts in 
experimental animals in vivo, the liver tissue and ultrastructural organization of 
hepatocytes in control rats and in rats treated with CcE D´1 and CcE D´2 were 
examined. In the control rats, the cellular organization of hepatocytes was found to 
be very similar to that described by Baratta et al. (Baratta et al., 2009). Following 
exposure to CcE D’1 and CcE D’2 no significant alterations were found in liver 
tissue and cell ultrastructure of the hepatocytes when compared with that of the 
untreated rats (control). Our results show that treatment with effective 
concentrations of the CcE induced no hepatotoxicity in rats and that, therefore, 
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the administration of CcE can be considered safe under the experimental 
conditions used. 
In conclusion, our results support the traditional use of C. citratus infusion 
as an anti-inflammatory agent and suggest that CcE or its polyphenols, namely the 
flavonoid- and tannin-rich fractions, may be used to obtain a new anti-
inflammatory medicine, effective in the treatment of inflammatory-related 
pathologies. 
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Abstract 
Ethnopharmacological relevance: A variety of plant polyphenols have been 
reported to have anti-inflammatory, frequently associated with erythema, oedema, 
hyperplasia, skin photoaging and photocarcinogenesis. Cymbopogon citratus is a 
worldwide known medicinal plant, used in traditional medicine in inflammation-
related conditions. 
Aim of the study: In this work, the anti-inflammatory potential of Cymbopogon 
citratus (DC). Stapf (Poaceae) infusion (CcI) and its polyphenols as topical agents 
was evaluated in vivo.  
Materials and Methods: The plant extract was prepared and its fractioning led 
two polyphenol-rich fractions: flavonoids fraction (CcF) and tannins fraction 
(CcT). An oil/water emulsion was developed with each active (CcI, CcF+CcT and 
diclofenac), pH and texture having been evaluated. Release tests were further 
performed using static Franz diffusion cells and all collected samples were 
monitored by HPLC–PDA. In vivo topical anti-inflammatory activity evaluation 
was performed by the carrageenan-induced rat paw oedema model. 
Results: The texture analysis revealed statistically significant differences for all 
tested parameters to CcF+CcT, supporting its topical application. Release 
experiments lead to the detection of the phenolic compounds from each sample in 
the receptor medium and the six major flavonoids were quantified, by HPLC-PDA: 
carlinoside, isoorientin, cynaroside, luteolin 7-O-neohesperidoside, kurilesin A and 
cassiaoccidentalin B. The CcF+CcT formulation prompted to the higher release 
rate for all these flavonoids. CcI4%, CcI1% and CcF+CcT exhibited an oedema 
reduction of 43.18, 29.55 and 59.09%, respectively.  
Conclusions: Our findings highlight that CcI, containing luteolin 7-O-
neohesperidoside, cassiaoccidentalin B, carlinoside, cynaroside and tannins have a 
potential anti-inflammatory topical activity, suggesting their promising application 
in the treatment of skin inflammatory pathologies.  
Keywords: Cymbopogon citratus; lemongrass; topical application; anti-
inflammatory; in vivo studies; drug release. 
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1. Introduction 
Erythema, oedema, sunburn, hyperplasia, immunosuppression, skin 
photoaging and photocarcinogenesis are some of the causes of adverse skin 
reactions. All of these pathological conditions have in common a key trigger: 
inflammation (Yaar and Gilchrest, 2007). Two representative pro-inflammatory 
enzymes, cyclooxygenase-2 (COX-2) (Kundu et al., 2008) and inducible nitric 
oxide synthase (iNOS) (Chang et al., 2011), are aberrantly over-expressed in skin 
inflammatory conditions. Abnormally elevated expression of these enzymes as well 
as the NF-κB and IKK activation have been implicated in skin tumor promotion.  
A wide variety of plant polyphenols has been reported to possess anti-
inflammatory, immunomodulatory and antioxidant properties being among the 
most promising group of compounds that can be exploited as ideal 
chemopreventive agents for a variety of skin disorders in general and skin cancer in 
particular; especially flavonoids and tannins have been reported to exert 
pronounced anti-inflammatory and anti-carcinogenic effects both in vitro and in 
vivo (Das et al., 2008; Singh and Katiyar, 2013). 
Cymbopogon citratus (DC.) Stapf (Poaceae), commonly known as 
lemongrass, is a tropical perennial shrub originated from the Southeast Asia. In 
African and Latin American countries, this herb is highly consumed as an aromatic 
and pleasant-tasting herbal drink (Adeneye and Agbaje, 2007). Aqueous extracts of 
dried leaves are used in folk medicine for the treatment of several inflammation-
based pathologies (Shah et al., 2011). This plant is reported to possess antifungal, 
mosquito repellent, insecticidal, anti-diabetic, anti-septic, anti-mutagenic and anti-
carcinogenic activities as well as anti-inflammatory (Francisco et al., 2011; Garcia 
et al., 2015). The antioxidant and radical scavenging activities of hydrophilic 
extracts of Cymbopogon citratus have been reported by several authors and related 
to its polyphenols (Campos et al., 2014; Orrego et al., 2009; Roriz et al., 2014). In 
recent years, our group identified several compounds from lemongrass such as 
luteolin and apigenin glycosides and condensed tannins, respectively, strongly 
contributed to the anti-inflammatory and antioxidant properties of CcI (Costa et 
al., 2015; Figueirinha et al., 2010; Francisco et al., 2011, 2013). Moreover, we 
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recently disclosed the anti-inflammatory activity of CcI in vivo after oral 
administration (Garcia et al., 2015). 
However, CcI topical anti-inflammatory effect on skin has not been yet 
reported. In the current work, we have studied the in vivo topical anti-
inflammatory activity of a C. citratus leaves infusion and polyphenol-enriched 
fractions prepared from this extract. 
 
2. Materials and Methods 
2.1 Chemicals and drugs 
Ethanol, methanol and formic acid were purchased from Merck 
(Darmstadt, Germany). Sephadex LH-20 was purchased from Sigma-Aldrich 
(Amersham, Sweden). Propylene glycol (99.5%) and oleic acid (>99%) were 
purchased from Fluka (Steinheim, Switzerland). Stearic acid 70 extra pure was 
obtained from Scharlau (Sentmenat, Spain) and glycerol (>99.5%) from José M. 
Vaz Pereira (Benavente, Portugal). Diclofenac sodium was purchased from 
Novartis Pharmaceuticals SA (Barcelona, Spain). κ-Carrageenan and 
triethanolamine were obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
Ketamine (Ketalar) was purchased from Parke-Davis, Pfizer (Seixal, Portugal).  
 
2.2 Plant material, extract preparation and fractioning 
Dry leaves of C. citratus were acquired from ERVITAL (Mezio, Castro 
Daire, Portugal). A voucher specimen was then deposited in the Herbarium of 
Aromatic and Medicinal Plants of the Faculty of Pharmacy – University of 
Coimbra (A. Figueirinha 0109). The identity of the plant was confirmed by J. 
Paiva (Life Sciences Department, University of Coimbra, Portugal).  
A lipid- and essential oil-free infusion was prepared (CcI) as previously 
described (Figueirinha et al., 2008). Briefly, 150 ml of boiling water were added to 
5 g of grinded dry leaves, the mixture being kept hot and left to stand for 15 min. 
Afterwards, the polyphenol-enriched fractions were obtained as described by Costa 
et al. (Costa et al., 2015a). Briefly, CcI was fractionated by a Flash 
Chromatography® apparatus (Buchi Labortechnik AG) on a reverse phase 
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preparative C18 column Buchi® (150 × 40 mm; particle size 40 - 63 μm) (Flawil, 
Switzerland), eluted with aqueous methanol, in a discontinuous gradient: 5% (0-40 
min), 5-10% (40-55 min), 10% (55-85 min), 10-15% (85-90 min), 15-25% (90-
110 min), 25-50% (110-140 min), 50% (140-160 min), 50-80% (160-180 min), 
80-100% (180-200 min) and 100% (200-220 min) at a flow rate of 3 ml/min. The 
HPLC profile was registered at 280 and 320 nm by the UV detector C-640 Buchi® 
(Flawil, Switzerland), and the data was acquired using the software ECOMAC® 
0.238 (Prague, Czech Republic). Two fractions were selected: F1 (0-120 min) and 
F2 (120-220 min). F1 and F2 were then sub-fractionated separately on a 
Sephadex LH-20 column (35 x 4 cm) using ethanol as mobile phase. All 
fractionation processes were monitored by HPLC and thin layer chromatography 
(TLC) for polyphenols, providing two major fractions: flavonoids fraction, CcF 
(yield 7.4%) and tannins fraction, CcT (yield 3.8%). These fractions were chosen 
because they contained the most promising groups of phenolic compounds 
contained in CcI (Costa et al., 2015a; Francisco et al., 2014, 2013, 2011). Both 
extract and fractions were freeze-dried and kept at -20ºC until use. 
 
2.3 Phenolic profile 
2.3.1 HPLC-DAD-ESI/MSn 
HPLC-DAD-ESI/MSn analysis was performed in a Surveyor liquid 
chromatograph hyphenated to a diode-array detector (DAD) (Surveyor) and a 
Finnigan LCQ mass spectrometer (San Jose, CA, USA) equipped with an API-ES 
ionization chamber. Separation was performed on an Spherisorb ODS-2 C18 
reverse phase column, 150 x 2.1 mm i.d. and particle size of 3 µm (Waters 
Corporation, Milford, Massachusetts, USA) and a Spherisorb ODS-2 guard 
cartridge C18 (10 x 4.6 mm i.d. and particle size of 5 µm; Waters Corporation, 
Milford, Massachusetts, USA) at 25ºC, using 2% aqueous formic acid (A) and 
methanol (B) as mobile phase. The gradient profile used was 5-15% B (0-10 min), 
15-30% B (10-15 min), 30-35% B (15-25 min), 35-50% B (25-35 min), 50-80% B 
(35-40 min), 80% B (40-60 min), isocratically, at a flow rate of 0.2 mL/min. The 
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first detection was done with the PDA detector in a wavelength range of 200-600 
nm, followed by a second detection in the mass spectrometer. 
Mass analyses were obtained in the negative ion mode. The mass 
spectrometer was programmed to perform three consecutive scans: full mass MS1 
(m/z 160-1300), MS2 of the most abundant ion in MS1, and MS3 of the most 
abundant ion in MS2. Source voltage was 4.5 kV and capillary voltage and 
temperature were -10 V and 250ºC, respectively. Nitrogen was used as sheath gas 
at flow rate of 20 arbitrary units. The normalized energy of collision was 45%, 
using helium as collision gas. 
 
2.3.2 HPLC-DAD 
HPLC analyses were performed in a chromatograph GILSON equipped with 
a diode-array detector (DAD) (Gilson Electronics SA, Villiers le Bel, France). The 
studies were carried out on a Spherisorb S5 ODS-2 column (250 x 4.6 mm i.d.; 
particle size, 5 µm; Waters Corp., Milford, MA, USA) at 25ºC and a Nucleosil 
C18 guard cartridge (30 x 4 mm i.d.; particle size, 5 µm; Macherey-Nagel, Düren, 
Germany). A mobile phase of 5% (v/v) aqueous formic acid (A) and methanol (B) 
was used with a discontinuous gradient: 5–15% B (0–10 min.), 15–30% B (10–15 
min.), 30–35% B (15–25 min.), 35–50% B (25–35 min.) and 50–80% B (35–40 
min.), followed by an isocratic elution for 20 min., at a flow rate of 1 ml/min. An 
injection volume of 100 l was used for all standards and samples. 
Chromatographic profiles were acquired in the wavelength range 200–600 nm, and 
recorded at 280 nm. Data treatment was carried out with Unipoint 2.10 software 
(Gilson). The quantification of the analytes was achieved through HPLC-DAD. 
The main validation parameters of the analytical method employed were in 
agreement with the international guidelines (FDA, 2013) and are summarized in 
Table II.8. 
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Table II.8. Validation parameters of the HPLC method employed for the 
quantification of phenolic compounds in samples (n = 3). 
Standard 
Concentration 
range 
(g mL-1) 
Calibration curve R2 Fcalculated* 
LOD 
(g mL-
1) 
LOQ 
(g mL-
1) 
Caffeic acid 0.50 – 10.00 
y = 9957547x –  
1980541 
1 1.37 0.65 1.97 
p-Coumaric 
acid 
0.50 – 10.00 
y = 65289976x +  
522431 
1 3.19 0.11 0.32 
Isoorientin 7.81 – 250.00 
y = 1939071x –  
4248388 
1 2.87 0.13 0.40 
Isovitexin 7.81 – 250.00 
y = 19173001x + 
1904129 
1 3.15 0.11 0.33 
*Fcalculated should be lower than 3.26 (Ftabulated at 95% with 4 and 12 degrees of freedom). 
 
2.4 Topical formulations 
An oil/water emulsion was used to convey the extract and fractions. The 
excipients were previously screened (data not shown) in order to achieve the 
optimal formulation for the crude extract, yielding the following final formula: 
stearic acid (14%, w/w), triethanolamine (1.2%, w/w), glycerol (13.5%, w/w), 
propylene glycol (5%, w/w), oleic acid (10%, w/w) and water (qs 100%, w/w). Five 
formulations were prepared: placebo, 1% (w/w) diclofenac, 4% (w/w) extract 
(CcI4%), 1% extract (CcI1%) and 1% polyphenol-enriched fraction containing 
0.66% (w/w) CcF + 0.34% (w/w) CcT (CcF+CcT). Flavonoid-enriched and 
tannin-enriched fraction concentrations were calculated, taken in consideration the 
relative proportion of each fraction in the extract.  
 
2.5 Formulation assessment 
2.5.1 pH Evaluation 
In order to verify the chemical stability of all tested formulations, the pH 
was monitored, using a Five Easy FE20 pH reader (Mettler Toledo, Greifensee, 
Switzerland). Aliquots of the samples were measured at 0, 3, 4, 7, 10 and 15 days. 
 
2.5.2 Texture profile analysis 
Texture characteristics of the formulations were inspected through a Texture 
Analyzer TA.XT Plus (Stable Micro Systems Ltd., Surrey, UK). TPA mode was 
performed using an analytical probe (P/10, 10 mm Delrin) which was twice 
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depressed into the sample at a defined rate (5 mm/s) to a desired depth (15 mm), 
allowing 15 sec of delay between consecutive compressions, as previously described 
by Vitorino and co-workers (Vitorino et al., 2013).  
Six replicates were performed at 32 ºC, the temperature at skin surface, in 
the temperature controlled Peltier Cabinet for each formulation. Data analysis was 
carried out through the Texture Exponent 3.0.5.0 software package of the 
instrument.  
 
2.6 In vitro release studies 
In vitro release studies were performed using static Franz diffusion cells 
(PermeGear, Inc., PA, USA) with a diffusion area of 0.636 cm2 and a receptor 
compartment of 5 ml. A dialysis cellulose membrane (MWCO~12000, avg. flat 
width 33 mm, D9652, Sigma-Aldrich), as artificial membrane, was placed between 
both compartments and a receptor solution of phosphate buffer saline (PBS, pH = 
7.4) with 30% ethanol (v/v)  to warrant sink conditions was used. This receptor 
phase was stirred at 600 rpm and maintained at 37 ± 0.5 ºC by a thermostatic 
water pump, assuring a temperature of 32 ºC at the surface, thus mimicking 
human skin conditions. The samples (400 l) were applied in the donor 
compartments, and occluded with Parafilm® to prevent evaporation. The 
experiments were carried out over a period of 48 h, at several time points, 300 μl 
aliquots were collected of the receptor compartment, replacing this volume by fresh 
medium. All aliquots were analyzed and the major flavonoids quantified by HPLC-
DAD. 
 
2.7 In vivo assays 
2.7.1 Animals 
Male Wistar rats weighing 120-220 g and male mice weighing 20-30 g were 
acquired from Charles River (Barcelona, Spain). The animals were maintained with 
food and water ad libitum and kept at 22 ± 1ºC with controlled 12 hour light/dark 
cycle at the Faculty of Pharmacy (University of Coimbra). The animals were 
allowed to adapt to the laboratory for 7 days before testing and fasted with free 
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access to water at least 24 h prior to experiments. The research was conducted in 
accordance with the internationally accepted principles for laboratory animal use 
and care as found in Directive 2010/63/EU. 
 
2.7.2 Carrageenan-induced paw oedema assay 
The carrageenan-induced rat paw oedema test (Green and Green, 1971) was 
used to evaluate the topical acute anti-inflammatory activity of the samples. 
Diclofenac sodium was used as reference drug. The animals were divided into five 
groups (n = 6): carrageenan control group received negative control formulation; 
positive control group received 1% diclofenac sodium formulation; and test groups 
received CcI4%, CcI1% and CcF+CcT, respectively. All formulations were 
administrated in an amount of 1 ml.  Negative control and test groups were dosed 
1 h and positive control group was dosed 30 min before a subplantar injection of 
0.1 ml of 1% (w/v) solution of carrageenan in saline, administered to the right hind 
footpad of each animal. The paw oedema volume was measured with a digital 
plethysmometer (model LE7500, Panlab, Barcelona, Spain) after carrageenan 
injection and then every hour during six hours, for the animals of control group. 
For the test groups, the anti-inflammatory effect was calculated 4 h (tmax) after 
carrageenan administration and was expressed as percentage of oedema inhibition 
in the treated animals with respect to the carrageenan control group. The 
percentage of oedema inhibition was calculated according to the following 
equation: % oedema inhibition = 1 - (Vt/Vc) x 100, where Vt is the mean 
variation of the paw volume in rats treated with the sample or diclofenac sodium 
and Vc is the mean variation of the paw volume in the carrageenan control group. 
 
2.8 Statistical analyses 
Data obtained from animal experiments were expressed as mean and 
standard error of the mean (mean±S.E.M.). Comparison between groups was 
carried out by One-way ANOVA followed by Bonferroni’s multiple comparison 
test. Values of p<0.05 were considered to be statistically significant. For the 
remaining data, the statistical package Windows® MS Excel 2007 was used. 
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3. Results and Discussion 
3.1 Phenolic profile 
In order to characterize CcI, the phenolic profile was achieved by HPLC-
DAD (Figure II.18). The detected phenolic compounds were identified by HPLC-
DAD-ESI/MSn (Table II.9). In order to better characterize CcI and CcF, some 
marker compounds were quantified (Table II.10). The markers were chosen 
because they are the most abundant bioactive flavonoids of lemongrass infusion. 
CcT have been already characterized by our group (Costa et al., 2015a). 
 
 
 
 
 
Figure II.18. HPLC fingerprint of CcI, recorded at 280 nm, by HPLC-DAD. 
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Table II.9. Phenolic compounds identification of Cymbopogon citratus infusion, 
by HPLC-DAD-ESI/MSn (cont.). 
Peak Identification 
λmaxima 
(nm) 
[M-
H]- 
(m/z) 
MS2 
[m/z (rel. 
abundance, %)] 
MS3 
[m/z (rel. 
abundance, %)] 
1 Feruloylquinic acid 290, 325 367 193(100) 149(100) 
2 Neochlorogenic acid 290, 326 353 
191(100), 179(10), 
109(2) 
191(60), 173(100), 
93(68) 
3 Chlorogenic acid 290, 326 353 
191(100), 179(60), 
109(10) 
191(60), 173(100), 
93(70) 
4 p-Coumaric acid 295, 310 163 - - 
5 Carlinoside 
258sh, 
272, 329 
579 
519(2), 489(32), 
459(100), 399(25) 
441(26), 399(100), 
369(80) 
6 Isoschaftoside 272, 331 563 
545(30), 503(79), 
473(100), 443(76), 
383(43), 353(40) 
383(15), 353(100) 
7 Isoorientin 
258sh, 
269, 348 
447 
429(35), 387(2), 
357(100), 327(75), 
285(1) 
357(100), 339(60), 
297(28), 285(10) 
8 
Isoorientin 2''-O-
rhamnoside 
258sh, 
269, 350 
593 
575(2), 473(100), 
429(60), 357(24), 
339(10) 
399(2), 327(100), 
298(20), 285(2) 
9 
Luteolin 7-O-
neohesperidoside 
258sh, 
268, 347 
593 
447(100), 327(18), 
285(74), 199(1) 
327(2), 285(100) 
10 Kurilensin A 
258sh, 
270, 350 
563 
545(19), 503(13), 
473(100), 459(16), 
399(34), 369(16) 
399(100), 369(73) 
11 
Luteolin 6-C-
pentoside 
258sh, 
272, 348 
417 
399(22), 357(100), 
327(35) 
339(100), 327(16), 
311(20), 297(87), 
285(17) 
12 Cassiaoccidentalin B 
258sh, 
270, 348 
575 
531(21), 513(10), 
429(21), 411(100), 
367(42), 337(12) 
411(2), 393(12), 
364(90), 337(100), 
311(12), 285(8) 
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Table II.10. Cymbopogon citratus marker compounds 
quantified in CcI and CcF by HPLC-DAD. 
Peak Compound 
Measured concentration 
mean ± SD (g mL-1) 
CcI CcF 
1 3-Feroylquinic acida 3.82 ± 0.04 n.d. 
3 Chlorogenic acida 4.40 ± 0.30 n.d. 
4 p-Coumaric acid 8.01± 0.21 n.d. 
6 Isoschaftosideb 11.35 ± 0.23 563.28 ± 0.05 
7 Isoorientinc 52.02 ± 0.54 688.53 ± 0.21 
8 Cynarosidec 23.45 ± 0.26 462.42 ± 0.18 
10 Luteolin 7-O-neohesperidosidec 11.12 ± 0.13 180.59 ± 0.09 
11 Kurilensin Ac 26.48 ± 0.29 535.69 ± 0.12 
12 Cassiaoccidentalin Bc 13.78 ± 0.16 316.21 ± 0.40 
aConcentration expressed in g equivalents of caffeic acid per mL; 
bConcentration expressed in g equivalents of isovitexin per mL; 
cConcentration expressed in g equivalents of isoorientin per mL. 
 
3.2 Formulation assessment 
3.2.1 pH measurement 
The pH values are presented at Figure II.19. All formulations were stable 
during the 15 days period. With the exception of CcI4%, all formulations 
exhibited a pH value very similar to that of the placebo and compatible with a 
topical skin application. 
 
 
Figure II.19. pH measurement values of the topical formulations over time. 
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3.2.2 Texture evaluation 
In order to assess interactions between formulation components and their 
impact upon the respective biological performance, mechanical properties of the 
different formulations were monitored through the texture profile analysis (TPA). 
From the force-time curve obtained, the following mechanical parameters can be 
extracted (see Figure II.20): hardness, which corresponds to the maximum peak 
force during the first compression cycle; compressibility, i.e., the work required to 
deform the sample during the first compression of the probe and estimated from 
area under the force–time curve 1 (AUC1); adhesiveness, the work required to 
overcome the attractive forces between the surface of the sample and the surface of 
the probe and calculated from the negative force area for the first compression 
cycle (AUC2); cohesiveness, determined by the ratio of the area under the force–
time curve produced on the second compression cycle to that on the first 
compression cycle, where both compressions are separated by a defined recovery 
period; elasticity, obtained from the ratio of the time required to achieve maximum 
structural deformation on the second compression cycle to that on the first 
compression cycle. The results are presented in Table II.11. Regarding hardness, 
which expresses the ease with which the cream is applied on the skin, an increase 
was observed when the extract was included. Note that small values of hardness are 
often associated with a large relative uncertainty. Maximal values were obtained for 
the CcF+CcT formulation (9.0 g), while no difference was obtained between 
CcI1% and CcI4% formulations (1.0 and 0.9 g, respectively). An increased force 
/unit time required for compression and, subsequently, increased hardness is 
related to the increased viscosity of the formulation. However, according to 
previous studies (Vitorino et al., 2013), the hardness values obtained in this work 
are acceptable for skin application. 
Concerning to compressibility and adhesiveness, again higher values were 
obtained for CcF+CcT formulation (10.0 and -16.0 g.sec, respectively), followed 
by CcI1% formulation (4.0 and -8.0 g.sec, respectively). These parameters are 
correlated to the spreadability of the cream on the skin surface and bioadhesion, 
respectively. Despite the increase in compressibility values, it still reflects an easy 
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application, which is combined with a higher adhesion. This is consistent with the 
results obtained from release studies (see In vitro release studies), where the higher 
release rate observed is possibly favored by a better contact with the skin.  
In relation to the elasticity, which is defined as the rate at which the 
deformed sample returns to its original condition after the removal of the 
deforming force, the same trend was observed. It is described that lower 
quantitative values of elasticity obtained from TPA indicate larger gel elasticity. 
Although the higher elasticity value corresponds to the CcF+CcT formulation 
(0.8), the cream has an acceptable elasticity compared to previous literature 
findings (Vitorino et al., 2013). 
Regarding cohesiveness, it provides information on the structural 
reformation following cream application, and usually, a high value is associated 
with a full structural recovery (Senyiğit et al., 2011). The analysis of the present 
results revealed statistically significant differences in this parameter for CcF+CcT, 
supporting its topical application.  
 
 
Figure II.20. Graphical output from texture profile analysis 
(H=hardness; AUC1= compressibility; AUC2= adhesiveness; 
AUC3/AUC1 corresponds to the cohesiveness; elasticity is given by 
time diff 3:4/time diff 1:2). 
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Table II.11. Mechanical properties of the formulations extracted from the 
TPA mode.  
Formulations 
Compressibility 
(g.sec) 
Hardness 
(g) 
Adhesiveness 
(g.sec) 
Elasticity Cohesiveness 
Negative Control 0.7 ± 0.7 0.4 ± 1.6 -2.0 ± 3.0 0.3 ± 0.1 0.6 ± 0.3 
Diclofenac 4.6 ± 0.9* 0.7 ± 1.7 -6.1 ± 3.9 0.8 ± 0.2* 0.9 ± 0.1* 
CcI4% 1.2 ± 0.3 0.9 ± 1.8 -2.0 ± 2.6 0.3 ± 0.4 0.6 ± 0.4 
CcI1% 4.0 ± 1.3* 1.0 ± 3.0 -8.0 ± 2.0* 0.5 ± 0.1* 0.8 ± 0.2 
CcF+CcT 10.0 ± 4.0* 9.0 ± 5.1* -16.0 ± 4.1* 0.8 ± 0.2* 0.9 ± 0.1* 
Results are indicated as a mean of six replicates ± standard deviation (*p<0.05 vs. 
negative control). 
 
3.3 In vitro release studies 
Release profiles for the formulations containing 4% (w/w) and 1% (w/w) of 
CcI, and CcF+CcT are shown in Figure II.21. The cumulative amount of the 
major flavonoids: 6-C--glucopyranosyl-8-C--arabinopyranosyl-luteolin 
(carlinoside), 6-C--glucopyranosyl-luteolin (isoorientin), 7-O--glucopyranosyl-
luteolin (cynaroside), luteolin 7-O-neohesperidoside, 6-C-(2’’-O--
rhamnopyranosyl)--arabinofuranosyl)-luteolin (kurilensin A) and 6-C-(2’’-O--
rhamnopyranosyl)-(6-deoxy--ribo-glucopyranosyl)-luteolin (cassiaoccidentalin B) 
– was determined by HPLC-DAD, using isoorientin as standard. Release profiles 
revealed a burst effect after 30 minutes of formulation application, followed by a 
sustained release throughout the period of the experiment. This suggests its 
efficacy for application on skin, particularly for the treatment of inflammation 
disorders. It can be also observed that all flavonoids were generally released to a 
higher extent in the formulation containing CcF+CcT, even with a lower loading 
in comparison to the other formulations. On the other hand, CcI1% exhibited 
higher release values, for all detected flavonoids, than CcI4%. This fact may be 
explained by the different matrix effect of each sample in the semisolid 
formulation. 
These results are in good agreement with the mechanical properties 
previously referred. Note that for the CcF+CcT formulation higher values of 
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adhesion, hardness and compressibility were obtained, thus suggesting the 
increased release observed, which might possibly be a result of a closer contact with 
the stratum cornea. A thorough examination of the compound behavior reveals 
that luteolin 7-O-neohesperidoside, cassiaoccidentalin B and carlinoside generally, 
exhibited higher release rates. These findings may be ascribed to their different log 
P (-0.6, -0.3, -2.5, respectively vs. -0.2 and 0.5 for isoorientin and cynaroside, 
respectively) and high polar surface area (PSA) (245, 233, 267 Å, respectively vs. 
197 and 186 Å for isoorientin and cynaroside, respectively) (National Center for 
Biotechnology Information, n.d.). Moreover, the use of an oil/water emulsion itself 
further contributes to an increase of the release of the referred compounds. 
 
3.4 Carrageenan-induced paw oedema assay 
The results show a statistically significant reduction of oedema volume for 
CcI4%, CcF+CcT and diclofenac formulations, compared to the placebo (Figure 
II.22). There was a reduction in the volume of the oedema induced by carrageenan 
of 43.18% for CcI4%, 29.55% for CcI1%, 59.09% for CcF+CcT formulation and 
65.91% for the positive control, respectively. These results confirm the anti-
inflammatory activity of the C. citratus infusion topical formulation, as well as the 
resulting formulation combining the fractions enriched in flavonoids and tannins, 
suggesting that the major contribution to the observed activity may rely on these 
polyphenols. These results well correlate with the in vitro experiments, which 
revealed that the CcF+CcT was the formulation that prompted to the highest 
amount of released compounds. More recently, the luteolin derivatives, present in 
the tested samples, have been co-related with the inhibition of inflammatory 
mediators like iNOS and cytokines TNF-, IL-1 and IL-6  (Francisco et al., 
2014). 
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Figure II.21. Franz diffusion cells release profiles of 
carlinoside, isoorientin, cynaroside, luteolin 7-O-
neohesperidoside, kurilensin A and cassiaoccidentalin B for 
the CcI4% (a), CcI1% (b) and CcF+CcT (c) formulations.  
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Figure II.22. Effect of topical application of the placebo, positive control 
(diclofenac sodium, 1%), CcI4%, CcI1%, CcF+CcT formulations on the oedema 
volume induced by 1% carrageenan, 4 h after inflammation induction. Each result 
represents the mean ± SEM (n = 6/group). **p<0.01, ***p<0.001 and 
****p<0.0001, compared with the control group. #p<0.05, ##p<0.01 and 
###p<0.001, compared with the placebo group. 
 
 
4. Conclusions 
In conclusion, our results suggest that CcI, and its polyphenols, tannins and 
flavonoids, mainly, luteolin 7-O-neohesperidoside, cassiaoccidentalin B, carlinoside 
and cynaroside, may contribute to the topical anti-inflammatory effect, observed in 
this work. In light of this study, these polyphenols could be active constituents to 
integrate in a new anti-inflammatory agent, effective for the treatment of skin 
inflammatory-related pathologies.  
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Abstract 
Cymbopogon citratus, commonly known as lemongrass, is a tropical herb 
used in worldwide traditional medicine for centuries. Studies previously conducted 
by our team demonstrated its antioxidant and anti-inflammatory effects, and 
recently, the anti-inflammatory potential was also observed in vivo. However, little 
is known about its pharmacokinetics. The current study aimed at obtaining, for the 
first time, the pharmacokinetic profile of lemongrass infusion after a single dose 
oral administration to rats.   
All in vivo experimental procedures were approved by the Portuguese 
Veterinary General Division. Male Wistar rats were administered with a single oral 
dose of lemongrass infusion (68.24 mg/kg) and aliquots of plasma were collected at 
0.5, 1, 1.5, 2, 4, 8, 12 and 24 h post-dosing. Liver and kidney samples were 
collected at 1, 2, 4, 8 and 24 h post-dosing. Plasma and tissues homogenates were 
pre-treated by a solid-phase extraction procedure and luteolin (LUT), luteolin 7-O-
glucuronide (L7G), chrysoeriol (CHR), diosmetin (DIO) and luteolin 3’-O-
sulphate (L3’S) were quantified employing a RP-HPLC-PDA method. The mean 
concentration-time profiles obtained were analyzed by a non-compartmental 
pharmacokinetic analysis using the WinNonlin®. The plasma and tissues Cmax, Tmax, 
T1/2, AUC(0-t), AUC(0) and MRT(0)  were determined.  
The pharmacokinetic studies revealed the presence of LUT, L7G, CHR, DIO 
and L3’S. L7G and L3’S were rapidly detected, with maximum plasma 
concentration at 30 min after oral administrations. The concentration-time profile 
of liver samples evidenced compounds undetected in plasma: LUT, CHR and DIO. 
L7G, CHR and L3’S were detected in the liver from the first hour and stayed in 
the tissue until at least 24h. The kidney concentration-time profile revealed the 
presence of the same compounds detected in plasma.  
The pharmacokinetic analysis showed that the compounds present in 
lemongrass infusion are not detected in plasma, liver or kidneys. On the other 
hand, L7G and L3’S were the major metabolites found in plasma and tissues, 
suggesting that lemongrass polyphenols are promptly metabolized in vivo and their 
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metabolites may be the ones responsible for the anti-inflammatory activity of C. 
citratus, when orally administered. 
 
Keywords: Cymbopogon citratus, lemongrass, flavonoids, pharmacokinetics, in 
vivo. 
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1. Introduction 
Cymbopogon citratus (DC.) Stapf is a tropical herb of the Poaceae family 
from Southeast Asia, commonly known as lemongrass. Studies previously 
conducted demonstrated its hypoglycemic, hipolypidemic, anxiolytic, sedative, 
antioxidant and anti-inflammatory effects (Adeneye and Agbaje, 2007; Campos et 
al., 2014; Orrego et al., 2009; Salim et al., 2014; Tapia et al., 2007). Some 
researchers have studied diverse-origin samples of lemongrass regarding their 
phenolic composition and antioxidant and anti-inflammatory properties 
(Figueirinha et al., 2008; Roriz et al., 2014; Soares et al., 2013; Tiwari et al., 
2010). In the past years, the phenolic composition of lemongrass infusion was 
described: 3-feroylquinic acid, neochlorogenic acid, chlorogenic acid, p-coumaric 
acid, carlinoside, isoschaftoside, isoorientin, cynaroside, veronicastroside, luteolin 
7-O-neohesperidoside, kurilensin A and cassiaoccidentalin B (Costa et al., 2015b). 
We also demonstrated that flavonoids, such as luteolin and apigenin glycosides, 
and tannins strongly contributed to antioxidant and anti-inflammatory properties 
of an essential oil-free infusion from lemongrass (Costa et al., 2015a; Figueirinha et 
al., 2010, 2008; Francisco et al., 2014, 2013, 2011). Very recently, the anti-
inflammatory and analgesic potential of lemongrass infusion was also revealed in 
vivo by our research group (Garcia et al., 2015). These activities were ascribed to 
mono- and polymeric flavonoid-enriched fractions of the crude extract, in which 
flavones O- and mainly C-glycosides and flavanic tannins, respectively, were 
identified, suggesting, therefore, a straight relationship between these phenolic 
compounds and their properties aforementioned.  
Biological effects of flavonoids imply them to be bioavailable and to 
effectively reach target tissues. Thus, a number of studies have been conducted in 
order to investigate the metabolism of naturally occurring flavonoids, focusing 
particularly on the role of the gut microflora in the metabolic transformation of 
flavonoids (Marín et al., 2015; Rice-Evans, 2004). Accordingly, following the 
ingestion of flavonoid O-glycosides and before their intestinal absorption, the 
corresponding sugar moieties (as in quercetin 3-O-glucoside) are cleaved from the 
phenolic backbone by enzymes expressed at the enterocyte membrane such as 
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lactase phlorizin hydrolase (LPH) or cytosolic enzymes such as 𝛽-glucosidase 
(CBG), which hydrolyze glycosylated flavonoids, allowing the formed aglycones to 
enter epithelial cells by passive diffusion (Gee et al., 2000). However, flavonoids 
linked to a rhamnose moiety must reach the colon to be hydrolyzed by the 𝛼-
rhamnosidases secreted by the colon microbiota (as Bifidobacterium dentium), in 
order to be absorbed (Marín et al., 2015). Once the final derivative or the aglycone 
have been absorbed, they suffer phase II metabolism at enterocyte level; these 
reactions include methylation at C3’ or C4’ by catechol-O-methyltransferase 
(COMT), sulfation at C3’, C4’, C5, or C7 by sulfotransferases (SULT) and/or 
glucuronidation by UDP-glucuronosyltransferases. Afterwards, these products 
enter the blood stream by the portal vein, reaching the liver, where they may be 
subjected to more phase II metabolism, hence becoming conjugated and 
transported to the bloodstream again until they are secreted in urine (Chen et al., 
2011; Ouzzine et al., 2003; Selma et al., 2009). Some of the liver conjugates are 
then excreted as bile components and back into the intestine (enterohepatic 
recirculation), while deconjugated compounds are regenerated by gut microbial 
enzymes before being reabsorbed again (Cardona et al., 2013). The unabsorbed 
metabolites are eliminated via faeces. All these conjugation mechanisms are highly 
efficient, and free aglycones are generally absent or present in low concentrations 
in plasma after nutritional doses (Marín et al., 2015). 
In opposition, few studies have been performed regarding the absorption, 
tissue distribution, metabolism and excretion of flavone C-glycosides (Sheng et al., 
2014; Xue et al., 2014) in spite of the importance of the biodisposition of flavone 
C-glycosides after oral administration, which determines their potential benefit in 
pharmacotherapy or nutrition. In addition to the structural and physico-chemical 
attributes of the parent compounds, their pharmacokinetics is essential because 
determines their biological effects. However, the current understanding of 
absorption and biodisposition is limited to a small number of dietary flavonoids 
and few studies referred to the metabolism of flavone C-glycosides (Ma et al., 
2010; Zhang et al., 2010, 2007). A single oral dose administration of a Crataegus 
crude extract evidenced that only the intact forms of vitexin O-glucoside and O-
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rhamnoside were detected in plasma, tissues, urine and bile  and that 
deconjugation of C-glycosyl flavone was not a prerequisite for its absorption in rats 
(Ma et al., 2010).  Similarly, when orally administered, puerarin, another C-
glycosyl flavone, was also rapidly absorbed from the intestine without being 
previously metabolized (Prasain et al., 2004). High recovery of administered 
vitexin 4’’-O-glucoside and 2’’-O-rhamnoside in faeces indicated that the efficient 
absorption of these molecules from the gastro-intestinal tract of rats was low. In 
fact, it was reported that vitexin 2’’-O-rhamnoside has limited gastrointestinal 
absorption with an oral bioavailability of only 3.57% (Liang et al., 2007; Zhang et 
al., 2010). A recent work investigated the pharmacokinetic and excretion profile of 
Swertia pseudochinensis extract after its oral administration to rats and 
determined three secoiridoid glycosides and three flavonoid glycosides in plasma, 
bile, urine and faeces (Sheng et al., 2014). This study also found that, although 
both groups of components rapidly achieved the maximum peak concentration in 
plasma (Cmax) with a corresponding time to reach Cmax (Tmax) between 10 and 40 
min, the bioavailability of the secoiridoid glycosides was significantly higher than 
that of the flavonoid glycosides and the elimination half-life (T1/2) ranged from 
58.4 to 263.0 min. These results demonstrated that both the absorption and 
elimination processes of all analytes were fast, and mainly by urine excretion. 
The objective of the current study was to investigate, for the first time, the 
pharmacokinetic profile of phenolic acids and flavonoids in rats after oral 
administration of a single dose of C. citratus infusion which has very recently 
revealed anti-inflammatory activity in vivo (Garcia et al., 2015). 
 
2. Materials and Methods 
2.1 Chemicals and drugs 
Isovitexin (ISV), isoorientin (ISO), luteolin (LUT), luteolin 7-O-glucuronide 
(L7G), chrysoeriol (CHR) and diosmetin (DIO) were purchased from 
Extrasynthese (Lyon, France). Caffeic acid (CAF) and p-coumaric acid (COU) 
were acquired from Sigma-Aldrich (St. Louis, MO, USA). Rutin (RUT), sodium 
chloride, potassium chloride, disodium phosphate, monopotassium phosphate, 
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formic acid, acetone, n-hexane and methanol (HPLC gradient grade) were 
purchased from Merck (Darmstadt, Germany). Ultra-pure water (HPLC grade 
>18 M; homemade) was prepared by means of a MilliQ water apparatus from 
Millipore (Milford, MA, USA). Isoflurane (Isoflo®) was acquired to Siloal, S.A.    
 
2.2 Plant material and extraction 
Dry leaves of Cymbopogon citratus were acquired from Ervital (Mezio, 
Castro Daire, Portugal). Cymbopogon citratus was bred in the region of Mezio, 
Castro Daire (Portugal) and a voucher specimen was deposited in the Herbarium 
of Aromatic and Medicinal Plants of the Faculty of Pharmacy – University of 
Coimbra (A. Figueirinha 0109). The identity of the plant was confirmed by J. 
Paiva (Life Sciences Department, University of Coimbra, Portugal).  
A lipid- and essential oil-free infusion was prepared as previously described 
(Figueirinha et al., 2008). The infusion was obtained by adding 150 mL of boiling 
water to 5 g of powdered plant material, the mixture being kept hot and left to 
stand for 15 min. The extract was then washed with n-hexane (1:1) three times to 
eliminate the lipophilic compounds and filtered under vacuum, concentrated in a 
rotavapor and freeze-dried. This freeze-dried extract (CcI) was kept at -40ºC, until 
further use. 
 
2.3 In vivo pharmacokinetic studies 
All the animal experiments were conducted in accordance with the European 
Directive (2010/63/EU) for animal experiments and approved by the Portuguese 
Veterinary General Division. 
Adult male Wistar rats (330-380 g) were obtained from Charles River 
(Barcelona, Spain), maintained under controlled environmental conditions 
(temperature 20 ± 2ºC; relative humidity 55 ± 5%; 12 h light/dark cycle) and 
receiving a standard rodent diet (4RF21, Mucedola, Italy) during almost all 
experimental procedures and tap water ad libitum. At the night before CcI 
administration, animals were anesthetized with isoflurane and their lateral tail vein 
was cannulated by inserting the Introcan Certo IV indwelling cannula (22 G; 0.9 
x 2.5 mm) for serial blood sampling. The rats fully recovered from anesthesia 
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overnight, and were fasted for 12–14h before CcI administration with free access 
to water. An additional fasting period (4 h post-dose) was considered to avoid the 
effect of food on the oral bioavailability. A single-dose (68.24 mg/kg) of a CcI 
aqueous solution was administered by oral gavage to male Wistar rats (4 mL/kg of 
body weight). The dose of CcI was calculated based on the traditionally used 
doses, and taking into account the Food and Drug Administration (FDA) 
Guidance for Industry on conversion of animal doses to human equivalent doses 
according to body surface area (US DHHS, FDA, 2005).  
In the plasma pharmacokinetic study, six rats (n = 6) were treated with the 
single-dose of CcI extract aqueous solution (68.24 mg/kg, p.o.) and multiple serial 
blood samples (approximately 0.3 mL) were collected through the cannula into 
heparinized tubes at 0.5, 1, 1.5, 2, 4, 8, 12 and 24 h post-dosing. Blood sampling 
was conducted in conscious and freely moving rats, which were appropriately 
restrained only at the moment of blood collection.  Blood samples were 
immediately centrifuged at 3000 g for 10 min (4ºC) to separate the plasma, which 
was stored at -80ºC until analysis.  
In the tissue pharmacokinetic studies, liver and kidneys were harvested, 
after decapitation and exsanguination under anesthesia, at 1, 2, 4, 8 and 24 h 
following CcI administration at the same dose of plasma pharmacokinetic study (n 
= 2, per time). The organs were excised and stored at -80ºC; the tissues were 
weighed and homogenized in phosphate buffer saline (PBS) pH 7.4 (4 mL per 
gram of tissue) before analysis. 
 
2.4 Samples analysis 
Concentrations of analytes in plasma and tissues (liver and kidneys) were 
determined by using a solid-phase extraction procedure followed by a reversed-
phase high performance liquid chromatography (HPLC) analysis, according to a 
previously validated method with slight modifications (Costa et al., 2015b). 
Briefly, 20 L of a 50% methanolic solution of internal standard (RUT) 
(100 g/mL) was added to an aliquot of rat plasma sample (100 L) or tissue 
homogenate supernatant sample (1 mL) and mixed with 400 L of PBS buffer. 
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Afterwards, the pre-treated sample was subjected to a solid-phase extraction (SPE) 
on the Oasis® HLB (30 mg, 1 mL) cartridge (Waters®, Milford, MA, USA), which 
was previously conditioned with 1 mL of 0.5% formic acid in methanol followed 
by 1 mL of 0.5% aqueous formic acid. The loaded cartridge was subsequently 
submitted to −60 kPa and washed four times with 1 mL of 0.5% aqueous formic 
acid. After drying the sorbent under vacuum for 5 min, analytes were eluted with 1 
mL of methanol-acetone (50:50, v/v) using a gentle vacuum. The eluate was 
evaporated to dryness at 40ºC in a vacuum oven and reconstituted with 150 L of 
water–methanol (50:50, v/v) by vortexing and ultrasonication. At last, 100 L of 
the final mixture were injected into the chromatographic system.  
HPLC analyses were performed according to Costa et al. (Costa et al., 
2015b), by using a chromatograph equipped with a photo diode-array detector 
(PDA) (Gilson Electronics SA, Villiers le Bel, France). The studies were carried 
out on a Spherisorb S5 ODS-2 column (250 x 4.6 mm i.d.; particle size, 5 µm; 
Waters Corp., Milford, MA, USA) at 25ºC and a Nucleosil C18 guard cartridge 
(30 x 4 mm i.d.; particle size, 5 µm; Macherey-Nagel, Düren, Germany). A mobile 
phase of 5% (v/v) aqueous formic acid (A) and methanol (B) was used with a 
discontinuous gradient: 5–15% B (0–10 min.), 15–30% B (10–15 min.), 30–35% B 
(15–25 min.), 35–50% B (25–35 min.) and 50–80% B (35–40 min.), followed by 
an isocratic elution for 20 min., at a flow rate of 1 mL/min. An injection volume of 
100 L was used for all standards and samples. Chromatographic profiles were 
acquired in the wavelength range 200–600 nm, and recorded at 280 and 320 nm. 
The quantification of each compound was achieve through the absorption at 320 
nm. Data treatment was carried out with Unipoint 2.10 software (Gilson). The 
main partial validation parameters of the analytical method employed were in 
agreement with the international guidelines (EMA, 2011; FDA, 2013) and are 
summarized in Table II.12.  
HPLC-PDA-ESI/MSn analysis, based on a previously optimized method 
(Tavares et al., 2015), was performed in a Surveyor liquid chromatograph 
hyphenated to a photo-diode-array detector (PDA) (Surveyor) and a Finnigan 
LCQ mass spectrometer (San Jose, CA, USA) equipped with an API-ES ionization 
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chamber. Separation was performed on a Spherisorb ODS-2 C18 reverse phase 
column, 150 x 2.1 mm i.d. and particle size of 3 µm (Waters Corporation, 
Milford, Massachusetts, USA) and a Spherisorb ODS-2 guard cartridge C18 (10 x 
4.6 mm i.d. and particle size of 5 µm; Waters Corporation, Milford, 
Massachusetts, USA) at 25ºC, using 2% aqueous formic acid (A) and methanol (B) 
as mobile phase. The gradient profile used was 5-15% B (0-10 min), 15-30% B 
(10-15 min), 30-35% B (15-25 min), 35-50% B (25-35 min), 50-80% B (35-40 
min) and 80% B (40-60 min), isocratically, at a flow rate of 0.2 mL/min. The first 
detection was done with the PDA detector in a wavelength range of 200-600 nm, 
followed by a second detection in the mass spectrometer. Mass analyses were 
obtained in the negative ion mode. The mass spectrometer was programmed to 
perform three consecutive scans: full mass MS1 (m/z 160-1300), MS2 of the most 
abundant ion in MS1, and MS3 of the most abundant ion in MS2. Source voltage 
was 4.5 kV and capillary voltage and temperature were -10 V and 250ºC, 
respectively. Nitrogen was used as sheath gas at flow rate of 20 arbitrary units. The 
normalized energy of collision was 45%, using helium as collision gas. 
 
Table II.12. Validation parameters of the HPLC method employed for the 
quantification of caffeic acid (CAF), p-coumaric acid (COU), isovitexin (ISV), 
isoorientin (ISO), luteolin (LUT), luteolin 7-O-glucuronide (L7G), chrysoeriol 
(CHR) and diosmetin (DIO)  in plasma, liver and kidney homogenate supernatants 
(n = 3) (cont.). 
Analyte Validation parameters Plasma Liver Kidney 
CAF 
Calibration range 
Coefficient of determination (r2) 
LLOQ 
Precision (%CV)a 
Accuracy (%Bias)a 
Recovery (%) 
1-30 g/mL 
0.9944 
1 g/mL 
 3.13 
-7.21 – 14.61 
98.2 – 101.0 
0.4-12 g/g 
0.9872 
0.4 g/g 
 14.84 
-5.76 – 8.42 
74.3 – 91.9 
0.4-12 g/g 
0.9980 
0.4 g/g 
 2.30 
-4.32 – 5.07 
78.6 – 92.5 
COU 
Calibration range 
Coefficient of determination (r2) 
LLOQ 
Precision (%CV)a 
Accuracy (%Bias)a 
Recovery (%) 
1-30 g/mL 
0.9993 
1 g/mL 
 5.90 
-3.19 – 19.89 
88.7 – 89.2 
0.4-12 g/g 
0.9816 
0.4 g/g 
 16.70 
-2.81 – 12.71 
75.0 – 91.3 
0.4-12 g/g 
0.9960 
0.4 g/g 
 4.65 
-9.36 – 7.18 
74.9 – 90.5 
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Table II.12. Validation parameters of the HPLC method employed for the 
quantification of caffeic acid (CAF), p-coumaric acid (COU), isovitexin (ISV), 
isoorientin (ISO), luteolin (LUT), luteolin 7-O-glucuronide (L7G), chrysoeriol 
(CHR) and diosmetin (DIO)  in plasma, liver and kidney homogenate supernatants 
(n = 3). 
Analyte Validation parameters Plasma Liver Kidney 
ISV 
Calibration range 
Coefficient of determination (r2) 
LLOQ 
Precision (%CV)a 
Accuracy (%Bias)a 
Recovery (%) 
2-60 g/mL 
0.9996 
2 g/mL 
 5.78 
-2.58 – 1.67 
90.6 – 93.5 
0.8-24 g/g 
0.9858 
0.8 g/g 
 15.96 
-10.39 – 9.62 
72.9 – 99.4 
0.8-24 g/g 
0.9864 
0.8 g/g 
 14.55 
-18.90 – 8.45 
80.5 – 95.6 
ISO 
Calibration range 
Coefficient of determination (r2) 
LLOQ 
Precision (%CV)a 
Accuracy (%Bias)a 
Recovery (%) 
2-60 g/mL 
0.9988 
2 g/mL 
 4.69 
-18.28 – 8.99 
89.4 – 91.1 
0.8-24 g/g 
0.9872 
0.8 g/g 
 14.84 
-5.76 – 8.42 
73.5 – 98.6 
0.8-24 g/g 
0.9979 
0.8 g/g 
 8.83 
-3.84 – 5.24 
76.0 – 86.2 
LUT 
Calibration range 
Coefficient of determination (r2) 
LLOQ 
Precision (%CV)a 
Accuracy (%Bias)a 
Recovery (%) 
2-60 g/mL 
0.9969 
2 g/mL 
 5.48 
-6.42 – 8.01 
81.2 – 93.2 
0.8-24 g/g 
0.9910 
0.8 g/g 
 20.34 
-4.87 – 11.02 
72.3 – 86.2 
0.8-24 g/g 
0.9979 
0.8 g/g 
 8.83 
-3.84 – 5.24 
70.5 – 82.9 
L7G 
Calibration range 
Coefficient of determination (r2) 
LLOQ 
Precision (%CV)a 
Accuracy (%Bias)a 
Recovery (%) 
2-60 g/mL 
0.9969 
2 g/mL 
 5.48 
-6.42 – 8.02 
82.7 – 93.2 
0.8-24 g/g 
0.9910 
0.8 g/g 
 20.34 
-4.79 – 11.07 
78.9 – 89.6 
0.8-24 g/g 
0.9979 
0.8 g/g 
 8.83 
-3.84 – 5.24 
77.9 – 87.6 
CHR 
Calibration range 
Coefficient of determination (r2) 
LLOQ 
Precision (%CV)a 
Accuracy (%Bias)a 
Recovery (%) 
2-60 g/mL 
0.9969 
2 g/mL 
 5.48 
-6.43 – 8.01 
82.9 – 92.6 
0.8-24 g/g 
0.9910 
0.8 g/g 
 20.34 
-4.73 – 11.08 
80.2 – 86.2 
0.8-24 g/g 
0.9979 
0.8 g/g 
 8.83 
-3.84 – 5.23 
79.2 – 83.5 
DIO 
Calibration range 
Coefficient of determination (r2) 
LLOQ 
Precision (%CV)a 
Accuracy (%Bias)a 
Recovery (%) 
2-60 g/mL 
0.9969 
2 g/mL 
 5.48 
-6.43 – 8.00 
84.9 – 94.0 
0.8-24 g/g 
0.9910 
0.8g/g 
 20.34 
-4.78 – 11.06 
79.2 – 84.3 
0.8-24 g/g 
0.9979 
0.8 g/g 
 8.83 
-3.84 – 5.24 
80.3 – 82.9 
aInter-day values, n = 3; Bias, deviation from nominal value; CV, coefficient of variation: LLOQ, 
lower limit of quantification; NC, not calculated. 
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2.5 Pharmacokinetic analysis 
The plasma concentration versus time data for each analyte obtained from 
each individual rat was submitted to a noncompartmental pharmacokinetic 
analysis using the WinNonlin® version 5.2. (Pharsight Co, Mountain View, CA, 
USA). 
The Cmax in plasma and tissues of each analyte and the corresponding Tmax 
were directly derived from the experimental data obtained. The remaining 
pharmacokinetic parameters evaluated included: the area under the drug 
concentration time-curve (AUC) from time zero to the last sampling time at which 
quantifiable drug concentrations were determined (AUC0t), calculated by the 
linear trapezoidal rule; the AUC from time zero to infinite (AUC0inf) that was 
calculated from AUCt + (Clast/kel), where Clast is the last quantifiable concentration 
and kel is the apparent elimination rate constant estimated by log-linear regression 
of the terminal segment of the concentration–time profile; the apparent terminal 
elimination half-life (T1/2) and the mean residence time (MRT). 
 
3. Results and Discussion 
The developed method was validated for eight different compounds: CAF, 
COU, ISV, ISO, LUT, L7G, CHR and DIO. L7G, L3’S, LUT, CHR and DIO were 
identified by HPLC-PDA-ESI/MSn. All compounds presented UV spectra 
characteristic of luteolin derivatives, with max at 251-255 and 344-349 nm. L7G 
([M − H]− at m/z 461) presented MS2 fragments at  m/z 357, 327, 285 and 115, 
suggesting the presence of luteolin 7-O-glucuronide (Yin et al., 2013). L3’S ([M − 
H]− at m/z 365) showed a MS2 fragmentation at m/z 285 and 257, associated with 
the chemical structure of luteolin O-sulfate. LUT ([M − H]− at m/z 285) showed 
the typical product-ions from the fragmentation of luteolin aglycone: m/z at 257, 
241, 199, 175, 151 and 133 (Roriz et al., 2014). CHR and DIO exhibited the 
same parent-ion ([M − H]− at m/z 299), and very similar fragmentation patterns: 
m/z at 284, 255, 151, 132, 107 and 284, 255, 179, 151, 107, respectively; 
indicating the presence of O-methylated luteolin derivatives, chrysoeriol and 
diosmetin, respectively (Brito et al., 2014; Radwan and Hamdy, 2006). Since the 
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method was not validated to L3’S due to the unavailability of standard, this 
analyte was quantified expressing the results in equivalents of L7G. In fact, this is 
an approach often employed by other authors (Granica et al., 2015; Kiselova et al., 
2006).   
Globally, the present pharmacokinetic study, in plasma and tissues, revealed 
the presence of LUT, L7G, CHR, DIO and also L3’S (Figure II.23),  while CAF, 
COU, ISV and ISO were not detected by the validated bioanalytical method, in all 
matrices.   
Although L7G and L3’S are not present in CcI, they were the only ones 
quantified in rat plasma. The plasma concentration-time profiles of the analytes 
found and quantified in rat plasma are shown in Figure II.24 and the 
corresponding estimated pharmacokinetic parameters are listed in Table II.13. 
Taking them together, it becomes evident that L7G and L3’S rapidly reached Tmax, 
with maximum concentrations at 30 min after oral administrations of CcI extract. 
Since they are not present in the initial extract and they quickly reach the Cmax, it 
can be possible to infer that the parent compounds are rapidly metabolized, 
probably in the gut and liver, before reaching the systemic blood flow. In fact, it is 
known that, at the intestinal tract, luteolin glycosides are hydrolyzed to luteolin, 
which is  rapidly metabolized to glucuronides and sulfates by UDP-
glucuronosyltransferases (UGTs), sulfotransferases (SULTs) and/or microbiota 
enzymes (Davis and Brodbelt, 2008; Tomás-Barberán and Andrés-Lacueva, 2012). 
Moreover, luteolin is also described as being rapidly metabolized to L7G by UGTs, 
or to L3’S by SULTs in the liver (Tomás-Barberán and Andrés-Lacueva, 2012). 
Although plasma concentration-time profiles for L7G and L3´S are almost parallel 
(Figure II.24), their pharmacokinetic parameters in plasma after oral 
administration of C. citratus extract revealed to be slightly different from each 
other (Table II.13), with L7G presenting higher values of Cmax, AUC, T1/2 and 
MRT. These findings, suggest not only a higher biodisposition in plasma but also 
that L7G remains for a longer period of time in the organism. These data are in 
accordance with previous works regarding the plasma pharmacokinetics of similar 
compounds, such as vitexin 2’’-O-rhamnoside, vitexin 4’’-O-glucoside, luteolin 3’-
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O-glucuronide, apigenin 7-O-glucuronide and acacetin 7-O-glucuronide (Liang et 
al., 2007; Qiang et al., 2015; Zhang et al., 2010). As for the L3’S, it was already 
reported as being a major ISO metabolite in rats (Shi et al., 2015).   
 
Figure II.23. Molecular structures of luteolin (LUT) and 
derivatives (isoorientin, ISO; chrysoeriol, CHR; 
diosmetin, DIO; luteolin 7-O-glucuronide, L7G; luteolin 
3’-O-sulfate, L3’S).  
 
 
Figure II.24. Plasma concentration-time profiles of luteolin 7-O-
glucuronide (L7G) and luteolin 3’-O-sulfate (L3’S) obtained after 
administering a single oral dose of CcI extract to rats (68.24 
mg/kg). Symbols represent the mean values ± standard error of 
the mean of six determinations per time point (n = 6). 
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Table II.13. Pharmacokinetic parameters of luteolin 
7-O-glucuronide (L7G) luteolin 3’-O-sulfate (L3’S), in 
rat plasma after oral administration of the CcI extract 
at 68.24 mg/kg (mean ± standard deviation, n = 6). 
Pharmacokinetic parameters 
Compounds 
L7G L3’S 
Cmax (g/mL) 26.87 ± 0.89 18.57 ± 0.31 
Tmax (h) 0.50 ± 0.00 0.50 ± 0.00 
T1/2 (h) 7.61 ± 0.34 3.03 ± 0.13 
AUC(0t) (h g/mL) 77.34 ± 2.26 41.95 ± 1.11 
AUC(0) (h g/mL) 105.36 ± 2.79 51.22 ± 1.37 
MRT(0) (h) 3.77 ± 0.04 2.57 ± 0.03 
 
Besides L7G and L3´S, the analysis of liver tissue samples, revealed the 
presence of compounds undetected in plasma, namely LUT, CHR and DIO. The 
respective concentration-time profiles and pharmacokinetic parameters of the five 
analytes are displayed in Figure II.25 and Table II.14, respectively. According to 
Cmax and AUC values, it becomes clear that the three major metabolites found in 
liver tissues were L7G, CHR and L3’S, which were detected from the first hour and 
remained in the tissue up to at least 24h. In opposition, DIO was detected only 8 
h post-dosing, exhibiting the lowest concentration of all the analytes studied, 
suggesting that it is a minor product of rat metabolism. Therefore, it is not 
expected to contribute significantly to the pharmacological effects of the CcI 
extract in spite of exhibiting pharmacological activity in other studies when highly 
bioavailable in vivo (Patel et al., 2013).  
The earlier Tmax values found in plasma rather than in liver, suggest that 
these metabolites are mainly produced at the small intestine level rather than in 
the liver. Similarly, Courts & Williamson recently reported that flavones C-
glycosides (e.g. vitexin, isoorientin and mangiferin) are promptly metabolized by 
gut microbiota and enterocytes enzymes (Courts and Williamson, 2013). This may 
explain the very low bioavailability of luteolin aglycone herein found.   
The kidney concentration-time profile revealed the presence of the same 
compounds detected in plasma, L7G and L3’S (Figure II.25), probably due to 
their high concentrations in plasma. The pharmacokinetic parameters (Table 
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II.14) of these analytes are very similar, L7G presenting higher Cmax and AUC 
values, but slightly lower T1/2 and MRT values than L3’S.  
 
 
Figure II.25. Liver (A) and kidney (B) concentration-time profiles of luteolin 7-O-
glucuronide (L7G) luteolin 3’-O-sulfate (L3’S), chrysoeriol (CHR), diosmetin 
(DIO) and luteolin (LUT) obtained after administering a single oral dose of CcI 
extract (68.24 mg/kg) to rats.   Symbols represent the mean values ± standard 
error of the mean of two determinations per time point (n = 2). 
 
Table II.14. Pharmacokinetic parameters in rat liver and kidney after p.o. 
administration at 68.24 mg/kg (mean ± standard deviation, n = 2). 
 
Cmax 
(g/g) 
Tmax 
(h) 
T1/2 
(h) 
AUC(0t) 
(h g/g) 
AUC(0) 
(h g/g) 
MRT(0) 
(h) 
Liver 
L7G 4.78 ± 0.35 2.00 ± 0.00 19.40 ± 0.51 49.90 ± 1.26 86.70 ± 0.11 9.30 ± 0.10 
L3’S 3.62 ± 0.23 2.00 ± 0.00 21.60 ± 5.08 35.00 ± 0.55 62.71 ± 7.74 9.21 ± 0.25 
CHR 4.03 ± 0.27 2.00 ± 0.00 21.20 ± 0.89 42.40 ± 1.53 77.80 ± 4.95 6.94 ± 0.08 
DIO 0.89 ± 0.04 8.00 ± 0.00 NC NC NC 8.00 ± 0.00 
LUT 1.93 ± 0.01 2.00 ± 0.00 8.38 ± 0.39 8.37 ± 0.18 21.50 ± 1.21 4.35 ± 0.02 
Kidney 
L7G 1.80 ± 0.01 2.00 ± 0.00 54.61 ± 4.38 31.14 ± 0.39 122.63 ± 9.94 11.37 ± 0.09 
L3’S 1.09 ± 0.00 2.00 ± 0.00 68.88 ± 2.08 21.83 ± 0.29 104.88 ± 4.41 11.58 ± 0.05 
NC, not calculated. 
 
The pharmacokinetic analysis herein performed in plasma, liver and kidney 
showed that the compounds present in CcI (Costa et al., 2015a; Figueirinha et al., 
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2010, 2008; Francisco et al., 2014; Orrego et al., 2009) are not abundant in 
plasma, liver or kidneys after a 68.24 mg/kg single-dose oral administration of the 
extract. In fact, the metabolites, L7G and L3’S, were the most abundant in plasma, 
particularly L7G which presented the highest AUC values, and, therefore, they are 
probably the main responsible for the anti-inflammatory activity previously 
reported (Garcia et al., 2015). Importantly it seems that, during the inflammatory 
process, the enzyme -glucosidase overexpressed by neutrophils leads to the 
deglucuronidation of L7G to LUT,  which, in turn, exerts the biological effect 
when reaching the target-tissue (Chen et al., 2014; Lamy et al., 2015; Shimoi, 
2001; Shimoi et al., 2000). Therefore, L7G and L3’S seem to be the main active 
circulating forms of the aglycone luteolin.  
The work herein exposed revealed, for the first time, how luteolin C-
glycosides are metabolized in vivo after CcI administration to rats, and which are 
the main metabolites probably responsible for the CcI pharmacological effects 
previously observed in vivo (Garcia et al., 2015). 
 
4. Conclusions 
In conclusion, to the best of our knowledge, this work is the first report 
documenting the quantification of LUT, L7G, L3’S, CHR and DIO in rat plasma, 
liver and/or kidney, after the oral administration of a single dose of C. citratus 
infusion. This work has successfully investigated the pharmacokinetics of CcI in 
rats, and could also be applied in future studies of lemongrass preparations. The 
pharmacokinetics of the two major luteolin conjugates in vivo (L7G and L3’S) 
herein obtained support the pharmacological effects of C. citratus in vivo.  
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Cymbopogon citratus (lemongrass) is an herb commonly used in traditional 
medicine for gastrointestinal disorders, namely gastritis, diarrhea, stomach 
problems, abdominal pain, digestive ailments, and for diseases related with 
inflammation, such as  fever, arthritis, rheumatism, muscular pain, colds, cough 
(Chapter I). These several traditional uses are associated to lemongrass leaves and 
may be linked to the antioxidant, gastroprotective and/or anti-inflammatory 
properties, which were intended to be validated in this dissertation. In order to 
assess the phytochemicals that may be responsible for the referred traditional uses, 
in the past years, great attention has been payed to the phenolic compounds 
present in this plant and to their anti-inflammatory effects (Figueirinha et al., 
2010, 2008; Francisco et al., 2011). The anti-inflammatory activity verification of 
phenolic compounds enriched fractions, through in vitro assays, suggests that these 
phytochemicals may be suitable for extracts standardization, which, in turn, may 
be used in C. citratus derivated anti-inflammatory products. Therefore a validated 
method is crucial to obtain standardized extracts or products, in order to guarantee 
the proper quality for human consumption. 
 
A. Development and validation of a simple and sensitive RP-HPLC method 
for quantitation of flavonoids in Cymbopogon citratus infusion 
In this work, a simple and efficient RP-HPLC-PDA method was successfully 
validated (section II.A) for simultaneous identification and quantification of 
phenolic compounds, namely phenolic acids and flavonoids, for the first time, in 
three different extracts: infusion and 50% aqueous ethanol and ethanol macerates. 
The developed HPLC method was validated according to ICH and FDA guidelines. 
The validated method is simple, precise and accurate, presenting acceptable LOD 
and LOQ values. It may also be applied for phenolic compounds quantification in 
other polar extracts as well as for quality control of herbal formulations, with 
promising use in pharmaceutical and food supplement industries. 
B. Influence of harvest time and material quality on phenolic content and 
antioxidant activity of Cymbopogon citratus infusion 
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In the case of C. citratus, this crop is harvested along a wide period of the 
year (from the beginning of spring till the end of summer). Additionally, it is 
known that phenolic compounds vary with sunlight exposure and climatic 
conditions (Booij-James et al., 2000; Cohen et al., 2008; Spayd et al., 2002). So, 
the amount of these compounds in the plant leaves may suffer significant 
variations, leading to chemically and, therefore, therapeutically different products, 
the phenolic compounds characterization and quantification revealing to be of 
extraordinary importance. In order to address that issue, a work to study the 
influence of harvest time, but also the plant quality on lemongrass phenolic 
composition and antioxidant power was carried out (section II.B). Our results 
indicated that the content on polyphenols and the antioxidant capacity of C. 
citratus infusion is strongly related with the quality of the plant at the moment it 
is harvested. The total phenols assay showed a substantial loss from August to 
September, suggesting that the biosynthesis of these compounds is affected by the 
sunlight. Moreover, each group of phenolic compounds is affected by the harvest 
time. Therefore, it is not indifferent to extract the phenolic compounds from this 
plant with different quality grades or harvested on different months of the year. It 
was possible to find out the best month to harvest the plant to get the most of 
each phenolic group: April and June for hydroxycinnamic acids; June and 
September for flavonoids; June, July and August for tannins. Regarding the 
influence of plant quality on the composition of lemongrass extract, it is clear the 
correlation between these two parameters. Regardless the group of phenolic 
compound addressed, its content was always inversely proportional to the degree 
of leaves ageing, and therefore, to the time of sunlight and/or UV light exposition. 
This work also shed lights on how the harvest time and the oxidation state of the 
plant leaves affected the polyphenolic profile and antioxidant activity. Among the 
different groups of phenolic compounds, both phenolic acids and tannins seem to 
be the most decisive in the overall antioxidant activity of the extract. In what 
concerns the quality of the harvested material and its antioxidant capacity, the 
relationship could not be more explicit. For all tested oxidant species, the high-
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quality samples exhibited the best antioxidant results, and samples collected at the 
same month, but with low-quality presented the poorest potential.  
To sum up, both harvest date and plant quality are key criteria that have to 
be taken into account when selecting the material for human consuming, in order 
to receive benefits that have been allocated to phenolic compounds, namely to 
those who are present in this plant. In addition, these results indicate that the 
plant must be protected from light, also during the post-harvest stage, namely 
during drying, chopping and packing processes.   
These results taken together with those of section II.A revealed that the 
extraction method and essentially the extraction solvent have a much greater 
influence on flavonoid amount than the harvest date. On the other hand, the 
harvest date is more determinant for the phenolic acids amount than the solvent 
used. To further investigate the relationship between the extraction solvent and the 
quality and quantity of phenolic compounds extracted, a complementary study was 
carried out (see Attach 2). This study confirmed how flavonoids are greatly 
influenced by the extraction solvent, its contents being greatly increased when an 
ethanol percentage of 80% or more is used.   
The results showed that also tannins are remarkably influenced. In the case 
of this group of polyphenols, water or a hydroalcoholic mixture up to 60% ethanol 
should be used. Higher percentages of ethanol severely affect the tannins 
extraction yield. Additionally, the extraction solvent influence on the antioxidant 
power was also investigated. The results (see Attach 3) showed that the extraction 
process also has an important role on the antioxidant capacity. In the case of 
DPPH radical, the best solvents are the 50% and 60% aqueous ethanol, while 40% 
aqueous ethanol extraction leads to the poorest scavenging activity. For FRAP, 
50% ethanolic extract proved to be the one with the highest activity, being 100% 
ethanolic extract the weakest one. In ABTS (pH=7), there were not significant 
differences among the studied extraction solvents. On the other hand, 50% 
aqueous ethanol demonstrated once again to be the one solvent to extract the 
greatest amount of antioxidant compounds against ABTS radical (pH=4), while C. 
citratus infusion and absolute ethanol extract were the less effective. These results 
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corroborate the previous ones, demonstrating that the solvents which better extract 
tannins lead to extracts with greater antioxidant activities against the tested 
oxidant species. Another complementary study was performed to observe the 
antioxidant effect of each enriched fraction of phenolic acids, flavonoids and 
tannins (Attach 4). In this study, it was observed that both tannins and flavonoids 
have a greater antioxidant capacity than the C. citratus infusion, for all tested 
radicals. Moreover, the tannin fraction is the strongest one in what concerns 
antioxidant activity, even stronger than Trolox, with the exception of ABTS at 
pH=4. In this case, the phenolic acids fraction surpasses the tannins. This fact 
may be associated with the pK of the referred compounds, which favors the 
performance of phenolic acids at acidic environments, and the tannins at higher 
pHs (Friedman and Ju, 2000). This certainly has clinical implications, namely if 
the compounds are administrated per os. Hence, tannins and phenolic acids are 
tightly associated with the overall activity of lemongrass extracts. On the other 
hand, the tannin fraction is the one showing the best activity in FRAP assay. This 
fact may be explained by the known property of metal ions complexation 
attributed to tannins (Schmidt et al., 2013). 
 
C. Flavan hetero-dimers in the Cymbopogon citratus infusion: tannin 
fraction obtaining, evaluation of its contribution to the antioxidant activity 
and structural elucidation 
On the other hand, tannins and flavonoids have been reported to 
possess anti-inflammatory properties in vitro (Figueirinha et al., 2010; 
Francisco et al., 2014, 2011). Since the chemical characterization of 
flavonoids has already been disclosed (Figueirinha et al., 2008; Francisco et 
al., 2014), the necessity to characterize the tannins structure was evident. 
A study by HPLC-PDA-MSn identified, for the first time in C. citratus, 
hetero-dimeric flavan structures (section II.C). These flavonoid oligomers 
consist of apigeniflavan or luteoliflavan units linked to a flavanone, either 
naringenin or eriodictyol, and occur as aglycone and glycosylated forms. The 
detected proanthocyanidin hetero-dimers, along with some common 
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procyanidin dimers, constitute the main compounds in the tannin fraction of 
lemongrass. The findings of this study support the antioxidant potential of 
this plant and emphasize the contribution of the tannin fraction to this 
activity. Furthermore, tannin-rich fractions from C. citratus leaves have 
already been associated with antioxidant and anti-inflammatory properties 
(Figueirinha et al., 2010, 2008; Francisco et al., 2011) and the tannins 
similar to those present in C. citratus have also been suggested as anti-
inflammatory and antioxidant (Bors et al., 2000; Riedl and Hagerman, 
2001), which may lead to a structure-activity relationship based on this 
biological effect and the tannin structure disclosed here for the first time.  
 
D. Gastroprotective effect of Cymbopogon citratus infusion on acute 
ethanol-induced gastric lesions in rats 
Oxidative and inflammatory processes episodes may be the root of gastric 
disorders (Mario et al., 2014) so that in this work the gastroprotective effect of a 
C. citratus infusion, the most commonly application to this extract, was studied 
through an in vivo model. 
This extract, administered before and after ethanol-induced gastric lesions 
(section II.D), significantly reduced the incidence and severity of gastric lesions 
and, consequently, the ulcer index. These data suggest a gastroprotective activity of 
C. citratus infusion and corroborate the traditional medicinal use of this plant to 
ameliorate gastritis and/or peptic ulcers symptoms, and that the antioxidant 
properties of lemongrass phenolic compounds could be partially responsible for the 
observed gastroprotective effects, as has been verified to other polyphenols (La 
Casa et al., 2000). Additionally, the gastroprotective effect has also been associated 
with anti-inflammatory mechanisms (Maity et al., 2009). So, both antioxidant and 
anti-inflammatory properties of lemongrass polyphenols may contribute to the 
overall gastroprotective activity of this plant. 
With the purpose of further investigate the anti-inflammatory potential of 
C. citratus infusion and/or its phenolic compounds two different approaches of 
administration routes were taken into account: oral and topical. 
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E. In vivo evaluation of anti-inflammatory and analgesic activities of 
flavonoid and tannin fractions from Cymbopogon citratus infusion 
The first in vivo anti-inflammatory validation of C. citratus after an oral 
administration (section II.E) was performed with the carrageenan-induced paw 
oedema and pointed the traditional use of C. citratus infusion (CcI) as an anti-
inflammatory agent. The observed effect on oedema inhibition for an 
administration of 68.24 mg/kg was 82.30%, value very similar to that obtained by 
10 mg/kg of the reference NSAID used -diclofenac (84.00%), flavonoid- (7.42 
mg/kg) and tannin-rich (5.96 mg/kg) fractions contributing significantly to anti-
inflammatory activity (59.0 and 61.0%, respectively). On the other hand, our 
results also showed that effective CcI concentrations induced no hepatotoxicity in 
rats and, therefore, the administration of CcI may be considered safe under the 
conditions used. These results suggest that lemongrass infusion and its 
polyphenols, namely the flavonoids and tannins, may be used to obtain a new anti-
inflammatory medicine, effective in the treatment of inflammatory-related 
pathologies. 
 
F. Polyphenols from Cymbopogon citratus leaves as topical anti-
inflammatory agents 
The topical anti-inflammatory activity of CcI was also addressed in vivo 
(section II.F). Firstly, the topical formula was optimized in order to obtain the 
most efficient anti-inflammatory effect in vivo. This feature was monitored using 
the carrageenan-induced paw oedema model in rats (Attach 5).  The first 
formulation tested was a hydrogel which led to a 12% reduction in the oedema 
volume. Afterwards, an oil/water emulsion was experimented, revealing a 31% 
reduction. Hence, it was possible to conclude that, in this case, an oil/water 
emulsion is more effective in delivering the active compounds to the site of action 
than the hydrogel. Additionally, one or two permeability enhancers were added to 
the emulsion formula and the anti-inflammatory effect increased 10% and 16%, 
respectively. Therefore, the formula of choice was the last one tested: stearic acid, 
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triethanolamine, glycerol, water, propylene glycol, oleic acid, which was used in 
further investigations. 
With the data obtained from the Franz cells releasing assay, it was possible 
to presume that the topical anti-inflammatory effect was due, at least in part, to 
the most abundant compounds detected in the receptor medium, namely luteolin 
7-O-neohesperidoside, cassiaoccidentalin B, carlinoside and luteolin 7-O-glucoside. 
Curiously, a study performed with flavonoids glycosides reported the topical anti-
inflammatory effect in rats (Antunes-Ricardo et al., 2015). These data corroborate 
our results, which may suggest that CcI polyphenols can exert their effect in loco, 
without the necessity of being firstly metabolized by the enterocytes or 
hepatocytes.  
Further investigations were applied to test separately the topical anti-
inflammatory activities of the tannins (CcT) and flavonoids (CcF) fractions in the 
in vivo model, using the same formulation (Attach 6). Formulations containing 
0.3% of CcT and 0.6% of CcF (concentrations calculated taken into consideration 
the yields of these phenolic fractions obtained from CcI) diminished the oedema 
volume by 47% and 43%, respectively. Regarding these results, it is possible to 
conclude that CcT has a greater power to reduce the inflammatory oedema than 
CcF. Moreover, for a CcT+CcF formulation (0.34% and 0.66%, respectively) it 
was verified an higher anti-inflammatory effect (59%), that is more approached to 
the positive control (1% diclofenac formulation), 65.9%. In light of this study, we 
may suggest that tannins and flavonoids of the C. citratus possess a synergistic 
mechanism of action. Anti-inflammatory synergistic effects have already been 
described among various flavonoids and tannins (Mythilypriya et al., 2008).  
In conclusion, CcI flavonoids and tannins could be active constituents to 
integrate in a new topical anti-inflammatory agent, effective for the treatment of 
skin inflammatory-related pathologies. 
 
G. Pharmacokinetic profile of Cymbopogon citratus polyphenols in rats 
Through section II.G, the pharmacokinetics of C. citratus flavonoids was 
studied in order to better understand the biodisposition of these compounds 
CHAPTER III | GENERAL DISCUSSION and CONCLUSIONS 
 
214 
 
present in the extract. The pharmacokinetic analysis performed in plasma, liver 
and kidney showed that the compounds present in CcI were not detected in vivo 
after a single-dose oral administration. In fact, the metabolites, luteolin 7-O-
glucuronide, luteolin 3’-O-sulfate, luteolin, chrysoeriol and diosmetin were the 
most abundant in plasma, particularly luteolin 7-O-glucuronide and luteolin 3’-O-
sulfate, which presented the highest bioavailability, and, consequently, they are 
probably the main responsible for the anti-inflammatory activity previously 
reported, after an oral administration. Therefore, luteolin 7-O-glucuronide and 
luteolin 3’-O-sulfate seems to be the main active circulating forms of the aglycone 
luteolin.  
The work herein exposed revealed, for the first time, how luteolin glycosides 
are metabolized in vivo after CcI administration to rats, and that glucuronides and 
sulfates are probably the ones responsible for the in vivo pharmacological effects 
attributed to flavonoids. 
 
To conclude, all the objectives of this thesis were fulfilled and an important 
piece of knowledge was added about the phytochemical polyphenols and its anti-
inflammatory properties, as well as those of C. citratus infusion. Furthermore, for 
the first time, the anti-inflammatory effect, after oral and topical administration, 
and the pharmacokinetic profile of the compounds with therapeutic interest have 
been described in vivo. 
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In the future, further investigation must be undertaken in order to improve 
the chemical characterization of this plant, namely in what concerns its tannins. 
Therefore, it is appropriate to isolate and characterize each molecule, using more 
powerful techniques such as 1H and 13C NMR.  
The research undertaken to evaluate the influence of the harvest time and 
plant quality should be extended to the anti-inflammatory activity, since this 
property is tightly dependent on the quality and quantity of the phenolic 
compounds present in lemongrass. Besides, it would be of great importance to 
study the degradation profile of phenolic compounds in lemongrass leaves, during 
the post-harvest processes (drying, chopping and packing), in different light, 
temperature and humidity conditions.  
Also further in vitro and in vivo evaluations are required to elucidate the 
potential existence of synergistic behaviors.  
In addition, the pharmacokinetics approach must be deepened to flavonoids 
and tannins fractions by studying the profile of each fraction individually and in 
combination. Only then, the bioavailability and the pharmacodynamic interactions 
between phenolic compounds and target-tissues may be fully comprehended. 
Subsequently, studies in humans are absolutely crucial to better understand 
the biological effect of this plant in the body and thus be able to make the best of 
it. 
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Attach 1. Excerpt of the original description of the accepted 
name “Cymbopogon citratus” in the Bulletin of Miscellaneous 
Information (Royal Botanical Gardens, Kew, 1906). 
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Attach 2. Phenolic compounds amount (%, g of respective 
standard equivalents per 100 g of extract) quantified in lemongrass 
infusion (CcI), 40% ethanolic (CcM40%), 50% ethanolic 
(CcM50%), 60% ethanolic (CcM60%), 80% ethanolic (CcM80%) 
and absolute ethanolic (CcM100%) macerates. Results are 
expressed as mean ± SEM (n=3). 
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Attach 3. Antioxidant activity (expressed in TEAC value) of 
lemongrass infusion (CcI), 40% ethanolic (CcM40%), 50% 
ethanolic (CcM50%), 60% ethanolic (CcM60%), 80% ethanolic 
(CcM80%) and absolute ethanolic (CcM100%) macerates. Results 
are expressed as mean ± SEM (n=3). 
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Attach 4. Antioxidant activity (expressed in TEAC value) of 
lemongrass infusion (CcI), CcI phenolic acids fraction (CcPA), CcI 
tannins fraction (CcT) and CcI flavonoids fraction (CcF). Results are 
expressed as mean ± SEM (n=3). 
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Attach 5. In vivo anti-inflammatory activity of diferente topical formulations of 
CcI, by carrageenan-induced oedema reduction in rats. 
Formulation type HydroGel O/W Emulsion O/W Emulsion O/W Emulsion 
Formula 
Carbopol 940 Stearic acid Stearic acid Stearic acid 
Triethanolamine Triethanolamine Triethanolamine Triethanolamine 
Glycerol Glycerol Glycerol Glycerol 
Water Water Water Water 
Isopropanol - Propylene glycol Propylene glycol 
- - - Oleic acid 
CcI 4% CcI 4% CcI 4% CcI 4% 
Oedema reduction 
(%) 12 31 41 47 
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Attach 6. Effect of topical application of the 
placebo, positive control (diclofenac sodium, 
1%), CcT 0.3% and CcF 0.6% formulations on 
the oedema volume induced by 1% 
carrageenan, 4 h after inflammation induction. 
Each result represents the mean ± SEM (n = 
6/group). **p<0.01 and ***p<0.001, compared 
with the control group. 
 
 
